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Oral administration is the most practical way of vaccination of fish.  It has 
advantages over intraperitoneal injection and immersion methods that include no stressful 
handling, no interference with routine fish husbandry and antigens can be delivered to 
the fish in their feed. 
An oral antigen delivery system was developed for salmonides using fluid-bed 
spray dry technique. The delivery system was prepared by spraying antigen on to non­
pareil sugar beads to form an antigen layer,  then an enteric protected polymer­
polymethacrylic  acid-ethylacrylate  (Eudragit®-L30D)  layer  was  applied.  The 
physicomechnical characteristics of the delivery system and antigen release was evaluated 
by scanning electronic microscope and in vitro dissolution testing.  The delivery system 
was optimized in terms of enteric protection,  antigen release rate and the storage 
stability.  It was observed that the film processing temperature should be above 40°C to 
have a good quality enteric film coat, and the film thickness should be 29/4m to ensure 
Redacted for Privacythe enteric protection.  Different types and amounts of plasticizer were tested to 
differentiate their effects on the antigen release. 
The efficacy of immunization of oral ECAMs was carried out by comparing four 
different administration routes in Naive juvenile Coho salmon (Oncorhynchus kisutch): 
oral ECAMs, intraperitoneal injection, immersion and anal intubation.  Fish given a 
high oral dose of trinitrophenylated lipopolysaccharide (TNP-LPS) had significantly 
higher antibody levels than the immersion method and negative control could induce at 
4 and 6 weeks post immunization.  Also the serum antibody titers of fish elicited by 
oral enteric-coated trinitrophenylated keyhole limpet (TNP-KLH) was significantly 
greater than that of negative control but in a dose dependent manner. Oral immunization 
of a variety of antigen forms may have the equivalent efficacy as other conventional 
vaccination methods. 
Modification of oral ECAM by incorporation of sodium glycolate starch increased 
antigen release rate when the delivery system was at a high pH environment.  The dual 
functionality of sodium starch glycolate,  i.e.,  outstanding water wicking capacity and 
good swelling properties facilitate the antigen release from ECAMs and may improve 
their in vivo performance in fish. Fish Oral Antigen Delivery System Development and Optimization
 
by
 
Jia Ai (Allen) Zhang
 
A THESIS
 
submitted to
 
Oregon State University
 
in partial fulfillment of
 
the requirements for the degree of
 
Doctor of Philosophy
 
Completed January 4, 1995
 
Commencement June 1995
 Doctor of Philosophy thesis of Jia Ai (Allen) Zhang presented on January 4. 1995 
APPROVED: 
professor of Pharmacy in charge of Major 
Dean of College of Pharmacy 
Dean of Graduate Sc 
I understand that my thesis will become part of the permanent collection of Oregon State 
University libraries.  My signature below authorizes release of my thesis to any reader 
upon request. 
Jia Ai (Allen) Zhang, Author 
Redacted for Privacy
Redacted for Privacy
Redacted for Privacy
Redacted for PrivacyACKNOWLEDGEMENTS
 
I would like to dedicate this thesis to my parents, Ji-xing and Yuan-qin Zhang, 
my wife Hua Ma, my daughter Grace, my elder brother, Jia-ming and my aunt Mei­
zhen Chang (in Taiwan) for their love, encouragement and financial support during my 
graduate study in the United States. My parents are the persons whom have been the 
source of my strength since my beginning: without their unconditional love and support 
I would not be the person I am today. My greatest gratitude goes to my beloved wife, 
Hua Ma. Her love, encouragement, patience and understanding will always be a part of 
my life and my world. 
I wish to thank my major professor, Dr. J. Mark Christensen, for the opportunity 
to learn and prove myself,  the freedom to express myself,  and the knowledge from 
which I drew upon to improve myself.  I would like to thank the members of my 
committee, Drs. James W. Ayres, David Thomas, Paul Franklin and Lorraine Miller, 
for their advice and assistance.  I would also like to thank my colleague and friend in 
the Microbiology Department, Dr. Jon D. Piganelli,  for his help and collaboration. TABLE OF CONTENTS
 
CHAPTER I: 
INTRODUCTION  1 
CHAPTER II:
 
QUANTITATIVE DETERMINATION OF LPS AND TNP-LPS
 
BY SIZE EXCLUSION HPLC METHOD  3
 
ABSTRACT  3
 
INTRODUCTION  5
 
MATERIALS AND METHODS  7
 
RESULTS AND DISCUSSION  11
 
CONCLUSIONS  30
 
REFERENCES  45
 
CHAPTER III:
 
ORAL ANTIGEN DELIVERY SYSTEM DEVELOPMENT
 
AND OPTIMIZATION  49
 
ABSTRACT  49
 
INTRODUCTION  51
 
MATERIALS AND METHODS  56
 
RESULTS AND DISCUSSION  74
 
CONCLUSIONS  106
 
REFERENCES  121
 CHAPTER IV:
 
IN VIVO CHARACTERISTICS OF ORAL ENTERIC-COATED
 
ANTIGEN MICROSPHERES IN SALMONIDES  125
 
ABSTRACT  125
 
INTRODUCTION  127
 
MATERIALS AND METHODS  133
 
RESULTS AND DISCUSSION  140
 
CONCLUSIONS  149
 
REFERENCES  163
 
CHAPTER V:
 
EFFECT OF SUPERDISINTEGRANT ON ANTIGEN RELEASE
 
FROM ENTERIC-COATED ANTIGEN MICROSPHERES  169
 
ABSTRACT  169
 
INTRODUCTION  171
 
MATERIALS AND METHODS  173
 
RESULTS AND DISCUSSION  179
 
CONCLUSIONS  193
 
REFERENCES  200
 
BIBLIOGRAPHY  202
 LIST OF FIGURES
 
Figure  Page 
Figure II.1  A Typical Chromatogram of a Sample of E. Co li LPS Serotype 
055:B5 (peak 1) and 2-Acetamidophenol (peak 2) as an Internal 
Standard, pH 6.5 Potassium Phosphate Buffer as Mobile Phase.  12 
Figure 11.2  The Effects of pH of the HPLC Mobile Phase on LPS Retention 
Time in Size Exclusion Column.  Mobile phase: Potassium 
phosphate buffer with different pH levels. HPLC column: DuPont 
ZORBAX® bio series GF-450.  13 
Figure 11.3  The Effects of pH of the HPLC Mobile Phase on Chromatographic 
Behavior of LPS and 2-Acetamidophenol.  Mobile phase: 
Potassium phosphate buffer with different pH levels.  HPLC 
column: DuPont ZORBAX® bio series GF-450. No significant 
changes in peak resolution of LPS (1) and 2-acetamidophenol (2) 
at pH ranges from 5.5  to  6.5.  Peak area ratio (LPS/2­
acetamidophenol) increased as pH of mobile phase increased.  14 
Figure 11.4  The Effects of pH of the HPLC Mobile Phase on Chromatographic 
Behavior Of LPS and 2-Acetamidophenol.  Mobile phase: 
Potassium phosphate buffer with different pH levels.  HPLC 
column: DuPont ZORBAX® bio series GF-450. No significant 
changes in peak resolution of LPS (1), but the peak resolution of 
2-acetamidophenol (2) decreased at pH ranges from 7.0 to 8.0. 
Peak area ratio (LPS/2-acetamidophenol) significantly increased as 
pH of mobile phase increased (p < 0.05).  15 
Figure 11.5  The Effects of Ionic Strength of the HPLC Mobile Phase on LPS 
Retention Time in Size Exclusion Column.  Mobile phase: 
Potassium phosphate buffer with different pH levels.  HPLC 
column: DuPont ZORBAX® bio series GF-450.  17 
Figure 11.6  A Typical Chromatogram of a Sample of Trinitrophenylated 
-lipopolysaccharide TNP-LPS ( E. Coli LPS, serotype 055:B5) and 
2-Acetamidophenol as an Internal Standard (3). pH 6.5 potassium 
phosphate buffer was used as mobile phase. Peak (1) and peak (2) 
were counted as the total amount of antigen (TNP-LPS).  19 
Figure 11.7  The Effects of pH of the HPLC Mobile Phase on TNP-LPS 
Retention Time in Size Exclusion Column.  Mobile phase: 
Potassium phosphate buffer with different pH levels.  HPLC 
column: DuPont ZORBAX® bio series GF-450.  20 Figure 11.8  The Effects of Ionic Strength of the HPLC Mobile Phase on TNP­
LPS Retention Time in Size Exclusion Column. Mobile phase: 
Potassium phosphate buffer with different pH levels.  HPLC 
column: DuPont ZORBAX® bio series GF-450.  21 
Figure 11.9  Standard Curves of LPS Concentrations vs. Peak Area Ratios. LPS 
concentration ranged from 0.5 to 50 µg /ml.  Solid line indicates 
the regression line of LPS within-day assay,  dash line indicates 
the regression  line of LPS day to day assay.  Correlation 
coefficients (r) for () within-day assay and (v) day to day assay 
are 0.999 and 0.999, respectively (both significant at 1% level).  25 
Figure II.10  Standard Curves of LPS Concentrations vs. Peak Area Ratios. LPS 
concentration ranged from 50 to 5000 ng/ml. Solid line indicates 
the regression line of LPS within-day assay,  dash line indicates 
the regression  line of LPS day to day assay.  Correlation 
coefficients (r) for (II) within-day assay and (v) day to day assay 
are 0.997 and 0.998, respectively (both significant at 1% level).  26 
Figure II.11  Standard Curves of TNP-LPS Concentrations vs. Peak Area 
Ratios. TNP-LPS concentration ranged from 20 to 200µg /ml in 
deionized water.  Solid line indicates the regression line of LPS 
within-day assay,  dash line indicates the regression line of LPS 
day to day assay.  Correlation coefficients (r) for () within-day 
assay and (v) day to day assay are 0.997 and 0.997, respectively 
(both significant at 1% level).  27 
Figure 11.12  Standard Curves of TNP-LPS Concentrations vs. Peak Area 
Ratios. TNP-LPS concentration ranged from 5 to 200µg /m1 in 
simulated gastric fluid.  Solid line indicates the regression line of 
LPS within-day assay,  dash line indicates the regression line of 
LPS day to day assay. Correlation coefficients (r) for () within-
day assay and (v) day to day assay are 0.994 and 0.993, 
respectively (both significant at 1% level).  28 
Figure 11.13  Standard Curves of TNP-LPS Concentrations vs. Peak Area 
Ratios. TNP-LPS concentration ranged from 10 to 200µg /ml in 
simulated intestinal fluid.  Solid line indicates the regression line 
of LPS within-day assay, dash line indicates the regression line of 
LPS day to day assay. Correlation coefficients (r) for () within-
day assay and (v) day to day assay are 0.997 and 0.997, 
respectively (both significant at 1% level).  29 Figure III.1 
Figure 111.2
 
Figure 111.3
 
Figure 111.4 
Figure 111.5 
Figure 111.6 
Figure 111.7 
Figure 111.8 
Figure 111.9 
Chemical  Structure  of an  Anionic Copolymer Based On 
Methacrylic Acid and Ethyl Acrylate (Eudragit® L-30D).  The 
ratio of the carboxyl groups to the easter group is approximately 
1:1. The mean molecular weight is 250,000.  67 
Cross  Section of STREA-1 Fluid-Bed Spray Coater Fully 
Assembled.  68 
The Dissolution Profiles of LPS Coated Oral ECAMs with 
Different Amounts Of Polymer. Dissolution was conducted at pH 
7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric-fluid pre-treatment.  80 
Time of 50% Release of LPS From Enteric Coated LPS 
Microspheres.  LPS loaded microspheres coated with different 
amount of Eudragit L-30D. Dissolution was conducted at pH 7.2 
simulated intestinal fluid with one hour pH 1.5 simulated gastric-
fluid pre-treatment.  81 
In vitro Dissolution Profiles of Different Size of ECAMs with 
Predicted Polymer Coating Levels. Dissolution was conducted in 
pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric fluid  pre-treatment. 100% release based on theoretical 
amount of antigen contained in beads.  83 
Scanning Electron Micrograph of a Non-pareil Sugar Bead without 
any Coating (magnification ==120). The sugar bead was cut in half 
with a sharp surgical knife.  85 
Scanning Electron Micrograph of a Non-pareil Sugar Bead With 
5 %(w/w) Gelatin Layer (magnification =120). The sugar bead was 
cut in half with a sharp surgical knife.  86 
Scanning Electron Micrograph of a Non-pareil Sugar Bead with 
5 %(w/w)  Gelatin  Layer and  20 %(w/w)  Eudragit®  L-30D 
(magnification =120). The sugar bead was cut in half with a sharp 
surgical knife.  87 
In  vitro Dissolution  Profiles of TNP-LPS Coated ECAMs. 
Dissolution was conducted in pH 7.2 simulated intestinal fluid with 
one hour pH 1.5 simulated gastric fluid  pre-treatment. 100% 
release based on theoretical amount of antigen contained in 
beads.  88 Figure III.10 In vitro Dissolution Profiles of BSA Coated ECAMs. Dissolution 
was conducted in pH 7.2 simulated intestinal fluid with one hour 
pH 1.5 simulated gastric fluid pre-treatment. 100% release based 
on theoretical amount of antigen contained in beads. 
Figure III.11 In vitro Dissolution Profiles of LPS From ECAMs with Different 
Polymer Coating Temperature. Dissolution was conducted in pH 
7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric fluid  pre-treatment. 100% release based on theoretical 
amount of antigen contained in beads. 
Figure 111.12 Scanning Electron Micrograph of a Non-pareil Sugar Bead with 
5 %(w/w)  Gelatin  Layer  and 20%(w/w)  Eudragit®  L-30D 
(magnification =1000). Upper = enteric film coated at 35°C; 
Lower =enteric film coated at 65°C. 
Figure 111.13 Dissolution Profiles of Oral Enteric-coated Antigen Microspheres 
Incorporated with Different Types of Plasticizers and Different 
Amounts of Dibutyl Sebacate (DBS).  Dissolution  test was 
conducted at pH 7.2 simulated intestinal fluid with one hour pH 
1.5 simulated gastric-fluid pre-treatment. 
Figure 111.14 Dissolution Profiles of Oral Enteric-coated Antigen Microspheres 
Incorporated with Different Types of Plasticizers and Different 
Amounts of Polyethylene glycol-6000 (PEG-6000).  Dissolution 
test was conducted at pH 7.2 simulated intestinal fluid with one 
hour pH 1.5 simulated gastric-fluid pre-treatment. 
Figure 111.15 Dissolution Profiles of Oral Enteric-coated Antigen Microspheres 
Incorporated with 10% of Different Molecular Weights of 
Polyethylene glycol (PEG). Dissolution test was conducted at pH 
7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric-fluid pre-treatment. 
Figure 111.16 Dissolution Profiles of Oral Enteric-coated Antigen Microspheres 
Incorporated with Different Types of Plasticizers and Different 
Amounts of Triethyl citrate (TEC). Dissolution test was conducted 
at pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric-fluid pre-treatment. 
Figure 111.17 pH Sensitivity of Oral Enteric-coated Antigen Microspheres Under 
Different pH Conditions. Dissolution test was conducted at pH 7.2 
simulated intestinal fluid without acid pre-treatment. 
90 
95 
97 
108 
109 
110 
111 
112 Figure 111.18 
Figure 111.19 
Figure IV.1 
Figure IV.2 
Figure IV.3 
Figure IV.4 
Figure IV.5 
Figure IV.6 
Figure V.1
 
Figure V.2
 
pH Sensitivity of Oral Enteric-coated Antigen Microspheres Under 
Different pH Conditions. Dissolution test was conducted at pH 7.2 
simulated intestinal fluid with one hour pH 1.5 simulated gastric-
fluid pre-treatment.  113 
Dissolution Profiles of Oral Enteric-coated Antigen Microspheres 
Stored at Various Conditions. Dissolution test was conducted at pH 
7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric-fluid pre-treatment.  114 
Serum Antibody Activities of Coho Salmon Immunized with Low 
Dose of TNP-LPS. Antigen dose regimen: IP= 1pg/fish, once; 
Immersion= 1pg/fish, once; Oral= 1pg/fish/day, 30 days;  Oral 
control =Opg/fish/day, 30 days.  150 
Serum Antibody Activities of Coho Salmon Immunized with Low 
Dose of TNP-LPS. Antigen dose regimen: IP =1077g/fish, once; 
Immersion= lOng/fish, once; Oral= lOng/fish/day, 30 days; Oral 
control =Ong/fish/day, 30 days.  151 
Serum Antibody Activities of Coho Salmon Immunized with Low 
Dose of TNP-LPS. Antigen dose regimen: IP =10/g/fish, once; 
Immersion = IP =10/2g/fish, once; Oral =10/2g/fish/day, 30 days; 
Oral control= IP =0/g/fish/day, 30 days.  152 
Serum Antibody Activities of Coho Salmon Immunized with TNP­
KLH. Antigen dose regimen:  IP =100/2g/fish,  once;  Anal 
intubation = IP =100/2g/fish, once; Oral =0.5pg/fish/day, 30 days; 
Oral control = IP =Opg/fish/day, 30 days.  153 
Serum Antibody Activities Of Coho Salmon Immunized with TNP­
KLH.  Antigen  dose regimen:  IP=100Ag/fish,  once;  Anal 
intubation= IP=100/2g/fish, once; Oral =577g/fish/day, 30 days; 
Oral control = IP =Ong/fish/day, 30 days.  154 
Serum Antibody Activities of Coho Salmon Immunized with TNP­
KLH.  Antigen  dose  regimen:  IP =100/g/fish,  once;  Anal 
intubation = IP =100µg /fish, once;  Oral =100µg /fish /day, 30 
days; Oral control= IP =0/2g/fish/day, 30 days.  155 
Apparatus For Measurement of Liquid Uptake and Swelling 
Capacity.  177 
Swelling Work of Sodium Starch Glycoloate as a Function of 
Time.  185 Figure V.3  Liquid Uptake of Sodium Starch Glycolate as a Function of 
Time.  186 
Figure V.4  Volumetric Liquid Uptake Rate Profiles for Enteric-coated Antigen 
Microspheres Containing Different Levels of Superdisintegrant. 
Each data point represents the mean of ten replicates.  187 
Figure V.5  Volumetric Liquid Uptake Rate Profiles for Non Enteric-coated 
Antigen  Microspheres  Containing  Different  Levels  of 
Superdisintegrant.  Each data point represents the mean of ten 
replicates.  188 
Figure V.6  Effect of Different Levels of Superdisintegrant on Swelling 
Capacity of Enteric-coated Antigen Microspheres.  189 
Figure V.7  Effect of Different Levels of Superdisintegrant on Swelling 
Capacity of Non Enteric -coated Antigen Microspheres.  190 
Figure V.8  Effect of Different Levels of Superdisintegrant on Enteric Film 
Coating Rupture Time.  191 
Figure V.9  LPS Dissolution Rate Profiles From Enteric-coated Antigen 
Microspheres  with  Different  Levels  of  Superdisintegrant 
Incorporated. Dissolution was conducted in pH 7.2 simulated 
intestinal fluid with one hour pH 1.5 simulated gastric fluid pre­
treatment.  192 LIST OF TABLES
 
Table  Page 
Table II.1  Composition of Cacodylic Buffer (0.28 M)  31 
Table 11.2  Composition of Phosphate Buffered Saline, PBS  32 
Table 11.3  Composition of U. S. P. Simulated Gastric Fluid 
without Enzymes  33 
Table 11.4  Composition of Intestinal Fluid without Enzymes  34 
Table 11.5  Size Exclusion HPLC Assay Condition  35 
Table 11.6  LPS and TNP-LPS Analysis: Peak Processing Related Parameters 
by Shimadzu Chromatopac C-R 3A Data Processor  36 
Table 11.7  The Components of Different pH's of Mobile Phase and Retention 
Times of LPS and TNP-LPS  37 
Table 11.8  Analytical Precision for Assay of TNP-LPS in Deionized Water  38 
Table 11.9  Analytical Precision for Assay of TNP-LPS in Simulated Gastric 
Fluid  39 
Table II.10  Analytical Precision for Assay of TNP-LPS in Simulated Intestinal 
Fluid  40 
Table II.11  Analytical Accuracy for Assay of TNP-LPS  41 
Table 11.12  Analytical Precision for Assay of LPS At Concentration Rang 
from 0.5  µg /ml to 50 µg /ml  42 
Table 11.13  Analytical Precision for Assay of LPS At Concentration of 
50ng/m1 to 5000 jg /ml  43 
Table 11.14  Analytical Accuracy for Assay of LPS At Concentration Range 
from 0.5 to 50 µg /ml and 50 jg /ml to 5000ng/m1  44 
Table III.1  Typical Process Condition for Antigen or Enteric-film Coating  69 
Table 111.2  Enteric-Protected Film Polymer Formulation with 100 g of 25-30 
Mesh Size Antigen Loaded Beads  70 Table 111.3 
Table 111.4 
Table 111.5 
Table 111.6 
Table 111.7 
Table 111.8 
Table 111.9 
Table III.10 
Table III.11 
Table 111.12 
Table 111.13 
Table 111.14 
Table III.15 
Table 111.16 
Enteric-Protected Film Polymer Formulation with 100 g of 30-35 
Mesh Size Antigen Loaded Beads  71 
Enteric-Protected Film Polymer Formulation with 100 g of 20-25 
Mesh Size Antigen Loaded Beads  72 
Enteric-Protected Film Polymer Formulation with 100 g of 14-18 
Mesh Size Antigen Loaded Beads  73 
Theoretical Enteric Film Coat Level Predication  78 
Cumulative Percentage Released of LPS form Enteric-Coated 
Antigen Microspheres Applied with Different Amounts of Polymer 
with One Hour Acid Pre-treatment  82 
Cumulative Percentage Release of LPS From Different Size of 
Enteric Coated Antigen Microspheres with Predicted Polymer 
Coating Level  84 
Cumulative Percentage Released of TNP-LPS form Enteric-Coated 
Antigen Microspheres Applied with Different Amounts of Polymer 
with One Hour Acid Pre-treatment  89 
Cumulative Percentage Released of BSA form Enteric-Coated 
Antigen Microspheres Applied with Different Amounts of Polymer 
with One Hour Acid Pre-treatment.  91 
Cumulative Percentage of Release of LPS From ECAMs Prepared 
Under Different Coating Temperatures 
Summary of Glass Transition Temperatures of Eudragit L-30D 
Latex incorporated with Different Plasticizers Measured by 
Differential Scanning Calorimetry (DSC) 
96 
103 
Cumulative Percentage Release of LPS from Enteric-coated 
Antigen Microsphere Incorporated with TEC as a Plasticizer  115 
Cumulative Percentage Release of LPS from Enteric-coated 
Antigen Microspheres Incorporated with PEG-6000 as a Plasticizer 116 
Cumulative Percentage Release of LPS from Enteric-coated 
Antigen Microspheres Incorporated with DBS as a Plasticizer  117 
Cumulative Percentage Release of LPS from Enteric-coated 
Antigen Microspheres  at  Different pH Dissolution Medium 
Without Acid Pre-treatment  118 Table III. 17 Cumulative Percentage Release of LPS from Enteric-coated 
Table 111.18 
Table IV.1
 
Table IV.2
 
Table IV .3
 
Table IV.4
 
Table IV.5
 
Table IV.6
 
Table V.1 
Table V.2 
Table V .3
 
Table V .4
 
Table V.5 
Table V.6 
Table V.7 
Table V.8 
Antigen Microspheres at Different pH Dissolution Medium with 
Acid Pre-treatment  119
 
Cumulative Percentage Release of LPS from Enteric-coated
 
Antigen Microspheres at Different Storage Condition  120
 
Antigen Dose Regimens For TNP-LPS Experiment  156
 
Antigen Dose Regimens For TNP-KLH Experiment  157
 
Abbreviation Used In Chapter IV  158
 
Buffer used in ELISA  159
 
Serum Antibody Activity of Fish Immunized with TNP-LPS  160
 
Serum Antibody Activities of Fish Immunized with TNP-KLH  161
 
Multiple Range Analysis of Disintegration Characteristics of
 
Enteric-coated Microspheres Incorporated with Explotab® by
 
Tukey's (HSD) Test  183
 
Multiple Range Analysis of Disintegration Characteristics of Non 
Enteric coated Microspheres Incorporated with Explotab®  184
 
Time of Breaking Up Explotab® Incorporated Enteric-coated
 
Films  194
 
Percentage  of LPS  Released  From  Enteric-coated  Beads
 
Incorporated with Explotab®  195
 
Water Uptake of Pure Explotab® Powder  196
 
Swelling Work Generated by Pure Explotab® Powder.  197
 
Liquid Uptake of Enteric-coated Beads Incorporated with Different
 
Level of Explotab®  198
 
Liquid Uptake of Non Enteric-coated Beads Incorporated with
 
Different Level of Explotab®  199
 FISH ORAL ANTIGEN DELIVERY SYSTEM DEVELOPMENT
 
AND OPTIMIZATION
 CHAPTER I
 
INTRODUCTION
 
Oral administration is the most practical procedure for vaccinating large numbers 
of fish.  Its advantages over immersion and intraperitoneal  injection include no extra 
labor involved and no stress in handling as is the case with conventional methods. 
However,  oral vaccination has relatively lower efficacy than  that of immersion and 
injection method due to denaturation or partial deactivation of antigens in fish stomach. 
Protection of the antigens against stomach acidity and enzymic secretions by an enteric 
film coat may allow passage of the intact antigens to the action site and induce optimal 
immune responses.  The successes of oral vaccination of fish are not only dependent 
upon the immune system and physiology of the fish,  but also the designed antigen 
delivery dosage form.  Chapter II deals with development and validation  of a size 
exclusion HPLC method for analysis of prototype antigens,  LPS and TNP-LPS.  The 
analytical conditions were optimized in terms of antigen's peak resolution and retention 
time.  Development and optimization of an oral antigen delivery  system are presented 
in Chapter III.  The suitable size of the antigen carrier, types and amounts of polymer, 
adjuvants in the delivery system and optimized processing conditions are described in 
detail in this chapter.  Dissolution, pH and storage stability of the system are also 
included.  Chapter IV focusses on the in vivo evaluation of developed antigen delivery 
system in coho salmon (Oncoryhnchus kisutch).  The result of fish antibody activities 
induced by two different types of antigen is described  in detail in this chapter.  The 
potential of new strategies for oral delivery of antigens are also discussed.  Chapter V 2 
mainly deals with the modification of the designed antigen delivery system.  The effects 
of sodium starch glycolate on the antigen release pattern and release rate are presented. 3 
CHAPTER II
 
QUANTITATIVE DETERMINATION OF LPS AND TNP-LPS BY
 
SIZE EXCLUSION HPLC METHOD
 
ABSTRACT 
A simple and sensitive size exclusion HPLC method has been developed for 
quantifying E. Co li lipopolysaccharide (LPS) and trinitrophenylated-lipopolysaccharide 
(TNP-LPS).  Lipopolysaccharides are an important immunogenic class of antigens. 
Simple quantitative determination procedures for LPS and TNP-LPS are important both 
for studying immunological response in fish and developing oral vaccine delivery system. 
Size exclusion chromatography (SEC) was employed and 2-acetamidophenol was used 
as an internal standard to quantify LPS.  The standard curves for LPS were linear and 
reproducible over a 100-fold range of concentrations in  distilled water from 50 rig /ml 
to 5 µg /ml and 0.5 µg /ml to 50 µg /ml.  Correlation coefficients of 0.999 were observed 
for both within-day and day-to-day standard curves of concentration range from 0.5 to 
50 µg /ml.  At the concentration range from 50 ng/m1 to 5000 jg /ml,  the correlation 
coefficients were 0.995 and 0.997 respectively for within-day and day-to day standard 
curves. The within-day coefficient of variation (CV%) of LPS standard curves was 0.4 
to 8.36%, and corresponding day-to-day variation was 0.51 to 8.90%.  The mean 
accuracy of this assay was 98.98% and 102. 99% at two concentration levels.  The 
method also allows a linear response over a 40-fold range of TNP-LPS concentrations 
in simulated gastric fluid,  intestinal fluid and distilled water. The effect of eluent ionic 4 
strength, flow rate and pH on retention and resolution was investigated.  Retention time 
of LPS and TNP-LPS decreased as the mobile phase pH increased.  Increasing of the 
ionic strength caused the retention time of LPS and TNP-LPS to increase but the 
resolution decreased. The optimum condition for analysis of LPS and TNP-LPS was 
pH 6.5 potassium phosphate buffer as a mobile phase and flow rate at 1.8 ml/min. The 
standard curve of TNP-LPS was also reproducible with correlation coefficient of 0.99, 
mean accuracy of 98.85%. 5 
INTRODUCTION 
Using an enteric-protected vaccine to immunize fish is believed to be the most 
efficient way to orally deliver the vaccine to the fish'.  Antigens can be delivered to the 
intestine where the gut associated lymphoid tissue reside without being denatured by 
stomach's low pH environment and enzyme system. Lipopolysaccharide (LPS) of gram-
negative microorganisms used in this study has proven to be a useful tool to study 
lymphocyte activation and differentiation2.  Conjugated LPS with trinitrophenyl hapten 
(TNP) can be used to examine the role of various carrier molecules in the production of 
antibody to a defined antigenic determinant.34  However bacterial LPS also elicits a 
complex pattern of inflammatory reactions when introduced  into circulation  of 
mammals'''.  The levels of LPS in plasma have been quantitatively reflected in  a 
multitude of parameters that are assumed to play a significant role in the development 
of multiple organ failure: tumor necrosis factor-a; interleukin 1 and interleukin 6; the 
activation state of the complement, kallekrein- kinin,  coagulation,  and fibrinolytic 
system; polymorphonuclear granulocyte activation products; and the circulating levels 
of vasoactive intestinal polypeptide 7,8,9,10,11,12.  Quantitative determination of LPS in 
biological fluids could be essential for examination of various stages of illness associated 
with gram negative infections.  Quantitative determination of LPS release rate from 
antigen delivery systems can be helpful for dosage form design and accessing optimum 
antigen dose response in fish.  In the past, LPS as an endotoxin was mostly assayed by 
biological means such as pyogenicity tests  in rabbits'3'14,  the local Sanarelli­6 
Shwartzman reaction'',  silver stain in polyacrylamide gels' and metachromatic 
The most favored approach now is the Limulus Amebocyte lysate assay (LAL) which 
was first applied by Cooper et al. to test for pyrogens in parenteral pharmaceuticals's. 
No method has been reported thus far to quantify TNP-LPS directly.  Inhibition ELISA 
may be used to determine  the amount of TNP-LPS.  But biological assays require 
skilled technical personnel to perform in order to maintain the methods accuracy and 
precision. The whole process of biological assays are not only time consuming, but also 
impractical for testing large number of samples.  The metachromatic assay, because of 
its low sensitivity and lack of specificity, has limited usage in practice. The LAL assay 
provides highest sensitivity and selectivity but the greatest limitation of LAL assay is the 
problem of interference of the lysate-endotoxin interaction that is caused by a variety of 
drugs and other substances. 19,20,21,22 
The purpose of this study was to develop a reliable, simple and more specific 
method to quantifying LPS and TNP-LPS in non-biological fluid. 7 
MATERIALS AND METHODS 
Chemicals 
Lipopolysaccharide (LPS,  Sigma Chemical Co., St. Louis, MO, serotype: 
055:B5),  Potassium phosphate, monobasic (Aldrich Chemical Company, Inc., 
Milwankee, WI),  2,4,6-trinitrobenzensulfonic acid (TNBS, Lot 120115951, Sigma 
Chemical Co.,  St.  Louis, MO, 95% hydrate,  5 %(w/v) aqueous solution),  2­
acetamidophenol ( Sigma Chemical Co. St. Louis, MO). 
TNP-LPS preparation 
TNP-LPS (trinitrophenyl hapten-lipopolysaccharides) was prepared as described4. 
In brief, dissolve 100 mg LPS in Cacodylic buffer (table II.1) and adjust the pH to 11.5 
with 1N NaOH. Add 60 mg TNBS to 5 ml of Cacodylic buffer in another container and 
add dropwise into above LPS solution.  Rotate the suspension for 2 hours at room 
temperature,  then dialyze using molecularporous dialysis membrane (Spectra/por® 1, 
Vol/cm: 1.7 ml, molecular weight cutoff: 6,000-8,000, Spectrum Medical Industries, 
Inc., Los Angeles, CA) against a phosphate buffer saline solution (PBS, table II. 2) for 
four times before placing the final product in a serum vial and pasteurized 30 minutes 
at 70°C.  The final product was transferred into a sterile stoppered serum bottle and 
stored at 4°C. 8 
Apparatus 
Chromatographic separation was carried out with a high performance liquid 
chromatography (HPLC) system which consists of a delivery pump (Waters M-45 Solvent 
Delivery System, Waters Associates, Milford, MA),  an automatic sample injector 
(Waters WISP Model 712, Waters Associates, Milford, MA), a C-1308 guard column 
with Perisorb® RP-18 packing material (Upchurch Scientific, Inc., Oak Harbor, WA), 
a DuPont ZORBAX® Bio Series  GF-450 size exclusion column (DuPont Company, 
Wilmington, DE), a fixed wavelength UV spectrophotometer ( Model 440, Waters 
Associates, Milford, MA,  wavelength set at 254 gym) and an integrator (C-R3A 
Chromatopac, Shimadzu Corp., Kyoto, Japan).  All connecting tubings were 0.009 
in.i.d. stainless steel.  The HPLC running conditions and data acquisition parameter 
settings were summarized in tables II. 5,  II. 6. 
Mobile Phase 
Potassium phosphate monobasic buffer solutions were prepared as mobile phase 
with pH varying from 5.5 to 8.0 (pH 5.5, pH 6.0, pH 6.5, pH 7.0, pH 8.0) and ionic 
strength changing from 0.025 to 1 Mole (0.025, 0.05, 0.1, 0.3, 0.5,  1 Mole) with 
additional NaCL at constant pH of 6.5.  Mobile phase was degassed just prior to use and 
was delivered by a dual piston reciprocating pump. The flow rate of mobile phase was 
optimized at 1.8 ml/min,  pressure at 1500+200 psi. 9 
Standard Curve 
LPS 
The LPS standard solutions were made by dissolving and diluting LPS with HPLC 
grade deionized water at different levels (tables II. 12 and II. 13).  The concentration 
of LPS standards range from 50 ng to 50 t.tg.  100 Al of each LPS dilution was vortexed 
with 100 /Al internal standard before analysis and standard curves were performed in 
triplicate. Standard solutions and internal standard can be stored at 4°C for two months 
with no detectable decomposition. 
TNP-LPS 
TNP-LPS standard solutions were prepared by dilution of TNP-LPS prepared in 
the Laba with HPLC grade deionized water, simulated gastric fluid without enzyme (table 
II. 3) and simulated intestinal fluid without enzyme (table II. 4) at different levels.  The 
serial dilutions are shown on tables II. 8, II. 9, II. 10. 100 Al of each TNP-LPS dilution 
was vortexed with 100 Al internal standard before analysis and standard curves were 
performed in triplicate.  Working standard and internal standard solutions can be stored 
at 4°C for 2 months with no detectable decomposition. 
Calculation 
Standard curves were constructed using average peak area ratios (PARs) of known 
concentrations of LPS or TNP-LPS and internal standard (2-acetamidophenol). Standard 
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curves were run each time when samples were assayed.  A linear model was fitted 
employing least-squares linear regression of peak area ratios of LPS to internal standard 
as a function of the standard LPS or TNP-LPS concentrations. 
Statistical Analysis 
Linear regression  analysis was performed on standard LPS or TNP-LPS 
concentration versus peak area ratio data. The strength of the relationship of standard 
LPS or TNP-LPS concentrations (x) and peak area ratios (y) was examined by a R test 
for independence in bivariate normal population"''. 
Let p =the correlation between standard LPS or TNP-LPS concentrations (x) and peak 
area ratios (y).
 
Null hypothesis:  Ho: p =0 (x and y are independent)
 
Alterative hypothesis:  Ha: p  0 (x and y are dependent)
 
Test Statistic: t=r/ V(1-r2)/n-2)
 
where,  r is the sample correlation coefficient,
 
r= [ E (xxave)(YYave)]/ (n-1) Sx S, 
n is the number of x, y pairs.  S>,  Sy are the x and y sample standard deviation
 
respectively.
 
The t critical value for a two-tailed test based on n-2 degree of freedom.
 
Analysis of variance (ANOVA) was used to compare the differences of retention 
time in various conditions of mobile phase. 11 
RESULTS AND DISCUSSION
 
Size exclusion chromatography (SEC) or gel chromatography25'26 is now a widely 
used technique for purification, characterization and quantifying of organic polymers''', 
proteins29,3"1,32, RNA33'34'35 and DNA''' fragments.  It is a liquid chromatography 
method,  whereby,  the  biomaterials  are  separated  by  their  molecular  size  or 
"hydrodynamic volume" in solution as solvent elutes through a column packed with a 
porous support.  The degree of retention of the bio-molecules in the pores is the 
phenomenon which affects the separation.  Smaller molecules are retained in the pores 
to a greater degree than larger molecules.  As a result the largest size molecule or the 
molecule having the greatest hydrodynamic volume elute from the column first followed 
by smaller molecules.  Pharmaceutical excipients, polymers and the antigen used in the 
designed vaccine delivery system, can be separated according to their molecular weight 
by this method. 
Chromatographic Behavior 
1. LPS 
The chromatogram of the LPS and 2-acetamidophenol separated by DuPont 
ZORBAX® Bio Series GF-450 size-exclusion column is shown in figure II.  1.  The 
retention time of LPS was affected by the pH of mobile phase.  With increasing pH, 
the retention time of LPS decreased (Fig. II. 2).  The resolution of LPS peak was not 
significantly effected by pH. As the pH increased above 7.5 the peak area ratio and the 12 
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Figure IL 1	  A Typical Chromatogram of A Sample of E.  Co li LPS Serotype 055:B5 (peak 1) and 2-Acetamidophenol (peak 2) as an Internal Standard, pH 6.5 Potassium Phosphate Buffer as Mobile Phase. 13 
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Figure II. 2	  The Effects of pH of the HPLC Mobile Phase on LPS Retention Time in 
Size Exclusion Column. Mobile phase: Potassium phosphate buffer with 
different pH levels. HPLC column: DuPont ZORBAX® bio series GF­
450. (1) (1) 
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Figure II. 3  The Effects of  pH of the HPLC  Mobile Phase  on Chromatographic Behavior of LPS  and 2-acetamidophenol.  Mobile phase:  Potassium phosphate buffer with  different pH levels.  HPLC column:  DuPont ZORBAX® bio series  GF-450. No significant changes in peak resolution of LPS (1) and 2-acetamidophenol (2) at pH ranges from 5.5 to 6.5. Peak area ratio (LPS/2-acetamidophenol)  increased as pH of mobile phase increased. (1)	  (1) 
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Figure II. 4	  The Effects of pH of the HPLC Mobile Phase on Chromatographic 
Behavior of LPS and 2-acetamidophenol.  Mobile phase: Potassium 
phosphate buffer with different pH levels.  HPLC column: DuPont 
ZORBAX® bio series GF-450. No significant changes in peak resolution 
of LPS (1), but the peak resolution of 2-acetamidophenol (2) decreased at 
pH ranges from 7.0 to 8.0.  Peak area ratio (LPS/2-acetamidophenol) 
significantly increased as pH of mobile phase increased (p < 0.05).  Ui 16 
resolution of 2-acetamidophenol decreased (Fig.II. 3,  Fig. II. 4).  The mobile phase 
buffered at pH 6.5 gave the best resolution both for LPS and internal standard peaks. 
At pH 6.5 a relatively short retention time for the analysis of LPS was needed.  At pH 
6.5,  six levels of ionic strength were employed in order to examine chromatographic 
behavior of LPS.  Results showed that increasing of the ionic strength caused the 
retention time of LPS to increase (Fig. II. 5), but no significant effects were observed 
on peak resolution.  Because halide salts are corrosive to stainless steel of the column 
during long term analysis,  it is suggested that pH 6.5 potassium phosphate buffer with 
no additional ion added is the optimal condition for analysis of LPS,  therefore this 
buffer was selected for the size exclusion HPLC mobile phase for routine assay. 
2. TNP-LPS 
The chromatogram of the TNP-LPS and 2-acetamidophenol separated by GF-450 
size-exclusion column is shown in Figure II. 6.  Peak 1 and peak 2 could be conjugated 
LPS and unconjugated LPS. Because these two peaks can not be separated well by size 
exclusion chromatography under the present conditions, the total area of these two peaks 
were counted as the total amount of antigen (TNP-LPS) in the sample.  The retention 
time of TNP-LPS was also affected by the mobile phase's pH.  With increasing pH, 
the retention time of TNP-LPS decreased (Fig.II. 7),  the resolution of TNP-LPS peak 
was slightly effected by pH.  pH 6.5 buffer gave the best peak resolution and retention 
time thus this pH was chosen from five different pH levels.  When the pH fixed was at 
6.5,  six levels of ionic strength were employed in order to examine chromatographic 17 
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Figure II. 5  The Effects of Ionic Strength of The HPLC Mobile Phase on LPS 
Retention Time in Size Exclusion Column.  Mobile phase: Potassium 
phosphate buffer with different pH levels.  HPLC column: DuPont 
ZORBAX® bio series GF-450. 18 
behavior of TNP-LPS. Results indicated that increasing of the ionic strength caused the 
retention time of TNP-LPS to increase (Fig. II.  8),  but the resolution decreased. 
Mobile phase of a pH 6.5 with no additional ions added was considered the optimal 
chromatographic condition. 
Assay Validation 
It is essential to employ well-characterized and fully validated analytical methods 
to yield reliable results which can be satisfactorily interpreted'. Accuracy and precision 
are the most important criteria in the assessment of an analytical method, and monitoring 
quality control during sample analysis to ensure the validity of reported results'. The 
validation of size exclusion HPLC analysis was performed to examine the assay method 
accuracy, precision,  reproducibility and standard curve linearity.  To achieve this 
purpose,  three independent standard  curves were prepared and three known 
concentration samples were assayed on the same day and on five consecutive days to test 
variances of peak-area ratios obtained during the analysis. 
Linearity and precision 
1. LPS 
The standard curves were linear over 100 fold ranges of LPS concentrations 
diluted by deionized water from 50 rig to 5µg and 0.5 pcg to 50 p, g .  The correlation of 
peak-ratio and standard concentrations of LPS proved to be statistically significant by R 
test at 1% level. The correlation of coefficients (r) were 0.999 for both within-day and 19 
Figure II. 6	  A Typical  Chromatogram  of  a  Sample  of  Trinitrophenylated­
lipopolysaccharide TNP-LPS (E. Coli LPS, serotype 055:B5) and 2­
acetamidophenol as an Internal Standard (3). pH 6.5 Potassium phosphate 
buffer was used as mobile phase. Peak (1) and peak (2) were counted as 
the total amount of antigen (TNP-LPS) 20 
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Figure II. 7	  The Effects of pH of The HPLC Mobile Phase on TNP-LPS Retention 
Time in Size Exclusion Column.  Mobile phase: Potassium phosphate 
buffer with different pH levels. HPLC column: DuPont ZORBAX® bio 
series GF-450. 21 
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Figure II. 8	  The Effects of Ionic Strength of The HPLC Mobile Phase on TNP-LPS 
Retention Time in Size Exclusion Column.  Mobile phase: Potassium 
phosphate buffer with different pH levels.  HPLC column: DuPont 
ZORBAX® bio series GF-450. 22 
day-to day standard curves at high LPS concentrations (Fig. II. 9), and 0.995 (within­
day), 0.997 (day-to-day, Fig. II. 10) for low LPS concentrations,  respectively (table 
II. 12,  table II. 13). 
Within-day precision was assessed by analysis three different standard curves. 
Day-to-day precision was determined from standard curves prepared on each of 5 
separate days.  The range of coefficients of variation was 0.55-4.83% (within-day 
precision) for low LPS standard concentrations and 1.07-8.36% for high LPS standard 
concentrations,  while the range of coefficients of variation (day-to-day precision) was 
0.51 to 5.53% and 0.36-8.90% for low and high LPS concentrations,  respectively 
(tables 11.7,  II. 8). 
2. TNP-LPS 
The standard curves were linear over 40 fold range of TNP-LPS concentrations 
diluted by deionized water, simulated gastric fluid and intestinal fluid. The correlation 
of peak-ratio and standard concentrations of TNP-LPS were statistically significant 
(p <0.01). The correlation of coefficients (r) were to 0.998, 0.997 and 0.998 respectively 
for deionized water,  gastric fluid and intestinal fluid (Fig. II. 8, II. 9, II. 10). 
Precision was based on the calculation of the coefficient of variation (CV%). 
Within-day variation was assessed by simultaneously analyzing three different standard 
curves.  Day-to-day variation was evaluated by preparing separate standard curves over 
a five day period.  Tables II. 8,  II. 9 and II. 10 show the coefficients of variation of 
within-day and day-to-day for TNP-LPS diluted by deionized water, gastric fluid and 23 
intestinal fluid.  The range of coefficients of variation of within-day was 0.44-8.28%, 
0.72-8.88% and 0.55-4.74%, while the range of coefficients of variation of day-to-day 
was 1.32-8.29%, 0.20-3.77% and 0.81-4.26% for deionized water, gastric fluid and 
intestinal fluid respectively. 
Accuracy 
1. LPS 
Known amounts of LPS were prepared at two different concentration ranges. 
Aliquots of these samples were analyzed for LPS in triplicate over a 5 day period. 
The accuracy was determined by comparing the nominal concentrations with measured 
concentrations.  The results of the study are summarized in table II. 9.  The mean 
accuracies were 98.98%, 102.99% and the coefficients of variation (CV%) were 3.13% 
and 0.5% for high and low concentrations of LPS, respectively. 
2. TNP-LPS 
The accuracy was determined by comparing the nominal concentrations with 
measured concentrations.  Known concentrations of TNP-LPS prepared in deionized 
water, simulated gastric fluid and intestinal fluid were analyzed in triplicate over a 5 day 
period.  The results of the study are shown in table II. 6.  The mean accuracy was 
98.59%, 98.83% and 100.26% and the coefficients of variation (CV%) ranged from 1.63 
to 6.43%. 24 
The present high performance size exclusion liquid chromatography analytical 
method can be used to quantify LPS in the range of 50 rig /ml to 50  ug /ml, TNP-LPS 
in the range from 5 to 200 µg /ml.  The method is simple and specific, making it 
suitable for oral vaccine delivery system studies.  Quantitative determination of LPS 
helps  to  characterize LPS release  rate  patterns from enteric-protected  antigen 
microspheres and develop an optimal oral antigen delivery system for fish". 25 
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Figure II. 9	  Standard Curves of LPS Concentrations vs. Peak Area Ratios. LPS 
concentration ranged from 0.5 to 50 µg /m1.  Solid line indicates the 
regression line of LPS within-day assay, dash line indicates the regression 
line of LPS day to day assay. Correlation coefficients (r) for () within-
day assay and (v) day to day assay are 0.999 and 0.999, respectively 
(both significant at 1% level). 26 
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Figure II. 10 Standard Curves of LPS Concentrations vs. Peak Area Ratios. LPS 
concentration ranged from 50 to 5000 rig /ml.  Solid line indicates the 
regression line of LPS within-day assay, dash line indicates the regression 
line of LPS day to day assay. Correlation coefficients (r) for () within-
day assay and (v) day to day assay are 0.997 and 0.998, respectively 
(both significant at 1% level). 27 
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Figure II. 11 Standard Curves of TNP-LPS Concentrations vs. Peak Area Ratios. TNP­
LPS concentration ranged from 20 to 200/4/m1 in deionized water. Solid 
line indicates the regression line of LPS within-day assay,  dash line 
indicates the regression line of LPS day to day assay.  Correlation 
coefficients (r) for () within-day assay and (v) day to day assay are 
0.997 and 0.997, respectively (both significant at 1% level). 28 
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Figure II. 12 Standard Curves of TNP-LPS Concentrations vs. Peak Area Ratios. TNP­
LPS concentration ranged from 5 to 200/2g/m1 in simulated gastric fluid. 
Solid line indicates the regression line of LPS within-day assay, dash line 
indicates the regression line of LPS day to day assay.  Correlation 
coefficients (r) for () within-day assay and (v) day to day assay are 
0.994 and 0.993, respectively (both significant at 1 % level). 29 
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Figure II. 13 Standard Curves of TNP-LPS Concentrations vs. Peak Area Ratios. TNP­
LPS concentration ranged from 10 to 200µg /ml in simulated intestinal 
fluid.  Solid line indicates the regression line of LPS within-day assay, 
dash line indicates the regression  line of LPS day to day assay. 
Correlation coefficients (r) for () within-day assay and (v) day to day 
assay are 0.997 and 0.997,  respectively (both significant at 1% level). 30 
CONCLUSIONS
 
The correlations of peak area ratios and standard concentrations of LPS and TNP­
LPS were significant (p <0.01) with correlation coefficients above 0.99. The coefficients 
of variations (CV%) of precision and accuracy of this analysis were within acceptable 
limits ( < 15 %)37. 
Size exclusion HPLC with UV detection appears to be an easy, specific, precise 
and accurate method to quantify LPS and TNP-LPS in non-biological fluids.  This 
technique will be an important technique for assessing various formulations developed 
for oral vaccine delivery.  With some modification, such as increasing the HPLC 
injection volume or using more sensitive detector or concentrating the samples,  this 
assay method may be used in quantifying LPS in biological fluid. 31 
Table II.  Composition of Cacodylic Buffer (0.28 M) 1 
Components  Amounts
 
Cacodylic Acida  60 g/ml (trihydrate)
 
44.8 g/ml (anhydrous) 
0.1 Molar NaOH  Adjust pH to 7.0 
aSigma Chemical Company, St. Louis, Missouri 32 
Table II. 2  Composition of Phosphate Buffered Saline,  PBS 
Components  Amounts / Volume 
NaCLa  8.0 g 
Na2HPO4. 7H20a  2.0 g 
KH2PO4a  0.2 g 
KCLa  0.2
 
Distilled Water  1000 ml
 
For convenience, a 10X PBS solution was usually prepared and diluted to one-tenth of 
its volume immediately before use. 
'Sigma Chemical Company, St. Louis, Missouri 33 
Table II. 3  Composition of U. S. P. Simulated Gastric Fluid without Enzymes 
NaC1  2.0 g 
HCL  7.0 ml 
H2O  add to  1000 ml 
pH adjusted to 1.2 ±0.1 34 
Table II. 4  Composition of Intestinal Fluid without Enzymes 
KH2PO4	  6.8 g 
0.2 N NaOH	  190 ml 
H2O	  add to  1000 ml 
pH adjusted to 7.5+0.1 35 
Table II. 5  Size Exclusion HPLC Assay Condition 
Column  ZORBAX, GF-450 
Guard Column  Perissorb® RP-18 
Detector  UV, 254 rim 
Mobile Phase  Phosphate Buffer, pH 6.5 
Flow Rate  1.8 ml/min 
Pressure  1500+200 Psi 
Running Time  10 Minutes 
Internal Standard  2-Acetamidophenola
 
Sample Injection Volume  50-70A1
 
'Lot 38F3584 Sigma Chemical Co. St. Louis, MO 36 
Table II. 6	  LPS and TNP-LPS Analysis: Peak Processing Related Parameters by Shimadzu 
Chromatopac C-R 3A Data Processor 
Peak Processing Parameters  Recording Parameters  Calculation Method 
WIDTH' (sec)  5  ATTENb (mV/fullscale)  4  41C 
SLOPE" (AV/min) 
MIN. AREAg 
(count) 
DRIFT" (V/min) 
T. DBI) 
STOP. TMj(min) 
2k-3.51e 
1500 
0 
0 
9 
SPEED' (mm/min)  5 
'minimum peak width 
brecorder sensitivity 
area normalization method 
"peak detection sensitivity 
`value setting is automated by S.TEST 
(chart speed 
speak area less than that setting are eliminated 
"degree of baseline drift, [0]: automatic 
`parameter alteration time, [0]: automatic 
analysis ending time Table II. 7  The Components of Different pH's of Mobile Phase and Retention Times of LPS and TNP-LPS 
Mobile Phase  0.1 Molar  0.1 Molar  Retention Time (min)  Peak Area Ratio'  Retention Time (min) 
pH  KH2PO4 (m1)  NaOH (m1)  LPS,  Mean+SDa  LPS, Mean+SlY  TNP-LPS,  Mean+SlY 
pH 5.5  1000  30  6.153 + 0.006  1.681+0.025  5.833±0.017 
pH 6.0  1000  112  6.108±0.014  1.736±0.033  5.826+0.011 
pH 6.5  1000  278  6.048+0.007  1.750±0.027  5.803+0.015 
pH 7.0  1000  582  6.010+0.018  1.707+0.062  5.797+0.013 
pH 7.5  1000  822  5.967+0.042  1.842 + 0.061  5.762+0.017 
pH 8.0  1000  934  5.963 ±0.008  2.014±0.071  5.747+0.010 
the mean and standard deviation of 4 replicates for each pH condition of mobile phase 
bpeak area ratio, LPS/2-Acetamidophenol 38 
Table II. 8  Analytical Precision for Assay of TNP-LPS in Deionized Water 
Within-day (n=3)'  Day-to-Day (n=5)b 
Conc.  Peak Area Ratio  CVd  Peak Area Ratio  CVd 
(µg /m1)  (mean±SD)`  (%)  (mean+SD)`  (%) 
0 0  0 
20  0.806 +0.038  4.715  0.769+0.025  3.251 
40  1.850+0.153  8.270  1.750+0.089  5.086 
60  2.826+0.012  0.425  2.635+0.218  8.273 
80  3.702+0.167  4.511  3.684+0.155  4.207 
100  4.644+0.222  4.780  4.595+0.257  5.593 
140  6.312+0.312  4.943  6.385 + 0.086  1.347 
160  7.883 + 0.280  3.552  7.524+0.296  3.934 
200  9.819+0.302  3.076  9.728 + 0.129  1.326 
Slope  0.048+0.001  3.544  0.047 + 0.001  4.834 
R2  0.997  0.997 
'analysis on the same day 
'analysis on five different days 
`the mean and standard deviation of 3 replicates 
d coefficient of variation (%) 
the mean and standard deviation of 3 replicates assay on 5 different days 39 
Table II. 9  Analytical Precision for Assay of TNP-LPS in Simulated Gastric Fluid 
Within-day (n=3)'  Day-to-Day (n=5)" 
Conc.  Peak Area Ratio  CVd  Peak Area Ratio  CVd 
(µg /m1)  (mean±SD)'  (%)  (mean±SD)'  (%) 
0 0  0 
5  0.055+0.005  9.091  0.050+0.005  9.862 
10  0.105+0.009  8.571  0.103+0.003  2.913 
20  0.363 + 0.020  5.510  0.327+0.005  1.529 
40  1.184+0.024  2.027  1.091 + 0.013  1.192 
60  1.995+0.014  0.702  1.944+0.073  3.755 
80  2.903+0.025  0.861  2.860+0.060  2.098 
100  3.805+0.229  6.018  3.779 + 0.037  0.979 
140  5.712+0.113  1.978  5.720+0.011  0.199 
160  6.931 +0.198  2.857  6.740+0.270  4.006 
200  8.605 +0.598  6.949  8.713+0.152  1.744 
Slope  0.044 + 0.001  2.273  0.044+0.001  2.262 
R2  0.994  0.993 
'analysis on the same day 
'analysis on five different days 
`the mean and standard deviation of 4 replicates 
d coefficient of variation (%) 
the mean and standard deviation of 3 replicates assay on 5 different days 40 
Table II. 10  Analytical Precision for Assay of TNP-LPS in Simulated Intestinal Fluid 
Within-day (n=3)"  Day-to-day (n=5)" 
Conc.  Peak Area Ratio  CVd  Peak Area Ratio  CVd 
(µg /ml)  (mean+SD)°  ( %)  (mean±SD)e  (%) 
0 0  0 
10  0.251+0.011  4.382  0.219+0.006  2.740 
20  0.802+0.004  0.499  0.779 + 0.033  4.236 
40  1.764+0.039  2.211  1.718+0.065  3.783 
60  2.710+0.020  0.738  2.752+0.059  2.144 
80  3.671 +0.174  4.740  3.633 ±0.053  1.459 
100  4.773 +0.163  3.415  4.696+0.110  2.342 
140  6.402+0.171  2.671  6.439+0.052  0.806 
160  7.810+0.191  2.446  7.693 + 0.166  2.158 
200  9.709+0.446  4.594  9.770+0.086  0.880 
Slope  0.048 ±0.001  3.642  0.048 ±0.001  1.023 
R2  0.997  0.997 
'analysis on the same day 
'analysis on five different days 
the mean and standard deviation of 4 replicates 
'coefficient of variation (%) 
`the mean and standard deviation of 3 replicates assay on 5 different days 41 
Table II. 11  Analytical Accuracy for Assay of TNP-LPS 
Deionized Water'  Gastric Fluidc  Intestinal Fluidd 
Mean+SDb (n=3, µg /m1)  Mean ±SDb (n=3, µg/ml)  Mean+SDh (n=3, µg /ml) 
True Conc.  100+00  True Conc.  100 ±00  True Conc.  100+00 
Obs. Conce.  98.59+6.34  Obs. Conce.  99.83+1.33  Obs. Conce.  100.26+0.83 
CV (%)`  6.43  CV (%)f  1.33  CV (%)f  0.83 
Accuracy(%)  98.59  Accuracy(%)  98.83  Accuracy(%)  100.26 
'TNP-LPS samples were prepared in deionized water 
b the mean and standard deviation of 3 replicates
 
eTNP-LPS samples were prepared in simulated gastric fluid
 
dTNP-LPS samples were prepared in simulated intestinal fluid
 
'measured concentration 
(coefficient of variation % 42 
Table II. 12 Analytical Precision for Assay of LPS At Concentration Rang 
from 0.5  µg /ml to 50 µg /ml 
Within-day (n=3)a	  Day-to-Day (n=5)b 
Conc.  Peak Area Ratio  CVd  Peak Area Ratio  CVd 
(item')  (mean±SD)`  (%)  (mean±SD)`  (%) 
0 0	  0 
0.5  0.0396+0.019  4.83  0.0411+0.0012  2.90 
1.25  0.1861 ±0.0080  4.30  0.1926+0.0107  5.53 
2.5  0.3493+0.0059  1.69  0.3471+0.0018  0.51 
5  0.7372+0.0020  0.27  0.7317 + 0.0074  1.01 
10  1.0812+0.0042  0.39  1.0607+0.0238  2.25 
15  1.7872+0.0080  0.45  1.738 ±0.0363  2.09 
20  2.3124+0.0373  1.61  2.2752+0.03146  1.38 
30  3.6314+0.0474  1.31  3.5282+0.1036  2.94 
40  4.6663+0.0243  0.52  4.6356+0.0686  1.48 
50  5.997+0.0793  1.32  5.8685+0.1167  2.00 
Slope	  0.119+0.001  0.83  0.117+0.009  0.76 
IV  0.999  0.999 
aanalysis on the same day 
banalysis on five different days 
C the mean and standard deviation of 3 replicates 
dcoefficient of variation (%) 
'the mean and standard deviation of 3 replicates assay on 5 different days 43 
Table II. 13  Analytical Precision for Assay of LPS At Concentration of 
50 ng/m1 to 5000 ,fig /ml. 
Within-day (n=3)a  Day-to-Day (n=5)b 
Conc.  Peak Area Ratio  CVd  Peak Area Ratio  CVd 
(ng/ml)  (mean±SD)°  (%)  (mean±SD)`  (%) 
0  0  0 
50  0.0112+0.0009  8.36  0.0103+0.0009  8.90 
125  0.0193 ±0.0010  5.02  0.0188+0.0005  2.57 
250  0.0281+0.0026  9.40  0.0363+0.0012  3.32 
500  0.0580+0.0044  7.68  0.0587+0.0006  1.10 
1000  0.1809+0.0090  4.95  0.1965+0.0156  7.94 
1500  0.3056+0.0203  6.65  0.3144+0.0088  2.79 
2000  0.4231+0.0058  1.37  0.4141 ±0.0089  2.15 
3000  0.6512+0.0159  2.43  0.6489+0.0023  0.36 
4000  0.8477+0.0196  2.31  0.8675+0.0197  2.27 
5000  1.1198+0.0120  1.07  1.1000+0.0203  1.84 
Slope  2.17x104+6.23x10-6  1.66  2.16x10-4+2.64x10'  1.22 
R2  0.995  0.997 
aanalysis on the same day 
b analysis on five different days 
the mean and standard deviation of 3 replicates 
d coefficient of variation (%) 
'the mean and standard deviation of 3 replicates assay on 5 different days 44 
Table II. 14	  Analytical Accuracy for Assay of LPS At Concentration Range 
from 0.5 to 50 µg /ml and 50 jg /m1 to 5000ng/ml. 
LPS Concentration from  LPS Concentration from 
0.5 to 50 µg /ml  50ng/m1 to 5000 ng/ml.
 
Mean ±SDa (n=3, µg /m1)  Mean+SlY (n=3, rig /ml)
 
True Conc.  40+00  True Conc.  3000+00
 
Obs. Conch.  39.59+1.24  Obs. Conch.  3089.75+15.35
 
CV (%)C  3.13  CV (%)C  0.50
 
Accuracy(%)  98.98  Accuracy(%)  102.99
 
a the mean and standard deviation of 3 replicates 
bmeasured concentration 
`coefficient of variation (%) 45 
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CHAPTER III 
ORAL ANTIGEN DELIVERY SYSTEM DEVELOPMENT AND
 
OPTIMIZATION
 
ABSTRACT 
Lipopolysaccharides (LPS), trinitropheylated lipopolysaccharides (TNP-LPS) and 
bovine serum albumin (BSA) are valuable immunogenic antigens in aquaculture. The 
enteric formulation of these antigens could be valuable to understand oral administration 
of vaccines and help develop oral vaccine delivery systems.  Antigen delivered to the 
intestine where the gut associated lymphoid tissues (GALT) reside can induce not only 
systemic specific antibody response, but also secretory immunity.  In this study a pH 
sensitive,  aqueous polymeric dispersion system,  Eudragit L-30D, was applied onto 
antigen loaded pellets by fluid-bed technique to form an enteric-coated antigen 
microsphere (ECAM) delivery system.  The antigen release characteristics of this 
ECAMs system was evaluated by a modified USP rotation basket method.  The 
thickness of polymer coated film of the ECAM should be about 29 ',cm (theoretical) for 
any size antigen carrier and for any type of antigen incorporated to have enteric 
protection.  20%w/w (based on polymer solid contents) TEC was the most efficient 
plasticizer in Eudragit L-30D mixture in terms of enteric protection and release rate, 
followed by total of 30% w/w of 1:1 combination of TEC and DBS.  DBS was not a 
good plasticizer  in the Eudragit L-30D coating dispersion.  PEG has relatively 
complicated effects on the film formation and antigen release.  The plasticization effect 50 
and antigen release pattern of PEG is dependent upon its molecular weight and the total 
amount of PEG in the coating dispersion.  It was observed that a high percentage of 
PEG and TEC in the coating film decreased the antigen  release rate. 
Key words: Lipopolysaccharide;  Enteric-coating; Antigen; Oral delivery system; oral 
vaccination; polymer; plasticizer. 51 
INTRODUCTION 
The best solution for preventing infectious diseases in fish is by immunization, 
and the emphasis for prevention was placed on the vaccine development. Many studies 
indicate that injection and immersion vaccination were the most common and successful 
methods. However, vaccination by injection has severe limitations when large number 
of small fish are involved.  Also immersion and injection create excessive stress on the 
fish caused by handling  or anaesthesia.  Among other methods,  the oral route was 
believed to be the only practical method for mass vaccination of fish of all sizes.  Its 
advantages over other methods of vaccination  include no stressful handling and  no 
interference with routine fish husbandry.  Antigens can be incorporated into fish feed 
and fed to fish for a suitable time course.  However, most trials of oral vaccination have 
resulted  in  relatively low efficacy 1,2,3,4,5,6  compared to  injection and immersion 
vaccination.  Previous studies revealed that orally delivered  antigens were totally or 
partially inactivated in fish stomach and did  not produce an immune response, 
However,  antibody production and protection against microorganism  challenge was 
successful when the antigens were placed into the lower intestine'.  This indicated that 
denaturation or partial deactivation of highly purified antigens such as isolated microbial 
products (viral glycoproteins, bacterial enzymes) by gastric hydrochloric acid followed 
by digestion with proteolytic enzymes, their limited absorption,8'9  essentially represents 
only minute amounts of ingested antigens  to small intestine,  therefore influence the 
outcome of the desired immune response. 52 
The optimal immune response will be induced  if delivery of the antigens is 
directly to the upper intestine where the gut associated lymphoid tissues (GALT) reside. 
Protection of the antigen against stomach acidity and enzymic secretions by enteric 
coating may allow passage of the intact antigens  to the intestinal tract where the 
interaction with the immune system and antigen uptake occurs.  Recently, Wong et al. 
confirmed that the serum and mucus antibody levels of salmonid fish after administration 
of enteric-coated Vibrio anguillarum vaccine were significantly higher than that of control 
fish and fish given unprotected vaccine.  They also found that the survival rate of 
enteric-coated vibrio group was significantly higher than that of control fish but was 
equivalent to fish given unprotected vaccine10.  Oral immunization of fish with enteric­
protected vaccine would be inexpensive,  easy and convenient. Frequent boosting would 
also possible.  Furthermore, because of the presence of a common mucosal immune 
system, oral administration of antigens might be expected to induce protective immune 
responses at multiple mucosal sites. 
Several novel antigen delivery approaches  are under development.  Antigen 
packing into liposomes, as discussed by Michalek et al." or biodegradable microcapsules 
(Eldridge et al.)' have yielded promising results.  In animals,  both vaccine 
formulations have been shown to enter Peyer's patches via M cells and initiate secretory 
and /or systemic immune responses.  Even more important is  the finding that 
microencapsulation of antigens into optimally sized particles that remain in the Peyer's 
patches for a desired  time period (depending on the chemical composition  of 
biodegradable material) would induce a prolonged immune response due to the continued 53 
stimulation of resident B and T cells.  Rombout et al. also found that the delivery of 
vaccine in the form of microencapsule preparations might provide a means of protecting 
the antigen from digestive secretions  thereby providing a more effective vaccination 
method of fish'. 
Oral vaccination of fish not only initiates secretory immune responses, but also 
the systemic immune response. However, the immune system and the physiology of the 
fish would be different from the animals  aforementioned,  therefore,  the successes of 
oral vaccination of fish is dependent upon the immune system of the fish and the antigen 
delivery system. The ideal oral antigen delivery system for fish should have the right 
size and release adequate amount antigens to the right site of action. Wong" found that 
the diameter of fish pyloric sphincter depended on the weight and length of fish.  He 
suggested that the size of oral delivery dosage form should be considered when applied 
to small fish. 
The main objective of the present study was to develop an enteric-protected 
antigen delivery system which would not only have the right size suitable for the fish, 
but also protect antigens from degradation and denaturing in the hostile environment of 
the stomach and target delivery of the antigens to the fish second gut segment to induce 
the desired immune  responses.  Physiological parameters such  as  the pH of 
gastrointestinal fluid may influence the rate of antigen release from the delivery system, 
therefore, the influence of the pH of the dissolution medium on antigen release rate was 
also investigated.  Several coating formulations and coating  process parameters were 
evaluated. 54 
In the pharmaceutical industry, fluid-bed  technique can be used for drying, 
granulation and in coating for controlled-release and enteric-release. A number of solid 
dosage forms have been produced in the form of film coated pellets that can be enclosed 
in hard gelatin capsules or compressed into tablets.  Film coats are used to provide 
good appearance, taste masking,  stability,  enteric-release,  sustained and controlled 
release. Many immunogenic antigens  are proteins,  peptides, polysaccharides and 
lipopolysaccharides. Orally administered antigens,  especially protein antigens, need to 
be protected from enzymatic and/or acid-catalyzed chemical degradation in the stomach 
to allow delivery to the major absorption sites in  the intestine.  An enteric-protected 
solid dosage form seems to be a rational approach for oral fish vaccination. Pellet type 
microspheres of the appropriate size, smaller than  the size of fish and the diameter of 
fish pyloric sphincter,  are usually less affected by the food contents in fish stomach. 
They will randomly distribute throughout the gastrointestinal (GI) tract when they are 
orally administered and tend to have a more reproducible upper GI transit pattern.  They 
provide a relatively more consistent antigen release rate than monolithic dosage forms, 
especially if comparing the dosing in the fed and fasted state. 
Because of drastic increases in the price of organic  solvents,  the explosion 
hazard, toxicity,  different aqueous based latex systems have  been developed.  In 
aqueous systems,  water-insoluble enteric polymers  can be applied either as the 
ammonium salt,  colloidal latex or pseudolatex dispersion  or as a micronized particle 
suspension.  The properties of film coats produced by ammonium salts are reported 
differently, and there is no evidence whether all these films provide protection against 55 
gastric juice14'15 or not'.  One study indicates that  some of the ammonium salt 
preparations produce coatings that  are less gastro-resistant than their corresponding 
organic-solvent based film'''.  Similar results were obtained using  suspensions of 
micronized polymer particles in which it was mentioned that a higher film thickness was 
necessary to provide gastro-resistance.  Chang' and Mehta et al. concluded that the 
latex dispersions had excellent enteric coating qualities after using fluid-bed technology. 
Among other aqueous dispersion enteric-coating polymers, Eudragit® L-30D can produce 
films with excellent enteric qualities and smooth homogenicity17,  thus in the present 
study 30% (w/v) of polymethacrylic acid-ethylacrylate (PMA-EA), Eudragit® L-30D, 
was  used  as  the  enteric-coating  material.  Lipopolysaccharide  (LPS)  and 
trinitrophenylated-lipopolysaccharides (TNP-LPS) were used as model antigens, since 
LPS of Gram-negative microorganisms  has proven to be a useful tool in  study of 
lymphocyte activation and differentiation's.  When LPS is conjugated with trinitrophenyl 
hapten (TNP),  it can be used to examine the role of various carrier molecules in the 
production of antibody to a defined antigenic determinant."  Bovine serum albumin 
(BSA) was also used as a model protein antigen. 56 
MATERIALS AND METHODS 
Antigen carrier 
14-18, 20-25, 25-30 and 30-35 mesh size of NU-PARELL® PG, Sugar Spheres 
NF (Ingredient Technology Corporation, Pennsauken, NJ) were used in the study.  NU­
PARELL® PG is a product of uniform,  mostly spherical, white beads,  composed of 
sucrose and starch NF. 
Antigens 
Lipopolysaccharide (LPS, Sigma Chemical Co.,  St. Louis, MO, serotype: 
055:B5),  trinitrophenylated-lipopolysaccharides (TNP-LPS), bovine  serum albumin 
(BSA, lot# 99F0017, Sigma).  TNP-LPS was prepared as described.'  In brief, 
dissolved 100 mg LPS in Cacodylic buffer and adjusted the pH to 11.5 with IN NaOH. 
Added 60 mg TNBS (2,4,6-trinitrobenzensulfonic acid, Lot #120H5951, Sigma Chemical 
Co., St. Louis, MO., 95% hydrate, 5 %(w/v) aqueous solution) to 5 ml of Cacodylic 
buffer in another container and added dropwise into above LPS solution.  Rotated the 
suspension for 2 hours at room temperature,  then dialyzed using molecularporous 
dialysis membrane (Spectra/por® 1, Vol/cm:  1.7 ml, molecular weight cutoff: 6,000­
8,000,Spectrum Medical Industries, Inc., Los Angeles,  CA) against a phosphate buffered 
saline solution (PBS) for four times before placing the final product in a serum vial and 
pasteurized 30 minutes at 70°C.  The final product was transferred into  a sterile 
stoppered serum bottle and stored at 4°C. 57 
Enteric Coating Materials 
Eudragit® L-30D (Rohm Pharma, Weiterstadt, West Germany) was chosen as 
enteric coating material.  It is 30% aqueous dispersion of an anionic copolymer based 
on methacrylic acid and ethyl acrylate, mean molecular weight is 250,000 daltons and 
the pH ranges from 2.0 to 3.0.  It is milk-white liquid of low viscosity.  When dry it 
forms a clear film.  This coating is insoluble in gastric fluid, in pure water and in buffer 
solutions of pH below 5.0,  but is soluble in intestinal juice and in neutral to weekly 
alkaline buffer solutions, pH above 5.5, and by forming salts with alkalis.  Figure III. 
1 is the general chemical structure of polymethacrylic acid-ethylacrylate (PMA-EA). 
Plasticizer and Lubricant 
The plasticizers impart flexibility to a polymer, they interpose themselves between 
the polymer chains and interact with the forces which hold the chains together thereby 
extending and softening the polymer matrix.  Triethyl citrate (TEC, Aldrich Chemical 
Company, Inc., Milwaukee, WI), Dibutyl sebacate (DBS, Sigma Chemical Co., St. 
Louis, MO), Dibutyl phthalate (DBP, Mailinckrodt, Inc, St. Louis, MO), Polyethylene 
glycol (PEG, Aldrich Chemical Company, Inc., Milwaukee, WI) were  used as 
plasticizers. 
Talc 
Small amount of talc (USP powder, Matheson Coleman & Bell, East Rutherford, 
NJ) was used as a separating substance and glidant to reduce the tendency of Eudragit® 58 
L-30D to agglutinate during the application process and helps to make the surface of the 
film smooth. 
Reagents for Lowry's Protein Assay 
Al (2% sodium tartrate) solution was made by dissolving 2.0 grams of sodium 
tartrate, Na2C4H4O6 in 100 ml of deionized water.  A2 (1 % copper sulfate) solution was 
prepared by dissolving 1.0 gram of CuSO4. 5H20 (Sigma Chemical Co., St. Louis, MO) 
in 100 ml of deionized water.  A3 (2% sodium carbonate) was made by dissolving 20.0 
grams of Na2CO3 (Sigma Chemical Co., St. Louis, MO) in 1 liter of 0.1 N NaOH. 
Solution A was prepared by mixing A1, A2 and A3 in  a 1:1:100 ratio.  Folin & 
Ciocalteu's Phenol Reagent in 2.0 Normal was purchased from Sigma and a 1:1 dilution 
in deionized water (solution B) was used during the assay. 
Antigen Coating 
The fluid-bed unit used in antigen and polymer coating has a bench-top spray 
coating chamber and a seven-inch Wurster column (Figure 111.2,  Strea-1,  Aeromatic 
Inc., Columbia, MD) which is approximately 1.5 cm away from the bottom of screen 
of the coater, and it is also incorporated with Lab-line/P.R.L.  High Speed Fluid Bed 
Dryer (Lab-line/PRL, Melrose Park, IL). 
100 grams of non-pareil sugar beads were loaded into pre-heated modified fluid 
bed bottom spray (Wurster) coater without air distributor plate  at 65°C (protein antigen 
coated at 40°C). When the sugar bead's temperature equilibrated with coating  unit, the 59 
beads were pre-coated with about 3% gelatin to increase the surface adhesiveness. After 
the precoating, 0.03% LPS or TNP-LPS or 5% BSA (based on weight of the sugar 
beads) dissolved or diluted with appropriate amount of gelatin solution was applied onto 
sugar beads. Antigen inlet was controlled at relatively slow speed to avoid the problem 
of sugar bead agglomeration caused by high solubility of sugar beads.  A 0.8 mm 
bottom spray nozzle was used and the nozzle pressure was maintained at 18 ± 2 psi, 
blower speed was set at 40 to 50% of full capacity to allow and keep the beads freely 
moving. Antigens were constantly delivered by a peristaltic pump (Mnipuls 2 peristaltic 
pump, Gilson Medical Electronics, Middleton, WI) at rate of 2 to 3 milliliter per minute. 
The antigen solution was kept mixing by using a magnetic stirring bar during the whole 
process of coating to ensure solution homogeneity. When smaller size beads were used 
in the study,  the top of the coating chamber was covered with fine nylon cloth to stop 
beads from flying out of the chamber. 
After the coating process, the pellets were dried in the coating chamber for 
another 5 minutes at the same temperature and air flow. When the antigen coated beads 
were removed from the coating chamber, they were kept in a 37°C oven overnight before 
application of enteric polymer.  After drying,  the beads were sieved to remove both 
agglomerated and fine particles. The coating conditions, antigen delivery rate, blower 
speed were varied depending upon the beads sticking /tackiness behavior during the 
antigen coating process.  The coating process conditions are summarized in table III. 1. 60 
Enteric Film Coating 
The apparatus used for enteric film coating was the same as that used in the 
antigen coating.  Eudragit® L-30D was diluted with deionized water and magnetically 
stirred for 45 minutes, Eudragit® L-30D  was sometimes sieved with 20 mesh size 
standard screen scale (The W. S. Tyler Company, Mentor,  OH) in order to remove the 
polymer clumps and to keep polymer dispersion homogeneity.  Plasticizers were added 
followed by another 45 minutes of stirring and then USP talc power was added to the 
above mixture and thoroughly mixed for 30 minutes.  A typical formulation used for 
enteric-coating was shown in table 11.2-5.  The container holding this suspension  was 
covered throughout the mixing and coating to prevent solvent evaporation.  100 grams 
of antigen loaded beads were used for enteric film application. The coating dispersion 
was supplied by a peristaltic pump from the bottom of the column  at a rate of 6 to 7 
ml/min. The inlet air temperature was set at 65°C (40°C for protein antigen), except in 
coating temperature effect study,  35°, 40° and 45°C inlet temperature  were also used. 
Due to the tackiness of polymer mixture,  manually changing of the polymer delivery 
speed from time to time was sometimes necessary to prevent the bead agglomeration 
within the coating chamber.  The coated spheres were dried in the coating chamber for 
10 minutes after completion of the coating  process. The 1:1 mixture of 15 % DBS and 
15% TEC (based on enteric coating solid contents)  was always incorporated into 
Eudragit® L-30D mixture in the enteric-coatings except in the plasticizer effect study. 
Different types and amounts of plasticizers  were tested in the plasticizer study. 
Different of percentages of the Eudragit L-30D was applied based on the dry 61 
weight of antigen loaded beads in order to optimize enteric protection  and antigen 
release.  5, 10, 20, and 30 % w/w (theoretical) polymer mixture coated beads were 
compared in terms of enteric protection and antigen release rate in this study. 
Dissolution 
The dissolution behavior of enteric-protected LPS, TNP-LPS or BSA was studied 
using a modified United States Pharmacopeia (USP) XXI rotation basket method in a six-
spindle dissolution tester (Vanderkamp® 6000, Van-Kel Industries,Inc.,  Chatham, NJ). 
Each 100 ml flask was filled with 50 ml of dissolution medium and placed in a waterbath 
cooled to 12°C.  Spindle rotation speed was set at 100 rotations per minute (rpm). 
Dissolution tests were performed in triplicate.  Each replicate contained 5 grams 
(2 grams for BSA microspheres) of formulated microspheres.  The first hour of 
dissolution testing was conducted in enzyme-free pH 1.5 simulated gastric fluid followed 
by transferring the coated beads to a pH 7.2 simulated intestinal fluid for the remainder 
of the test procedure.  All dissolution media was degassed for 30 minutes before  use. 
At one hour, when the spindle was stopped,  the level of the baskets was raised until 
they were above the gastric fluid and allowed to drain for 5 minutes.  The excess gastric 
fluid was absorbed by paper towels and the gastric fluid was replaced with temperature-
equilibrated intestinal fluid. 
Samples of 0.5 ml dissolution media were withdrawn from the dissolution medium 
and replaced with an equal volume of fresh temperature-equilibrated gastric  or intestinal 
fluid to maintain constant fluid volume. The samples were collected at 15, 30, 45 and 62 
60 minutes during the one hour acid pre-treatment in gastric fluid,  then samples were 
collected after switching to intestinal fluid at 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6 and 9 hours. 
The above samples were filtered through 20 Gage  5µm filter needle (Brunswick 
Company, St. Louis. MO) before assay.  The amount of LPS or TNP-LPS released in 
the dissolution medium as a function of time  was determined by a size exclusion high 
performance liquid chromatography (HPLC) method described in Chapter II.  100 ptl of 
each filtered dissolution sample was votexed with 100 µl internal standard prior to the 
HPLC assay.  The amount of BSA released in dissolution medium from ECAMs as 
function of time was determined by modified Lowry22 protein assay method.  In brief, 
to each dissolution sample, 2 ml of solution A was added.  After 10 minutes, 200 pl 
of reagent B was added.  The absorbance was read at 500 7im after 30 minutes of 
incubation. 
HPLC Apparatus 
Size exclusion high performance liquid chromatography (HPLC) system consists 
of a delivery pump (Water M-45 Solvent Delivery System, Waters Associates, Milford, 
MA), an automatic sample injector (Waters WISP Model  712, Waters Associates, 
Milford, MA), a C-1308 guard column with Perisorb® RP-18 packing material (Upchurch 
Scientific, Inc., Oak Harbor, WA),  a DuPont ZORBAX® Bio Series GF-450 size 
exclusion column (DuPont Company, Wilmington, DE),  a fixed wavelength UV 
spectrophotometer ( Model 440, Waters Associates, Milford, MA),  wavelength at 254 
77m and an integrator (C-R3A Chromatopac, Shimadzu Corp., Kyoto, Japan).  All 63 
connecting tubings were 0.009 in.i.d. stainless steel. 
Film Coat Thickness Estimation 
The film wall thickness was estimated using modified equation described by 
Madan et a123.  It is briefly derived as follows: 
% Coating = W, / Wb  (1) 
where W, is the weight of the coating polymer; Wb is the weight of bead core.  If the 
bead core is spherical then Equation 1 becomes: 
% Coating = 7 d2 T pp / (1/6)  7 d3 pb  (2) 
where d is the diameter of the sphere; T is the polymer coating thickness;  p, is the 
density of the polymer coating material;  pb is the density of the bead core.  Rearrange 
Equation (2), the relationship of polymer coating thickness and coating level  can be 
established: 
T = (d pb / 6 p d* (% Coating)  (3) 
Bead Core Density Measurement 
One thousand antigen loaded beads of 25-30 mesh size or the other mesh sizes of 
antigen uncoated beads were used to determine the average diameter and weight of a 
sphere of the various mesh sizes.  The density was calculated in terms of the sphere 
volume (g/m1): 
Pave = 6 Wave / 7r dave3  (4) 
where W is the average weight of a sphere;  d is the average diameter of a sphere. 64 
Scanning Electron Microscopy (SEM) 
Coated and uncoated antigen microspheres  were examined under a scanning 
electron  microscopy (Amray 1000A, Amray, Bedford, MA) to  determine the 
morphological differences of applied films  on the pellets under different coating 
conditions.  Sample beads were cut in half with a sharp surgical blade. The cross-
sectional SEMs and surface SEMs of the coated beads were obtained with a variety of 
magnifications. 
Plasticizer Effect Study 
TEC, DBS and PEG of different molecular weights  were incorporated in the 
Eudragit® L-30D suspension to examine plasticizer effects on the antigen release rate 
from enteric-films plasticized by different types and amounts of plasticizers. 
Thermal Mechanical Analysis (TMA) 
The TMA was used to investigate the effectiveness of the plasticizers in lowering 
the glass transition temperature (Tg) of polymethacrylic acid-ethylacrylate (PMA-EA) 
plasticizer mixtures. The thermal changes resulting from plasticizers dispersed in  the 
polymer were analyzed with a Perkin-Elmer Differential Scanning Calorimetry (DSC) 
4/TADS system (Perkin-Elmer Corp., Norwalk, CT) with  a computer and plotter 
interface.  Film samples were prepared by spraying coating material onto watch glass 
under the same conditions as the film coating of antigen microspheres.  The films were 
later pealed off and oven dried prior to thermal analysis. The instrument was calibrated 65 
with an indium standard. About 3-5 mg film samples were placed into aluminum pans 
and sealed.  Analysis was done over the temperature range of 25 to 200°C at a rate of 
20°C/min.  In glass transition measurements,  it is common to pre-heat samples above 
the glass transition temperature,  however this technique was not used in the present 
study because in many cases when it was employed, the thermograms obtained did  not 
show glass transitions. 
pH Sensitivity 
The pH sensitivity of Eudragit L-30D was determined by in vitro dissolution 
analysis. The enteric-coated antigen microspheres  were exposed to different pH levels 
of dissolution medium with or without pH 1.5 simulated gastric-fluid pre-treatment. 
Stability Test 
The antigen dissolution analysis was conducted after the enteric-coated antigen 
microspheres were stored at -5°C for one year and at room temperature for one year and 
six months. 
Antigen Coating Efficiency 
For each batch of enteric-coated product, 5 grams of coated beads  were randomly 
taken and ground into a fine powder and then transferred to a 50 ml volumetric flask 
with 30 ml of intestinal fluid.  The powder sample was agitated for 4 hours.  An 
aliquot of this solution was filtered through 20 Gage 5µm filter needle and assayed by 66 
the HPLC method.  Triplicate determinations were performed to obtain batch antigen 
coating process efficiency.  The amount of LPS, TNP-LPS and BSA released in the 
dissolution medium was normalized each time with batch coating efficiency. 67 
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Figure 111.1	  Chemical Structure of an Anionic Copolymer Based on Methacrylic Acid 
And Ethyl Acrylate (Eudragit® L-30D). The ratio of the carboxyl groups 
to the easter group is approximately 1:1. The mean molecular weight is 
250,000. 68 
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Figure III. 2. Cross Section of STREA-1 Fluid-Bed Spray Coater Fully Assembled 69 
1 Table III.  Typical Process Condition for Antigen or Enteric-film Coating 
Parameter  Amount or Setting 
Bed load  100 gm 
Wurster insert  bottom spray 
Pump  peristaltic 
Column  7" Wurster 
Nozzle size  0.8 mm 
Inlet temperature  65 or 40°C 
Atomization air  15-18 psi 
Fluidization air blower  40-50% of full capacity 
Flow rate  2.5-6.5 ml/min intermittentlya 
Spray time  0.5-1.5 hr 
Dry time  5- 15 min 
Coating level  very 
aPeristaltic pump was manually turned on or off as necessary to control clumping of 
beads during the coating process. 70 
Table III. 2  Enteric-Protected Film Polymer Formulation with 100 g of 25-30 Mesh 
Size Antigen Loaded Beads 
Components  Weight (g)  Dispersion (g) 
Eudragit L-30D  14.0 (polymer solids)  46.7 
(14% w/w based on antigen loaded beads) 
(70% w/w based on total Polymer & 
Plasticizer solids) 
TEC (Triethyl Citrate)  3.0  3.0 
(3% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
DBS (Dibutyl sebacate)  3.0  3.0 
(3% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
Talc  1.0  1.0 
(5% w/w based on total Polymer & 
Plasticizer solids) 
Water  46.7 
Total solids =21 % w/w based on dried antigen loaded beads 71 
Table III. 3  Enteric-Protected Film Polymer Formulation with 100 g of 30-35 Mesh 
Size Antigen Loaded Beads 
Components  Weight (g)  Dispersion (g) 
Eudragit L-30D  15.4 (polymer solids)  51.3 
(15.4% w/w based on antigen loaded beads) 
(70% w/w based on total Polymer & 
Plasticizer solids) 
TEC (Triethyl Citrate)  3.3  3.3 
(3.3% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
DBS (Dibutyl sebacate)  3.3  3.3 
(3.3% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
Talc  1.1 
(5% w/w based on total Polymer & 
Plasticizer solids) 
Water  51.3 
Total solids =23.1% w/w based on dried antigen loaded beads 72 
Table 111.4  Enteric-Protected Film Polymer Formulation with 100 g of 20-25 Mesh 
Size Antigen Loaded Beads 
Components  Weight (g)  Dispersion (g) 
Eudragit L-30D  11.9 (polymer solids)  39.7 
(11.9% w/w based on antigen loaded beads) 
(70% w/w based on total Polymer & 
Plasticizer solids) 
TEC (Triethyl Citrate)  2.55  2.55 
(2.55% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
DBS (Dibutyl sebacate)  2.55  2.55 
(2.55% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
Talc  0.85  0.85 
(5% w/w based on total Polymer & 
Plasticizer solids) 
Water  39.7 
Total solids =17.9% w/w based on dried antigen loaded beads 73 
Table 111.5  Enteric-Protected Film Polymer Formulation with 100 g of 14-18 Mesh 
Size Antigen Loaded Beads 
Components  Weight (g)  Dispersion (g) 
Eudragit L-30D  7.7 (polymer solids)  25.7 
(7.7% w/w based on antigen loaded beads) 
(70% w/w based on total Polymer & 
Plasticizer solids) 
TEC (Triethyl Citrate)  1.65  1.65 
(1.65% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
DBS (Dibutyl sebacate)  1.65  1.65 
(1.65% w/w based on antigen loaded beads) 
(15% w/w based on total Polymer & 
Plasticizer solids) 
Talc  0.55  0.55 
(5% w/w based on total Polymer & 
Plasticizer solids) 
Water  25.7 
Total solids =11.6% w/w based on dried antigen loaded beads 74 
RESULTS AND DISCUSSION 
The principal of a Lab-line/PRL Hi-Speed Fluid Bed Dryer is to constantly 
provide heated air which is blown through the material to be dried by exposing a vast 
surface area which enables the materials to be dried very quickly and at a relatively 
lower temperature.  The detrimental effects of excessive heat and moisture, especially 
hot moisture on moisture-sensitive antigens can be minimized by the use of fluid-bed 
drying processing.  It is designed to cause drying of atomized antigen liquid droplets 
having a large surface area allowing solvent evaporation to occur at a relatively lower 
temperature than normally required in conventional oven or vacuum oven. 
The properties of final porous beads and the thickness and intensity of the coat 
can be influenced by many factors.  The factors include the beads themselves, coating 
techniques such as inlet temperature, position of the spray nozzle, spraying air pressure, 
spray fluid volume and fluid sending velocity; characteristics of the spray fluid, such as 
density,  viscosity and temperature; equipment such as orifice diameter of the nozzle 
and the formulation used
24, 25 26, 27, 28.  The position of the spray nozzle directly affects 
the impingement of spray droplets on the substrates,  and hence,  the structure of the 
film. The coating chamber geometry influences particle motion and distribution,  and 
therefore,  affects the disposition of coating materials on the substrate.  It is essential 
that the coating conditions be optimized. The effect of bead load in the coating chamber 
on the release rate of coated pellets is also an important factor to be considered.  Yang 
et al.' reported that formulations with a bed-load of 600 grams released propranolol 75 
HCL at a slower rate than similarly coated pellets from bed-load of 300 grams due to the 
differences of the particle movement in the coating chamber.  In present study the bed-
load was kept constant in order to obtain batch-to-batch antigen release reproducibility 
and consistency. 
Film thickness after coating is another important parameter in the formulation of 
enteric dosage forms.  Too little coating can result in an antigen delivery system failure 
in the acidic environment of the stomach. Too much coating in the formulation  may 
delay antigen release in the intestinal tract such that antigen absorption and /or uptake 
are inadequate to induce an immune response.  Therefore an effective enteric coating 
in a well-designed antigen delivery system must protect antigens from the acid 
environment of the fish stomach and release most of antigens when the delivery system 
passes into the small intestine.  Because of increased concern over antigen or drug 
bioavailability, the reliability and predictability of enteric coating are of great importance. 
It is essential to develop an antigen delivery system which is capable of delivering 
antigens at an effective rate,  to the desirable site for an appropriate duration of time 
required for optimal absorption.  The antigen delivery system should be capable of 
modulating the gastrointestinal transit time of fish so that the antigen delivery system  can 
be transported to a target site or target cells and reside there for a prolonged period of 
time to maximize the delivery of antigens. 
One of the rate limiting steps for the bioavailability of vaccine is the dissolution 
of the antigens themselves.  The faster and more complete the dissolution, the more 
bioavailable of antigen becomes. The principle site for drug absorption usually resides 76 
in the small intestine, and for antigens, besides absorption,  uptake and interaction with 
the gut associated lymphoid tissues (GALT),  which is an important part of the total 
secretory immune system, also occur. Using an acid-insoluble, pH-sensitive polymer, 
polymethacrylic acid-ethylacrylate (PMA-EA) to target deliver antigen to the upper small 
intestine will result in the best absorption and/or uptake of antigens,  mass stimulation 
of lymphocytes and finally the optimal specific antibody response. 
Wong concluded that the gastric emptying time of salmonide fish was about 2 
hours and barium sulfate suspension would stay in the fish intestine about 6 to 8 hours". 
The desired antigen delivery system should be stable in the low pH condition for about 
2 hours and readily release the antigen when the system reaches the fish intestine. 
Enteric-Coating Level Effects 
Less than 1% of LPS was released from 20 % (w/w) Eudragit L-30D coated beads 
(25-30 mesh size) in simulated gastric fluid but no detectable LPS was released from 
30% Eudragit coated beads. When the beads were switched to intestinal fluid the rate 
at which LPS was released increased dramatically. Dissolution results indicated that time 
to reach 50% release of LPS for 5%, 10%, 20% and 30% (w/w) Eudragit L-30D coated 
beads was 10 minutes, 15 minutes, 2.5 hours and 3.5 hours respectively (Fig.II1.3). 5% 
and 10% Eudragit coated beads released LPS in simulated gastric fluid and did not 
provide any enteric protection.  With 5% Eudragit coating 100% of LPS was released 
from the formulation within a half hour in the gastric fluid, while the 10% Eudragit 
coated formulation released 89.4% during first hour of acid treatment and the rest of the 77 
LPS released 15 minutes after switching to the intestinal fluid.  In intestinal fluid 20% 
(w/w) Eudragit coated beads released 100% LPS in 7 hours and the 30% (w/w) Eudragit 
coated ones released 70% LPS at 8 hours (Fig.III. 4, table III. 6).  The optimum 
percentage of Eudragit L-30D film coating (for 25-30 mesh size beads) was 20% (w/w) 
to impart enteric protection of the delivery system (Fig.III. 1).  The observed average 
diameter and average weight of 20% (w/w) Eudragit coated microspheres were 0.75 mm 
and 0.269 mg respectively with a density of the coating being 1.199 g /ml calculated by 
Equation 4.  Therefore the theoretical film thickness of 20% (w/w) Eudragit L-30D 
coated microspheres was estimated as 28.28 Am using Equation 3.  The dissolution 
study suggests the  microspheres be covered with about 29 pm polymethacrylic acid­
ethylacrylate (PMA-EA) mixture for the antigen to be protected from gastric acid. 
Rearranging Equation 3, the following equation will be formed, 
%Coating Level = 6 T pp/ d pb  (5) 
where,  T is the coating film thickness,  pp is the density of the polymer coating 
material, d is the diameter of the beads to be coated,  pb is the average density of the 
bead core. 
If the average size and weight of the antigen carrier are known for polymer 
coating,  the estimation of theoretical protecting coat level can be obtained by using 
Equation 4 and 5.  Using the identical film thickness obtained for 25-30 mesh size 
microspheres,  the theoretical protecting polymer coat level of 14-18, 20-25 and 30-35 
mesh sized beads were estimated ( Table III. 7).  The theoretical enteric protecting film 
coat level calculated for 14-18, 20-25 and 30-35 mesh size beads were 11,  17 and 22% 78 
respectively. 
Table III. 6  Theoretical Enteric Film Coat Level Predication 
Bead Size  Diameter*  Density  Film Thickness  %Coating  Observed Film** 
(mesh)  (mm)  (g/m1)  (m)  Level (w/w)  Thickness(um) 
14-18  1.287  1.310  28.28  11  18.75 
20-25  0.846  1.239  28.28  17  20.00 
25-30  0.753  1.199  28.28  20  26.1 
30-35  0.599  1.371  28.28  22  not tested 
* average value of 50 measurements 
** average value determined from SEM observation of 5 coated beads 
Dissolution test results supported this estimation, as shown in Figures III. 5 and 
Table III. 8.  14-18 and 20-25 mesh size antigen loaded microspheres have very good 
enteric protection in simulated gastric fluid, while 30-35 mesh size antigen loaded beads 
released less than 9% LPS in gastric fluid.  The observed critical coating level is 
inversely proportional to sphere size and sphere density, which may be mathematically 
predicted. Fewer experiments,  such as dissolution tests to screen the optimal coating 
level,  would be necessary if this technique is employed. 
The average observed film thickness obtained from SEM as listed in table 11.7 
was thinner than theoretical value, possibly due to lost of the coating material to the 79 
coating chamber walls and through exhaust from the coating chamber during the coating 
process, thus less than 100% recovery was observed.  Figure III. 6,. 7 and 8 are the 
sugar beads without any coating, with only the gelatin layer and the enteric-protected 
coat respectively. 
Consistent  antigen  release  pattern  was observed  with TNP-LPS loaded 
microspheres.  Dissolution of 10%, 20% and 30% (w/w) enteric coated TNP-LPS 
microspheres showed that 10% (w/w) Eudragit coated TNP-LPS formulation released 
about 69% of the total antigen in gastric fluid within one hour and 100% of antigen 
released in 1.25 hours.  20% and 30% (w/w) Eudragit coated TNP-LPS microspheres 
released less than 6% of total of antigen in simulated gastric fluid in one hour, however, 
20%(w/w) Eudragit coated formulation's release rate was faster than 30% (w/w) coated 
formulation. It released about 84% of TNP-LPS in 6 hours while 30% Eudragit coated 
formulation released only 61% (Fig. III. 8, table III. 9). 
10% Eudragit coated BSA microspheres released about 43% BSA in simulated 
gastric fluid within one hour, while 20 and 30% Eudragit coated beads released less than 
6% of BSA in simulated gastric fluid. 20% Eudragit coated microspheres released BSA 
at relatively faster rate than the 30% Eudragit coated ones (Fig. III. 9,  table III. 10). 
Studies suggest that antigen release pattern of LPS, TNP-LPS and BSA loaded 
microspheres is dependent upon the polymer film thickness. 80 
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Figure 111.3	  The Dissolution Profiles of LPS Coated Oral ECAMs with Different 
amounts of Polymer.  Dissolution was conducted at pH 7.2 simulated 
intestinal fluid with one hour pH 1.5 simulated gastric-fluid pre-treatment. 81 
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Figure III. 4 Time of 50% Release of LPS From Enteric Coated LPS Microspheres. 
LPS loaded microspheres coated with different amount of Eudragit L-30D. 
Dissolution was conducted at pH 7.2 simulated intestinal fluid with one 
hour pH 1.5 simulated gastric-fluid pre-treatment. 82 
Table III. 7  Cumulative Percentage Released of LPS form Enteric-Coated Antigen 
Microspheres Applied with Different Amounts of Polymer with One Hour 
Acid Pre-treatment 
LPS cumulative percentage release from ECAMs, (mean +SD)a 
Time (Hr) 
5% Eudragit  10% Eudragit  20% Eudragit  30% Eudragit 
0.00  0.00 ± 0.00  0.00 +0.00  0.00 ± 0.00  0.00+0.00 
0.25  87.05 +5.16  50.73 +3.63  0.62 + 0.88  0.00+0.00 
0.50  95.22 ±5.82  75.18 ±2.77  0.86 + 1.21  0.00 + 0.00 
0.75  100.22 +3.59  78.33 ±2.98  0.60 + 0.85  0.00 + 0.00 
1.00  99.67 ±3.39  89.41 +7.46  0.60 +0.84  0.00 + 0.00 
1.25  100.00  100.00 ±3.07  7.36 + 0.78  0.88± 1.24 
1.50  100.00  100.00 ±7.64  20.36 ±4.85  11.45 ± 1.55 
1.75  100.00  100.00 ±3.93  30.28 + 7.91  20.46 + 0.74 
2.00  100.00  100.00 + 1.17  41.99 ±9.41  29.42 + 4.41 
2.50  100.00  100.00 + 0.72  54.34 ±7.12  43.33 + 4.87 
3.00  100.00  100.00 + 1.44  65.04± 10.24  65.37 ±6.99 
4.00  100.00  100.00 + 0.72  85.87 + 27.35  86.87 + 9.02 
6.00  100.00  100.00 + 0.99  100.00± 10.81  100.76 + 2.68 
9.00  100.00  100.00 + 3.20  100.00 + 4.64  100.22 +7.40 
a mean values of three replicates and standard error. Dissolution was conducted at 
pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric fluid pre­
treatment. 83 
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Figure III. 5	  In vitro Dissolution Profiles of Different Size of ECAMs with Predicted 
Polymer Coating Levels. Dissolution was conducted in pH 7.2 simulated 
intestinal fluid with one hour pH 1.5 simulated gastric fluid pre treatment, 
100% release based on theoretical amount of antigen contained in beads. 84 
Table 111.8  Cumulative Percentage Release of LPS From Different Size of Enteric 
Coated Antigen Microspheres with Predicted Polymer Coating Level 
LPS cumulative percentage release from ECAMs, (Mean + SD)a 
Time (Hr) 
14-18 Mesh  20-25 Mesh  25-30 Mesh  30-35 Mesh 
11 %Eudragie  17 %Eudragit2  20 % Eudragit  22 %Eudragit2 
0.00  0.00+0.00  0.00+0.00  0.00 ±0.00  0.00 + 0.00 
0.25  0.00 ±0.00  0.96 ±0.88  0.62 ±0.88  1.36 + 1.32 
0.50  0.00 +0.00  1.57 +0.24  0.86 +1.21  1.46+ 1.46 
0.75  0.00 + 0.00  1.59 ±0.16  0.60 ±0.85  4.21 ±2.15 
1.00  0.00 ±0.00  1.60+0.19  0.60 ±0.84  8.32 ±3.57 
1.25  23.46+3.75  25.88+9.04  7.36 +0.78  32.75 + 11.08 
1.50  44.55 ±9.18  49.42+10.04  20.36 + 4.85  39.05 ±9.51 
1.75  59.57 ±6.95  60.93 ±10.88  30.28+7.91  47.79 ±7.38 
2.00  75.05 ±7.34  69.16 ±14.09  41.99 ±9.41  55.66 ±7.58 
2.50  93.91+8.40  92.48+7.19  54.34+7.12  58.38 +5.08 
3.00  100.67 ±7.26  100.51 ±6.23  65.04 + 10.24  70.35 + 11.69 
4.00  100.67 +7.26  100.51 +6.23  85.87 +27.35  80.89 +5.77 
5.00  85.78+9.58 
6.00  100.67 +7.26  100.51 +6.23  100.00+ 10.81  92.06+ 11.62 
9.00  100.67 +7.26  100.51 +6.23  100.00 +4.64  100.31+12.97 
'mean values of three replicates and standard error. Dissolution was conducted at pH 
7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric fluid pre-treatment. 
b  predicted Eudragit coating levels.  Coating level is based on the dry weight of 
antigen loaded beads before polymer coating. 85 
Figure III. 6 Scanning Electron Micrograph of a Non-pareil Sugar Bead without any 
Coating (magnification =120). The sugar bead was cut in half with a sharp 
surgical knife. 86 
Figure III. 7 Scanning Electron Micrograph of a Non-pareil Sugar Bead with 5 % (w/w) 
Gelatin Layer (magnification =120). The sugar bead was cut in half with 
a sharp surgical knife. 87 
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Figure III. 8 Scanning Electron Micrograph of a Non-pareil Sugar Bead with 5 % (w/w) 
Gelatin Layer And 20 % (w/w) Eudragit® L-30D (magnification =120). The 
sugar bead was cut in half with a sharp surgical knife. 88 
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Figure III. 9 In vitro Dissolution Profiles of TNP-LPS Coated ECAMs. Dissolution was 
conducted in pH 7.2 simulated intestinal fluid with one hour pH 1.5 
simulated gastric fluid pre-treatment. 100% release based on theoretical 
amount of antigen contained in beads. 89 
Table III. 9	  Cumulative Percentage Released of TNP-LPS form Enteric-Coated 
Antigen Microspheres Applied with Different Amounts of Polymer with 
One Hour Acid Pre-treatment 
TNP-LPS cumulative percentage release from ECAMs, (mean±SD)a 
Time (Hr)  10% Eudragit  20% Eudragit  30% Eudragit 
0.00	  0.00+0.00  0.00+0.00  0.00+0.00 
0.25	  46.63+5.44  0.00+0.00  0.93+0.64 
0.50	  53.75 ±7.25  0.00+0.00  1.15+0.67 
0.75	  62.63+0.32  0.00+0.00  4.58± 1.75 
1.00	  69.13+0.17  0.00+0.00  5.47+0.92 
1.25	  100.91+2.21  14.49+3.93  21.69+3.89 
1.50	  100.52+2.07  34.99+6.32  25.71+2.01 
1.75  100.53 + 14.71	  26.63+1.52 
2.00  100.65+14.55  43.75+6.28  27.19+2.78 
2.50	  100.01 +2.67  43.77+0.95  29.55+1.98 
3.00	  100.55+3.13  70.64 + 15.33  33.73+7.49 
4.00  100.51±2.37  69.29+8.57  47.46+6.56 
6.00  100.99±9.98  84.25+10.60  61.21+0.82 
9.00  100.87+12.14  100.43+1.29  92.46+7.27 
a the mean values of three replicates and standard error. Dissolution was 
conducted at pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric 
fluid pre-treatment. 90 
120
 
100
  !'4 
80
 
60
 
10% EUDRAGIT
 
7 20% EUDRAGIT
 
40
  v 30% EUDRAGIT
 
20
 
1 I I I I I  1  I
  1
 
0  1  2 3 4 5 6 7 8 9
 
DISSOLUTION TIME(Hr) 
Figure III.10 In vitro Dissolution Profiles of BSA Coated ECAMs. Dissolution was 
conducted in pH 7.2 simulated intestinal fluid with one hour pH 1.5 
simulated gastric fluid pre-treatment. 100% release based on theoretical 
amount of antigen contained in beads. 91 
Table III.10	  Cumulative Percentage Released of BSA form Enteric-Coated Antigen 
Microspheres Applied with Different Amounts of Polymer with One Hour 
Acid Pre-treatment 
BSA cumulative percentage release from ECAMs, (mean +SD)a 
Time (Hr)  10% Eudragit  20% Eudragit  30% Eudragit 
0.00	  0.00+0.00  0.00+0.00  0.00+0.00 
0.50	  26.23+1.64  0.42+0.37  2.81+0.34 
1.00	  43.43+1.05  1.34+0.52  5.36+0.73 
1.50	  78.99+1.35  35.29+4.69  29.43+1.16 
2.00	  88.06+2.32  73.54 + 14.42  47.63+4.22 
2.50	  95.56+2.14  86.03+9.76  57.66+3.43 
3.00  100.11 ±4.37  91.93+4.17  66.05+1.79 
4.00	  100.23+2.50  97.31+2.65  75.34+2.33 
5.00	  100.14+ 1.45  97.23+1.23  82.01+2.48 
7.50	  100.13+2.44  98.87+1.78  94.08+6.08 
9.00  100.25+2.05  101.30+2.49  102.96+6.02 
athe mean values of three replicates and standard error. Dissolution was conducted 
at pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric fluid pre­
treatment. 92 
Coating Temperature Effect 
Four different inlet air temperatures were studied to examine the coating 
temperature effect on morphological appearance of the film and the antigen release from 
ECAMs. When the enteric-protected film was applied at 35°C, 25% of LPS released 
from ECAMs in gastric-fluid within one hour (Fig.  III.  10),  while the coating 
temperature was above 40°C, less than 2% of LPS released. Also 20 %(wlw) Eudragit 
coated BSA loaded microspheres, which were coated at 40°C released less than 5 % of 
total BSA in simulated gastric fluid in one hour (Fig.III. 9) indicating that if the polymer 
film coat is prepared above 40°C it can impart a reasonable enteric protection.  Scanning 
electronic microscopy (SEM) results indicated that the coat integrity appeared better, and 
smaller, fewer pores were observed when the polymer coating temperature was higher 
(Figure III.11). The film appeared more compact and coalesced when higher temperature 
was applied. 
Plasticizer Effects 
Since many polymeric materials used in pharmaceutical formulations are brittle 
in nature, they require the use of plasticizers.  Plasticizers increase the workability, 
flexibility, and distensibility of the polymeric materials31.  The addition of a plasticizer 
modifies the physical and mechanical properties of the polymer''" and lowers the melt 
viscosity,34 elastic modulus, and glass transition temperature.3"6,37  These plasticizing 
effects are the result of the plasticizer weakening the polymer intermolecular attractions 
and increasing the polymer's free volume,  thus allowing the polymer chains to move 93 
more readily and increase its flexibility. 
The basic requirements of any plasticizer in a polymer system, including latex 
emulsions, are compatibility and permanence. To be compatible, the plasticizer should 
be miscible with the polymer which indicates similar molecular forces in the  two-
component system.  It has been theorized that the most effective plasticizers will 
generally resemble most closely in structure of the polymers they plasticize.  There are 
many plasticizers that are compatible with polymethacrylic acid-ethylacrylate (PMA-EA) 
and can be used for plasticization.' 
For a polymer with a relatively high glass-transition temperature, a plasticizer 
with a strong affinity to the polymer must be found in order to form a resistant film and 
also to produce homogeneous coatings with latex dispersions. During the film formation 
process it is important to reach the minimum film-forming temperature (MFT) or exceed 
it by 10 to 20 °C.39 The MFT can be decreased as by using different types and amounts 
of plasticizers.  This reduction is accomplished by decreasing the glass transition 
temperature (Tg),  the temperature at which a polymer undergoes a marked change in 
material properties. Below the Tg, the polymer is in the glassy state and is characterized 
by a ordered structure in which there is minimal polymer chain movement. Above the 
Tg,  the polymer is in rubbery state, which is characterized by amorphous portions or 
regions with increased polymer chain movement and polymer elasticity.  Plasticizers, 
such  as  dibutyl  sebacate,  dimethyl phthalate and triethyl  citrate  are generally 
recommended for controlled release film and enteric protected film coatings.  The 
optimal proportion of plasticizer in the polymer dispersion should be determined through 94 
experimentation in relation with the most important requirements for enteric dosage 
forms: permeability of the coating, mechanical stability, and release pattern.  If a low 
level of plasticizer is not able to overcome the resistance of the latex  spheres to 
deformation, an incomplete or discontinuous film  may result. Conversely, a high 
proportion of plasticizer may lead to bead agglomeration, sticking, and poor fluidization 
caused by excessive softening of the polymer film. 
1. Effect of No Plasticizer 
The dissolution results of antigen loaded microspheres coated with Eudragit L­
30D without plasticizers gave no gastric acid protection. 100% of the LPS  was released 
within one hour in the simulated gastric fluid (Fig.III. 11, table III. 13).  This result 
demonstrates that copolymers of methacrylic acid are brittle substances.  Enteric coats 
will have cracks and splits if no plasticizer is incorporated.  The observed glass 
transition temperature of Eudragit film formed without plasticizer was 110°C. Because 
the coating temperature was well below the glass transition temperature of the polymer 
mixture (Tp < < Tg),  it was not surprising to see a non-continuous film formed under 
these conditions. The present study suggests that the addition of a plasticizer is essential 
to have effective enteric coating and a good quality film formation. 
2. Effect of DBS 
Eudragit ®L -30D mixture with 30%, 20% and 10 % (w/w, based on polymer solids) 95 
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Figure MA 1	  In vitro Dissolution Profiles of LPS From ECAMs with Different Polymer 
Coating Temperature. Dissolution was conducted in pH 7.2 simulated 
intestinal fluid with one hour pH 1.5 simulated gastric fluid  pre­
treatment. 100% release based on theoretical amount of antigen contained 
in beads. 96 
Table III.11	  Cumulative Percentage of Release of LPS From ECAMs Prepared under 
Different Coating Temperatures 
LPS cumulative percentage release from ECAMs, (Mean +SD)a 
Time (Hr) 
20%Eudragit  20%Eudragit  20%Eudragit  20%Eudragit 
35°C Coating  40°C Coating  45°C Coating  65°C Coating 
0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00 
0.25  7.30+0.79  0.00+0.00  0.00±0.00  0.62+0.88 
0.50  11.11+2.12  0.00+0.00  0.00+0.00  0.86± 1.21 
0.75  13.84+3.00  0.00+0.00  0.00+0.00  0.60+0.85 
1.00  25.59+8.40  1.60+0.93  0.00+0.00  0.60+0.84 
1.25  33.45+10.39  21.17+2.67  23.33 +2.48  7.36+0.78 
1.50  37.26+13.87  39.01 ±7.15  37.18+2.47  20.36 + 4.85 
1.75  40.48+17.03  49.18+9.24  48.89±3.29  30.28 ±7.91 
2.00  46.79+15.15  61.36+17.43  57.40+3.63  41.99+9.41 
2.50  51.29+19.66  63.55 + 11.08  69.54+5.98  54.34+7.12 
3.00  56.87+25.91  68.09 + 11.43  77.48+3.97  64.04 + 10.24 
4.00  77.46+ 11.67  78.91 + 11.60  83.49 + 8.13  85.87 + 27.35 
6.00  87.78 + 17.07  94.32 + 13.83  97.20 ±5.43  100.00 ±10.81 
9.00  99.48 + 18.50  98.70 + 12.00  107.07 ±9.16  100.00 + 4.64 
'mean values of three replicates and standard error. Dissolution was conducted at pH 
7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric fluid  pre-treatment. 97 
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Figure 111.12 Scanning Electron Micrograph of a Non-pareil Sugar Bead with 5 %(w/w) 
Gelatin Layer and 20%(w/w) Eudragit® L-30D (magnification =1000). 
Upper = enteric film coated at 35°C;  Lower =enteric film coated at 
65°C. 98 
DBS alone did not form an enteric protected film (Fig.III. 11, table III. 13).  Probably 
because DBS is a hydrophobic plasticizer,  when it is used alone in the coating solution, 
DBS increases the minimum forming temperature (MFT) of the polymer and when it 
added into the polymer aqueous latex solution,  there was not enough time for it to 
penetrate into polymer phase of the latex particles to give any plasticizing effect. 
Thermal analysis indicated that the glass transition temperature of film with 10 and 20% 
DBS were 83°C and 50°C respectively (table III. 12). 
3. Effect of TEC 
The release rate of LPS from ECAMs in intestinal fluid decreased as the level of 
TEC increased in the ECAMs (Fig. III. 12, table 111.14). Within the one hour acid pre­
treatment period,  antigen was protected in the TEC incorporated formulations. 
30 %(w/w) TEC showed very good enteric protection, but had the slowest antigen release 
rate, while 20 %(w/w) TEC performed the best in plasticizing of polymethacrylic acid­
ethylacrylate mixture.  Thermal analysis by DSC indicated that the Tg of the TEC 
incorporated film decreased significantly from 110°C of non-plasticizer included film to 
38°C for 30%TEC, 75°C for 20% TEC and 85°C for 10%TEC incorporated films 
respectively.  It was reported that the minimum film formation temperature (MFT) could 
be reduced from 27°C to about 0°C with 10 or 20% TEC added as plasticizer in Eudragit 
L-30D4°.  The desired enteric protected film with TEC as plasticizer may be due to the 
large reduction of MFT.  This reduction of MFT was accomplished by decreasing the 
glass transition temperature. When the Tg is lower,  the latex easily coalesces to form 99 
a continuous film when the processing temperature is close to or above the Tg.  Tsaur 
and Aronson suggested that for optimal spray coating with latex, the Tg of the polymer 
and the process temperature should be chosen to fall within the temperature range (Tg-10, 
Tg +20) and probably within the range (Tg-5, Tg +10)41.  Although the measured Tg of 
10% and 20 % (w/w) TEC incorporated polymethacrylic acid-ethylacrylate film was higher 
than the coat processing temperature, the MFT reduced by addition of TEC  was so low 
that even at the temperature 20°C below the Tg, the homogeneous and continuous films 
still formed. This suggests that the MFT is a critical factor in film formation. TEC, 
because of its partial solubility (6.5%), may also affect drug release  by a slightly 
different mechanism such as solubilized cavities,  porous dissolution transport,  which 
may facilitate antigen release in the intestinal region, and proving to be a very promising 
plasticizer for Eudragit L-30D latex. However, the ratio of the polymer and TEC has 
to be re-adjusted to ensure that the TEC should be sufficient to plasticize Eudragit L-30D 
latex, so that a good quality enteric film can be formed, and the optimized LPS release 
rate can be obtained. 
4. Effect of PEG 
The release of LPS was less than 5.5% with different amounts of PEG-6000 as 
a plasticizer within one hour acid treatment, but it was observed that with increasing 
amount of PEG in the film caused the release rate of antigen to decrease. The enteric­
coated films had good enteric protection with PEG-6000 as a plasticizer.  After 9 hours, 
the cumulative percentage of LPS released from 10%, 20% and 30%(w/w) PEG added 100 
microspheres were 63.01%, 40.33% and 37.29% respectively (Fig.III. 13, table III. 15). 
Although PEG is usually used as a plasticizer for acrylic polymers,  one would expect 
PEG to increase the permeability of the polymeric film and create water channels or 
pores through which drug will be released.'  Apparently this result did not occur. The 
addition of PEG-6000 retarded the LPS release from ECAMs.  It is assumed that the 
molecular weight of PEG-6000 is large, therefore making it difficult for the PEG-6000 
to leach out to form pores and water channels in the film.  When the level of PEG-6000 
reached 30%(w/w) in the enteric film a matrix system may be formed,  and with the 
higher amounts of PEG-6000 it becomes harder for LPS to pass through the PEG-6000 
matrix and therefore slows the LPS release rate. The effects observed with PEG-6000 
incorporated into the formulation could also be due to the formation of a film which is 
not fully permeable or highly soluble at p1-1 conditions where Eudragit L-30D normally 
dissolves.  The ratio of polymethacrylic acid-ethylacrylate  to PEG-6000 should be re­
adjusted if PEG-6000 is used  as a plasticizer.  10 to 15%(w/w) of PEG-6000 is 
sufficient to plasticize the Eudragit L-30D latex.  Too high a level of PEG-6000 will 
reduce the Tg of film coat close to or below the room temperature,  causing the final 
product to clump together and sinter under their  own weight.  The glass transition 
temperatures of the film by thermal analysis with 10% and  20%(w/w) PEG-6000 
incorporated were 71.3°C and 42°C respectively.  A DSC scan of the 30%(w/w) PEG­
6000 sample produced a very broad gradual incline in the baseline of the thermogram, 
from which it was not possible to determine of a Tg.  However,  it was observed that 
the final coated microspheres with 30 %(w/w) PEG-6000 as a plasticizer clumped together 101 
when stored at room temperature, suggesting a Tg is less than 23°C (room temperature). 
For a given amount of PEG,  the extent of the changes are dependent  upon the 
molecular weight of the PEG incorporated with the polymer.  The initial LPS release 
rate in gastric fluid increased as PEG molecular weight decreased (Fig.III. 14).  The 
Eudragit film with low molecular weight PEG provided less protection  from acid 
dissolution medium than with high molecular weight PEG's.  Less than 5 % LPS was 
released from ECAMs with PEG-6000,  20.3% LPS released with PEG-1000, and 
24.7% released with PEG-400 in simulated gastric fluid within  one hour. The reason 
may be because of the rapid migration of the hygroscopic and highly soluble PEG 
(especially the liquid grades, such as PEG-400) into dissolution medium,  thus pores 
were formed on the surface of film coat.  Because of the leaching out of low molecular 
weight PEG from the film coat results in loosened film  structure and increased 
permeability under gastric fluid condition.  Therefore, the effect of enteric protection 
of the coat against low pH was reduced by incorporation of low molecular weight PEG', 
however this phenomena would less pronounced with films incorporated  with high 
molecular weight PEG.  The high molecular weight of PEG may hinder its ability to 
diffuse out of the film coat at low pH conditions and influence antigen release  to an 
extent.  PEG, although used as a plasticizer, will,  above its solubility within the 
carrier, be present as crystalline units. PEG crystals may either retard drug diffusion by 
acting as a physical barrier or dissolve to leave a porous structure through which the drug 
may be quickly transported.  The solubility of PEG in the dissolution media was perhaps 
the predominant mechanism that controlled the rate of LPS release from this  system. 102 
5.	  Effect of the Combination of DBS and TEC 
The DSC scan of film samples with 15% TEC and 15% DBS  as plasticizers 
showed that the Tg of that film was 56°C.  If the coating temperature is within the range 
(Tg-10, Tg +20), a good enteric-coat would be formed. The combination of the DBS and 
TEC was an efficient to plasticizer for the enteric film to form for resistance to gastric 
fluid when the coating is under a proper temperature (Fig. III.11, table 111.13).  Hossain 
et al. concluded that the TEC and a combination of DBS and TEC  were efficient 
plasticizers for ethyl cellulose pseudolatex systems". The present study confirmed their 
observations.  The reason may be because not only did TEC decrease the MFT of the 
polymer so that a good enteric film can be formed under the present coating conditions, 
but also the DBS acted as a surfactant stabilizing the latex  system.  Thus a more 
homogeneous dispersion can be applied onto the antigen loaded microspheres. 
In general, by incorporation of different types and amounts of plasticizers in the 
Eudragit L-30D latex, the glass transition temperature  can be adjusted toward more 
reasonable processing coating temperatures, and a properly plasticized film could be 
formed with desired physical strength and flexibility as well as the desired permeability 
for its applications. 103 
Table 111.12	  Summary of Glass Transition Temperatures of Eudragit  L-30D Latex 
incorporated with Different Plasticizers Measured by Differential Scanning 
Calorimetry (DSC) 
% of Plasticizer in  Glass Transition Temperature Measured by DSC (°C) 
polymer latex 
TEC  PEG-6000  TEC & DBS (1:1)  DBS 
0  110  110	  110  110 
10	  85  71.3  not tested  83 
20  75	  42  not tested  50 
30  38  <23	  56  N/A 
pH Sensitivity 
A good enteric-coated product should be completely impermeable to gastric fluid 
even under prolonged exposure times.  In the small intestine the drug should be released 
fairly rapidly.  The designed enteric-coated antigen microspheres in this study without 
acid pre-treatment exhibited normal antigen release  at buffered pH 6.2 and 7.2. 
Leaching of antigen occurred at pH 5.2 after  two hours and released about 95 % of the 
LPS within seven hours.  Results indicated that protection  was provided at pH levels 
below 5.2.  Less than 5% of the antigen was released at pH 3.2 and 4.2 after 7 hours 
(Fig.III. 15,  table III. 16 ). 
The enteric-coated microspheres released less than 3% of LPS in the pH 3.2 and 104 
4.2 dissolution medium during the entire time of the test with acid pre-treatment,  while 
at pH 5.2 about 12% of the LPS was released.  Using buffered dissolution media of pH 
6.2 and pH 7.2 the microspheres released 100% of the LPS in a normal manner (Fig. 
III. 16, table III. 17).  Results observed were similar as the dissolution without acid pre­
treatment. 
Stability 
A year storage of ECAMs showed that the LPS release was nearly unaffected. 
The film coat still maintained enteric-protection after one year of storage at -5°C. The 
changes in LPS release were less than 15% at each time point. ECAMs stored at room 
temperature for one year and six months released 9.8% of the in gastric fluid,  while 
in intestinal fluid antigen release was nearly the same as observed  at the initial testing 
(Fig. 11.17) 
In summary, an aqueous latex dispersion employing film-formation polymer 
polymethacrylic acid-ethylacrylate,  is a useful approach to design an oral antigen 
delivery system.  The amount of the polymer applied onto the microspheres, the types 
and amounts of adjuvants incorporated into the aqueous latex dispersion and the film 
processing parameters should be optimized in order to develop a desired oral antigen 
delivery system.  It was found that the glass transition temperature decreases as the 
amount of plasticizer increases45. TEC, PEG-6000 and the 1:1 combination of TEC & 
DBS all have very good plasticizing effects on Eudragit polymer film,  however a 105 
30%(w/w) 1:1 TEC & DBS combination gives a more consistent effect on the antigen 
release. 
The delivery system developed in present study has sufficient enteric protection 
against a low pH environment as found in the stomach and may deliver the antigen to the 
action site of the small intestine.  The small intestine with its large surface area and 
specialized transport mechanisms serves as the main site of absorption,  uptake and /or 
interacting with lymphoid tissues for the majority of compounds including antigen  to 
induce immunity. 106 
CONCLUSIONS 
An oral vaccination delivery system of enteric-coated antigen microspheres 
(ECAMs) has been developed.  It is speculated from the study that this delivery system 
will protect the antigen as it passes through the acidic and enzymatic environment of the 
stomach and release antigen via diffusion and film coat dissolving  once it reaches the 
intestinal region where the antigen can be effectively absorbed into the circulation and 
interact with immune system. 
The amount of coating materials can be optimized by in vitro dissolution test, and 
the theoretical coating film thickness can be estimated.  Based upon the identical film 
thickness for each microsphere,  the amount of coating materials needed with any size 
of microspheres can be mathematically predicted. 
Consistent antigen release patterns can be obtained from ECAMs with different 
types of antigens if the coating temperature is above 40°C. Antigen release in present 
study was predominantly influenced by the physicomechnical properties of the film, such 
as film thickness,  types and amounts of adjuvants in the film and film processing 
temperature,  rather than the properties antigens themselves. 
Thermal analysis and dissolution studies suggest that the antigen release  was 
influenced by the type and amount of plasticizer used. The study also suggests that the 107 
minimum film formation temperature (MFT) is a critical factor in the film formation. 
10% to 15% TEC or PEG-6000 is sufficient to plasticize the Eudragit L-30D latex, 
while 30 %(w/w) of 1:1 combination of TEC & DBS provides the most consistent antigen 
release. 108 
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Figure 111.13 Dissolution  Profiles  of Oral  Enteric-coated  Antigen Microspheres 
Incorporated with Different Types of Plasticizers and Different Amounts 
of Dibutyl Sebacate (DBS).  Dissolution test was conducted at pH 7.2 
simulated intestinal fluid with one hour pH 1.5 simulated gastric-fluid pre­
treatment. 109 
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Figure 111.14 Dissolution  Profiles  of Oral  Enteric-coated  Antigen Microspheres 
Incorporated with Different Types of Plasticizers and Different Amounts 
of Polyethylene glycol-6000 (PEG-6000). Dissolution test was conducted 
at pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated 
gastric-fluid pre-treatment. 110 
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Figure 111.15 Dissolution  Profiles  of Oral  Enteric-coated  Antigen Microspheres 
Incorporated with 10% of Different Molecular Weights of Polyethylene 
glycol (PEG).  Dissolution test was conducted at pH 7.2 simulated 
intestinal fluid with one hour pH 1.5 simulated gastric-fluid pre-treatment. 111 
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Figure 111.16 Dissolution  Profiles  of Oral  Enteric-coated  Antigen Microspheres 
Incorporated with Different Types of Plasticizers and Different Amounts 
of Triethyl citrate (TEC).  Dissolution test was conducted at pH 7.2 
simulated intestinal fluid with one hour pH 1.5 simulated gastric-fluid pre­
treatment. 112 
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Figure 111.17 pH Sensitivity of Oral Enteric-coated Antigen Microspheres under 
Different pH Conditions. Dissolution test was conducted at pH 7.2 
simulated intestinal fluid without acid pre-treatment. 113 
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Figure 111.1 8 pH Sensitivity of Oral Enteric-coated Antigen Microspheres  under 
Different pH Conditions. Dissolution test was conducted  at pH 7.2 
simulated intestinal fluid with one hour pH 1.5 simulated gastric-fluid pre­
treatment. 114 
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Figure 111.19 Dissolution Profiles of Oral Enteric-coated Antigen Microspheres Stored 
at Various Conditions. Dissolution test was conducted at pH 7.2 simulated 
intestinal fluid with one hour pH 1.5 simulated gastric-fluid pre-treatment. Table 111.1 3  Cumulative Percentage Release of LPS from Enteric-coated Antigen Microsphere 
Incorporated with TEC as a Plasticizer 
Cumulative percentage release of LPS from ECAMs, (mean +SD)'
 
Time (Hr)
 
No-plasticizerb  TEC & DBS`  10%TEC  20% TEC  30% TEC
 
0.00  0.00+0.00  0.00±0.00  0.00+0.00  0.00+0.00  0.00+0.00 
0.25  68.83+6.18  0.62+0.88  0.00±0.00  0.00+0.00  0.39+0.67 
0.50  84.71+3.12  0.86±1.21  1.59+1.19  0.00 ±0.00  1.28+1.11 
0.75  95.85+4.27  0.60 ±0.85  1.59 ±0.00  0.00±0.00  1.22±1.15 
1.00  98.07 ±7.56  0.60+0.84  5.81±3.61  0.00±0.00  2.86+0.90 
1.25  100.88+6.34  7.36±0.78  19.15+7.34  5.83+4.44  5.69±1.78 
1.50  100.00 ±8.64  20.36 ±4.85  26.63+6.40  18.27 ±4.27  4.25+1.94 
1.75  100.00±3.86  30.28+7.91  35.20 ±7.36  26.40+7.97  8.29+2.66 
2.00  100.00+5.43  41.99+9.41  39.15+7.02  35.64+12.23  9.59+3.15 
2.50  100.00±3.68  54.34 ±7.12  53.57 ±12.14  44.71 ±16.40  14.07±1.92 
3.00  100.00+5.43  65.04±10.24  65.01±14.52  56.70+12.45  20.31±3.73 
4.00  100.00+2.47  85.87+27.35  72.52+16.27  67.27+19.11  25.59+4.31 
6.00  100.00+8.83  100.00+10.81  88.86+17.35  79.29+26.32  32.26+3.71 
9.00  100.00 ±5.33  100.00 ±4.64  100.91 ±22.81  87.56+25.46  39.62+3.57 
' mean values of three replicates and standard error. Dissolution was conducted at pH 7.2 simulated intestinal fluid 
with one hour pH 1.5 simulated gastric fluid pre-treatment. 
b20 %Eudragit and 0.03 %(w /w) LPS coated beads with no plasticizer in the film coating formulation. 
c20 % Eudragit coated beads with 15% TEC and 15% DBS(w/w, based on the polymer and plasticizer solids) as plasticizers. Table III.14  Cumulative Percentage Release of LPS from Enteric-coated Antigen Microspheres 
Incorporated with PEG-6000 as a Plasticizer 
Cumulative percentage release of LPS from ECAMs, (mean +SD)a
Time (Hr) 
No-plasticizer'  TEC & DBS`  10%PEG  20% PEG  30% PEG 
0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00 
0.25  68.83+6.18  0.62 ±0.88  0.00 ±0.00  0.00 ±0.00  0.00+0.00 
0.50  84.71 ±3 .12  0.86 ±1.21  0.00 ±0.00  0.00 ±0.00  2.86±0.53 
0.75  95.85+4.27  0.60+0.85  0.00+0.00  0.00+0.00  3.70+0.65 
1.00  98.07±7.56  0.60+0.84  1.13+1.60  3.03±0.20  5.07±0.50 
1.25  100.88+6.34  7.36+0.78  8.12+1.91  4.39+2.01  7.73±1.71 
1.50  100.00+8.64  20.36+4.85  17.58+1.47  7.13±3.00  9.65+0.98 
1.75  100.00±3.86  30.28±7.91  25.15 ±1.33  6.47±1.18  12.47±3.17 
2.00  100.00+5.43  41.99+9.41  28.55+6.47  15.08+0.91  14.85+2.57 
2.50  100.00+3.68  54.34±7.12  40.65+0.57  15.16+7.04  18.12 ±5.84 
3.00  100.00+5.43  65.04±10.24  43.39±2.44  20.68±5.20  22.30±1.92 
4.00  100.00+2.47  85.87+27.35  54.91+2.56  21.08+0.93  24.64+3.18 
6.00  100.00+8.83  100.00±10.81  62.08 ±2.26  31.56±0.78  28.22+4.60 
9.00  100.00+5.33  100.00±4.64  69.76±0.61  37.29+2.18  31.22 ±1.64 
a mean values of three replicates and standard error. Dissolution was conducted at pH 7.2 simulated intestinal fluid
with one hour pH 1,5 simulated gastric fluid  pre-treatment. 
b20 
%Eudragi t coated beads with no plasticizer in the film coating formulation. 
c20% Eudragit coated beads with 15% TEC  and 15% DBS(w/w, based on the polymer and plasticizer solids) as plasticizers. Table III. 15  Cumulative Percentage Release of LPS from Enteric-coated Antigen Microspheres
Incorporated with DBS as a Plasticizer 
Cumulative percentage release of LPS from ECAMs, (mean+SD)° Time (Hr)
 
No-plasticizer°  TEC & DBS`
  10%DBS  20% DBS  30% DBS 
0.00  0.00 ±0.00  0.00+0.00  0.00 ±0.00  0.00+0.00  0.00 ±0.00 
0.25  68.83+6.18  0.62+0.88  57.84+1.19  49.69+6.25  3.06+0.33 
0.50  84.71 ±3.12  0.86+1.21  102.72±28.15  90.51 ±14.88  19.45±1.97 
0.75  95.85±4.27  0.60+0.85  95.48+4.53  92.63+0.57  32.29+6.04 
1.00  98.07+7.56  0.60+0.84  104.60+2.72  99.94 ±6.54  48.17+7.60 
1.25  100.88+6.34  7.36+0.78  100.00+0.00  100.06+4.43  61.75+6.29 
1.50  100.00+8.64  20.36+4.85  100.00+0.00  100.00+0.00  62.59+5.88 
1.75  100.00+3.86  30.28+7.91  100.00+0.00  100.00 ±0.00  65.82 ±5.88 
2.00  100.00+5.43  41.99+9.41  100.00+0.00  100.00+0.00  71.01+4.79 
2.50  100.00+3.68  54.34+7.12  100.00+0.00  100.00 ±0.00  80.48+5.44 
3.00  100.00+5.43  65.04+10.24  100.00+0.00  100.00+0.00  84.77+5.81 
4.00  100.00+2.47  85.87 ±27.35  100.00+0.00  100.00+0.00  99.40+13.27 
6.00  100.00+8.83  100.00+10.81  100.00+0.00  100.00+0.00  101.71+12.75 
9.00  100.00+5.33  100.00+4.64  100.00+0.00  100.00+0.00  101.88+4.55 
a mean values of three replicates and standard error. Dissolution was conducted at pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric fluid  pre-treatment. 
b20 %Eudragit coated beads with no plasticizer in the film coating formulation. 
`20% Eudragit coated beads with 15% TEC and 15% DBS(w/w, based on the polymer and plasticizer solids) as plasticizers. Table 111.16  Cumulative Percentage Release of LPS from Enteric-coated Antigen Microspheres
at Different pH Dissolution Medium Without Acid Pre-treatment 
Cumulative percentage release of LPS from  ECAMs, (mean ±SD)' Time (Hr)
 
pH 3.2b  pH 4.2'  pH 5.2'
  pH 6.2'  pH 7.2b 
0.00  0.00 ±0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00 
0.00+0.00 0.25  2.50±1.55  0.00 ±0.00  1.94+3.36  21.72+0.69 
0.50  0.21+0.36  2.16+1.12  0.00+0.00  20.15+0.87  35.96+4.24 
0.75  0.21 ±0.36  1.59+0.80  0.00+0.00  34.34± 1.40  45.00+2.42 
1.00  0.41+0.71  1.86+1.00  1.81 +3.14  41.91 +4.45  56.17±4.11 
1.25  0.41+0.71  1.99+1.00  49.04+4.68  59.53±4.04 
1.50  0.40±0.34  1.21 ±0.67  2.04+2.01  55.74+5.00  67.22+5.96 
2.00  0.78+0.68  2.13±1.26  9.98+5.89  65.84±5.24  71.74±11.48 
2.50  0.78±0.68  1.66+0.96  22.45+1.45  69.68±2.00  73.61±4.41 
3.00  0.36+0.62  2.76±0.44  29.37±0.66  77.68+6.74  77.85±2.75 
4.00  0.80 ±1.40  2.94+0.66  49.89+2.73  79.05+2.24  85.58±5.00 
5.00  1.04+0.92  2.58±1.32  65.49±4.61  83.93+1.72  91.18±4.54 
6.00  0.74 ±0.69  3.21+1.07  80.04±4.77  89.40+6.83  102.89+10.45 
1.99+1.09 7.00  3.16±1.65  94.60 ±5.83  92.38 ±6.62  99.61+7.32 
a mean values of three replicates and standard error. Dissolution was conducted at pH 7.2 simulated
intestinal fluid with one hour pH 1.5 simulated gastric fluid pre-treatment. 
bdissolution at pH indicated without pH 1.5 acid pre-treatment. Table III. 17  Cumulative Percentage Release of LPS from Enteric-coated Antigen Microspheres
at Different pH Dissolution Medium with Acid Pre-treatment 
Time (Hr) 
Cumulative percentage release of LPS from ECAMs,  (mean +SD)° 
pH 3.26  pH 4.26  pH 5.26  pH 6.26  pH 7.26 
0.00  0.00±0.00  0.00 ±0.00  0.00±0.00  0.00±0.00  0.00±0.00 
0.25  0.55±0.52  0.79 ±1.36  0.00+0.00  0.00+0.00  0.00±0.00 
0.50  0.52±0.90  0.94±0.99  0.00±0.00  0.00+0.00  0.00±0.00 
0.75  1.86+1.14  0.48±0.83  0.00+0.00  0.00+0.00  0.00+0.00 
1.00  0.96+0.83  1.06+0.99  0.00±0.00  0.00+0.00  0.00+0.00 
1.25  2.35±0.55  1.06 ±0.00  0.00+0.00  0.00+0.00  11.37+5.73 
1.50  2.11±0.94  1.06 ±0.00  0.00±0.00  1.72+1.16  22.76±9.26 
2.00  1.30±0.24  1.06±0.00  0.00±0.00  12.36+0.59  32.47+10.41 
2.50  1.30±0.24  1.06+0.00  0.00+0.00  24.25+1.83  38.49±9.49 
3.00  1.30±0.24  1.06+0.00  0.00+0.00  41.20+1.41  49.91±11.49 
4.00  1.30±0.24  1.06+0.00  1.16±2.01  50.86±2.24  56.11±13.10 
5.00  1.30+0.24  1.06+0.00  2.68+2.03  67.05+1.78  63.08+6.19 
6.00  1.30+0.24  1.06+0.00  5.80±3.44  89.46+6.72  72.49±7.25 
7.00  1.49 ±0.48  1.06+0.00  12.26 ±2.41  96.37+2.54  90.34±9.19 
amean values of three replicates and standard  error. Dissolution was conducted at pH 7.2 simulated
intestinal fluid with one hour pH 1.5 simulated  gastric fluid pre-treatment. 
bdissolution at pH indicated  with pH 1.5 acid pre-treatment. 120 
Table 111.18  Cumulative Percentage Release of LPS from Enteric-coated Antigen 
Microspheres at Different Storage Condition 
Cumulative percentage release of LPS from 20% 
Time (Hr)  Eudragit ECAMs,  (mean+SD)a 
._5ocb  Room Temperature` 
0.00  0.00+0.00  0.00+0.00 
0.25  0.63+0.07  7.81+1.25 
0.50  0.86+0.25  7.74+1.42 
0.75  0.83+0.11  8.35+0.53 
1.00  0.96+0.48  9.80+0.67 
1.25  8.85+4.18  31.50+5.50 
1.50  32.84+5.14  39.77+2.66 
1.75  42.10+9.40  46.61+2.68 
2.00  53.11+13.32  54.97+5.00 
2.50  66.29+15.50  67.75+6.98 
3.00  82.38+17.70  76.41+7.78 
4.00  88.75+13.69  86.26+8.15 
6.00  100.61+15.51  100.28+9.27 
9.00  100.37+9.55  100.81+12.36 
'mean values of three replicates and standard error. Dissolution was conducted at 
pH 7.2 simulated intestinal fluid with one hour pH 1.5 simulated gastric fluid  pre­
treatment. 
1'20% Eudragit ECAM with 0.03% (w/w) LPS, 15%TEC and 15%  DBS (w/w, 
based on polymer and plasticizer solids) as plasticizers stored at -5°C for one year. 
c20% Eudragit ECAM with 0.03% (w/w) LPS, 15%TEC and 15% DBS(w/w, 
based on polymer and plasticizer solids) as plasticizers stored at room temperature for 
one year and six months. 121 
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CHAPTER IV 
IN VIVO CHARACTERISTICS OF ORAL ENTERIC-COATED
 
ANTIGEN MICROSPHERES IN SALMONIDES
 
ABSTRACT 
Trinitrophenylated lipopolysaccharide (TNP-LPS) and trinitrophenylated-keyhole 
limpet hemocyanin (TNP-KLH) are valuable immunogenic antigens in aquaculture. The 
efficacy of oral immunization may be increased by protection of antigens such as TNP­
LPS and TNP-KLH from acid proteolysis or chemical degradation in the gastrointestinal 
tract.  Antigens delivered, in an unchanged form, to the small intestine where the gut-
associated lymphoid tissues (GALT) reside can induce the specific immune responses. 
Enteric-coated antigen microspheres (ECAMs) were formulated by applying Eudragit® 
L-30D, an aqueous polymeric dispersion,  onto antigen loaded dextrose sugar beads with 
a fluid-bed technique. The efficacy of antigen immunization by ECAMs was carried out 
by comparing four different administration routes in Naive juvenile Coho  salmon 
(Oncorhynchus kisutch): oral ECAMs, intraperitoneal injection (IP), immersion and anal 
intubation.  Oral vaccination was conducted by feeding Eudragit® L-30D coated TNP­
LPS or TNP-KLH beads incorporated into Oregon Moisture Pellet (OMP)  to the fish for 
30 days.  Serum samples were taken from each group of fish and analyzed by an 
enzyme-linked immunosorbent assay (ELISA) at 4, 6 and 8 weeks post immunization to 
determine antibody activities.  Statistical analysis results showed that the anti-TNP-LPS 
activities of IP injection and oral high dose of ECAM were significantly higher than  that 126 
of control (p < 0.01) at 4 and 6 weeks after antigen administration,  but there were no 
differences between IP injection and oral administration ECAMs. The antibody titers 
between immersion and control fish were not significantly different.  In the TNP-KLH 
study,  the antibody titers of fish immunized by IP injection and oral ECAMs (low dose) 
were significantly higher in comparison with the levels detected in control fish at 6 and 
8 weeks post vaccination.  Similar results were observed in the anal intubation treatment 
group.  Oral administration of enteric-protected antigens elicited equivalent antibody 
titers in fish as IP injection does for TNP-LPS or TNP-KLH. The specific immune 
responses induced may be sufficient to produce protection against pathogenic diseases. 
Key words: enteric-coated microspheres; antigen delivery; TNP-LPS; TNP-KLH; oral 
vaccination 127 
INTRODUCTION 
Infectious diseases pose a constant and highly costly threat to the aquaculture 
industry. There are over twenty bacterial and ten viral diseases which affect this industry. 
Antibiotic treatment can provide a useful means of helping to control  many bacterial 
diseases but there are many problems associated with the development of antibiotic 
resistance and recurrent outbreaks necessitating further treatment.  Antimicrobial drugs 
which are usually incorporated with food are applied to fish, but this is not ideal since 
infected fish usually lose their appetite and therefore receive inadequate treatment. 
Furthermore,  there is concern about the effects on the environment with the use of 
large quantities of chemotherapeutic agents especially the potential of antimicrobial 
resistance acquired by animal bacterial pathogens being transferred to human pathogens. 
It is for these reasons that licensing authorities generally impose strict limitation  on the 
use of chemotherapeutic agents.  The therapeutics of viral diseases is not as easy as 
might be thought. So far there is no effective chemotherapy for control of viral diseases. 
Vaccination, among all other disease control methods, has proven to be an active and 
effective way to control the mortality caused by infectious diseases in fish. 
The control of infectious diseases by vaccination began in 1796, when a vaccine 
was used for smallpox in Humans. The work of Koch and Pasteur during the middle and 
latter years of 1800's demonstrated the usefulness of immunizing agents  to reduce or 
eliminate certain diseases in animals,  including humans.  The study of immune 
responses in fish was apparently not attempted prior to 1903,  when agglutinating 128 
antibodies against a bacterium were demonstrated in the blood of carp. During 1960's, 
there was an increased interest in immunological studies of fish mainly by comparative 
immunologists with prime interests in evolutionary processes and partly by a few people 
with an interest in finding ways of controlling troublesome diseases among cultured fish. 
The research of immunization of fish was given  an enormous boost in mid-1970's with 
the development of highly effective vaccines against vibriosis and enteric  red-mouth 
(ERM) which could be mass administered by simply dipping or bathing fish in a relative 
simply prepared killed broth culture of the pathogens.  These vaccines are cheap to 
produce, easy to administer, and provide long-term immunity against the  diseases. 
Similar vaccines against all other major diseases of cultured fish  were subsequently 
prepared and tested.  Few of them have proven to be consistently effective.  Great 
efforts have been made since that time by numerous scientists to develop fish vaccines, 
however,  there are only six commercial vaccines currently available.  All of these 
vaccines must be administered either by immersion  or intraperitoneal  injections. 
Injection usually produces a more rapid,  and possibly a more protective response to the 
pathogen than do other methods.  However, the disadvantage of injection is that it is 
usable only when small numbers of fish are to be inoculated.  It is impractical in large 
fish culture facilities because of the large numbers of fish to be immunized.  Immersion 
introduces additional stress to the fish by crowding and adds labor expense to the fish 
industry.  Mau le et al.' found that the immersion vaccination elevated fish plasma 
cortisol levels which was sufficient to result in immunosuppression.  Thus the 
administration of a vaccine itself may lead to,  at least temporality,  to a decreased 129 
ability to respond immunologically and perhaps an increase in disease susceptibility. 
The most practical procedure for immunizing large numbers of fish is by feeding 
the antigens.  Vaccines administered simply in fish feed involve  no extra labor in 
vaccine administration as is the case with immersion  or injection. The increased stress 
caused by immersion or injection are also avoided. 
Oral immunization of trout was first demonstrated in 19422. Trout  were fed a 
bacterin prepared from Aeromonas (Bacterium) salmonicida and  apparently developed 
moderated protection from furunculosis.  Other research has demonstrated humoral 
antibodies from bacterial antigens fed for long periods of time  (70 to 272 days). 
Reduction,  but not elimination, of mortality was possible when orally immunized fish 
were challenged with viable homologous bacteria3'4'5'6'7  Oral delivery of vaccine has 
been described  as the most desirable method for mass vaccination of fishs."" of all 
size and has the flexible dosing regime.  In marine fish species, good protection has 
been observed following oral immunization of turbot' and seabass".  In salmonides, 
oral immunization has yielded variable results.  Good protection resulted in the studies 
of Johnson & Amend' and Vigneulle15,  but it was ineffective in studies reported by 
Baudin Laurencin & Tangtrongpiros16 and Home et al.'7  Incorporation of vaccines into 
diets of fish has resulted in lower levels of protection compared  to injection,  spray or 
immersion methods. 18,19,20,21,22  These variable results could be in part due to the 
destruction of antigens by feed manufacturing or storage.  It is also possible that the 
antigens are partly degraded or denatured by gastric secretions when passing through GI 
tract. These assumptions were supported by Johnson & Amend". They found that the 130 
high levels of protection against vibriosis in sockeye salmon fifty-nine days  following 
single anal intubation of the bacterin,  a procedure allowing antigens to reach the 
posterior intestine unchanged.  The response with anal intubation was better than that 
obtained after either oral or immersion vaccination.  Kawano et al.' also found that 
when intact antigen was introduced into the intestinal tract by anal intubation induction 
of a high immune response than what occurred by immersion or injection. These studies 
suggest that oral administration may be as efficacious as other means of vaccination, 
as long as antigens can be delivered intact to the intestine. 
The gastrointestinal (GI) tract contains large numbers of lymphocytes.  Some 
lymphocytes are able to migrate to different areas in the gut, and a unique sequestration 
of lymphocytes is often noticed within the mucosal epithelium which overlays the gut-
associated lymphoid tissues (GALT). These lymphocytes are separated from the lumen 
of the gut by the intervening epithelial cell membranes. The epithelium is pinocytotically 
active and is capable of taking up antigens from the gut lumen and transferring them  to 
these lymphocytes as well as to the GALT.  The GI tract is capable of mounting an 
immune response that compares favorably with that produced by lymphocytes  from 
lymph nodes and spleen.25  Oral vaccination may be as effective as or even better than 
other methods if some confounding factors, such as antigen degradation or denaturation, 
antigen absorption and antigen bioavailability problems,  are considered, because oral 
vaccination may not only provide the systemic immunity but also  secretory immunity. 
Mucosal surfaces and gastrointestinal tract are the most frequent portals of entry of 
common viral,  bacterial,  parasitic infectious diseases and of potentially harmful 131 
antigenic substances from the environment.  Secretory antibodies elicited by oral 
vaccination are capable of limiting the penetration of infectious pathogens through 
mucosal membranes,  inhibit the attachment of bacteria to the epithelial cells,  and 
neutralize a broad spectrum of viruses that infect epithelial cells,  or cause more 
generalized diseases.26 
The present study was undertaken to probe the degree of immunity in fish initiated 
by molecularly defined classes of antigens with interchangeable carrier  or haptenic 
molecules.  Study of these type of antigens is essential for the development of vaccines 
for mammals and fish because it has led to the elucidation of 1) the cellular mechanisms 
of immunological memory generation,27'28  2) the existence and mechanisms of T-cell 
dependent (TI) responses,29'3° and 3) the existence of distinct subpopulations of antibody-
producing,  B lymphocytes.3',32  Lipopolysaccharide (LPS) and keyhole limpet 
hemocyanin (KLH) have proven to be useful tools in study of lymphocyte activation and 
differentiation.  By using trinitrophenylated (TNP) antigens,  the examination of the 
role of various carrier molecules in the production of antibodies to a defined antigenic 
determinant can be determined. 
Perhaps it would take less antigenic mass to induce the immune response as other 
methods if delivery of the antigen is to the upper intestine.  Protection of the antigens 
against stomach acidity and/or gastric secretions by enteric protected coating  may allow 
passage of the intact antigens to the intestinal tract and interact with the lymph system. 
The goals of this study were a) to test the ECAMs abilities to resist the digestion or 
possible degradation of antigen in the GI tract,  b) to compare the relative efficacy of 132 
oral ECAMs in eliciting antibody responses with respect to immersion, intraperitoneal 
injection and the anal intubation methods. 133 
MATERIALS AND METHODS 
Fish and Fish Handling 
Coho Salmon (Oncorhynchus kisutch) were used as the experimental animal 
model. These experimental fish were obtained from hatcheries operated by Sandy Fish 
Hatchery (SFH), Portland, Oregon.  After the fish were transported from SFH to the 
Salmon Disease Laboratory at Oregon State University, they were introduced into out­
door stock tanks. Fish were randomly selected from the stock tanks and were transferred 
to in-door 100 liter tanks prior to the experiment. Ten (TNP-LPS study) or six (TNP­
KLH study) tanks were randomly assigned for the treatment  Each tank holds 25 (TNP­
LPS) or 13 (TNP-KLH) fish.  Both out- and in-door tanks were supplied with consistent 
quality pathogen-free water at a constant temperature of 12.5°C.  Fish were maintained 
on a diet of Oregon Moist Pellets (OMP, Bioproducts, Astoria, Oregon).  The weight 
and length of fish were measured and they were acclimated for at least two weeks prior 
to the study. The fish  handling strictly followed the "Salmon Disease Laboratory, 
Procedure Manual, 1990" ( Department of Microbiology, Oregon State University, 
Corvallis, OR ) 
Antigen Preparation 
TNP-LPS Preparation 
Trinitrophenylated-lipopolysaccharides (TNP-LPS) was prepared as described.' 
In brief, dissolved 100 mg LPS ( Sigma Chemical Co., St. Louis, MO, serotype: 134 
055:B5) in Cacodylic buffer and adjusted the pH to 11.5 with 1N NaOH. Added 60 mg 
TNBS (2,4,6-trinitrobenzensulfonic acid, Lot 120H5951, Sigma Chemical Co., St. Louis, 
MO., 95% hydrate, 5%(w/v) aqueous solution) to 5 ml of Cacodylic buffer in another 
container and added dropwise into above LPS solution.  Rotated the suspension for 2 
hours at room temperature, then dialyzed using molecularporous dialysis membrane 
(Spectra/pot®  1, Vol/cm: 1.7 ml, molecular weight cutoff: 6,000-8,000, Spectrum 
Medical Industries, Inc., Los Angeles, CA) against a phosphate buffered saline solution 
(PBS) for four times. Then placed the dialyzed solution in a serum vial and pasteurized 
for 30 minutes at 70°C. The final product was transferred into a sterile stoppered serum 
bottle and stored at 4°C. 
TNP-KLH Preparation 
Trinitrophenylated-keyhole limpet hemocyanin (TNP-KLH) was prepared by the 
modified method described by Rittenberg and Amkraut et al.'  15.1 mg of 
Picrylsulfonic acid (TNPS) was dissolved in 5 ml cacodylate buffer and added dropwise 
to a constantly stirred solution of KLH (72 mg, Sigma Chemical Co., St. Louis, MO.) 
in 0.85% saline (5 ml at 14.4 mg/ml) contained in a foil-wrapped tube.  The 
Picrylsulfonic acid, KLH mixture was stirred at room temperature for 1 hour. TNP­
KLH was dialyzed against four one liter changes of 0.7M PBS of pH 7.4 and a final 
change of 500 ml RPMI 1640 (Gibco, Grand Island, NY). The dialyzed TNP-KLH was 
filter sterilized with 0.45,um pore size filter and placed in a sterile stoppered serum bottle 
at 4°C until used. The final product was assayed for protein content by a modified 135 
Lowry' method described in Chapter III  to determine the final concentration of TNP­
KLH. 
TNP-BSA Preparation 
Serum antibodies were quantified using the haptenated protein TNP-bovine serum 
albumin (TNP-BSA).  Use of this antigen allows specifically for the quantifying of 
antibodies to the TNP hapten without fear of reaction to the carrier.  TNP-BSA was 
prepared according to Garvey at al.36  Briefly, 500 mg of BSA (Sigma) was added to 
10 ml of borate buffer.  Trinitrophenylation was accomplished by first mixing 125 mg 
of Picrylsulfonic acid in 2.5 ml borate acid. The BSA solution was then transferred to 
a 10 ml foil-wrapped beaker. The Picrylsulfonic acid (TNBS) solution was added 
dropwise into BSA solution under constant mixing.  Mixing is continued for two hours 
at room temperature.  The solution was dialyzed extensively against borate buffered 
saline, and then the final product was filter-sterilized and stored in a sterile stoppered 
serum bottle at 4°C until used. 
Enteric-Coated Antigen Microspheres Preparation 
The enteric-coated antigen microspheres (ECAMs) were prepared as described in 
Chapter III. 
Incorporation of ECAMs into Fish Diet 
Daily maximal intake of food by the fish was determined by taking the average 136 
food consumption of the fish for five days. The average daily food intake was 10 grams 
of OMP/tank. The ECAMs were incorporated with food in a ratio that insure a full day 
of food and antigen intake per tank of fish. ECAMs were completely mixed with mesh 
form of OMP, then extruded through a defined pore size of extruder (Vitano, Eastlake, 
OH) and cut into pellets which were small enough to feed the fish. Deionized water was 
added during the process to form an appropriate mull for extrudation. 
Antigen Administration 
Ten tanks were randomly assigned to different treatments during TNP-LPS 
experiment,  three tanks as a group were prepared for oral ECAMs,  intraperitoneal 
injection (IP) and immersion method, and one tank as a control group (Table IV. 1). 
The oral vaccination group of fish was fed a normal fish diet in which enteric protected 
TNP-LPS ECAMs were incorporated. Fish were fed everyday for 30 days with ECAM 
loaded feed. 10 Ag, 10 rig and 1 pg TNP-LPS were given as high oral dose, medium oral 
dose and low oral dose per fish, per day, respectively. The Same three levels of antigens 
were applied to the IP and immersion groups.  In IP and immersion treatment groups, 
the antigens were given or applied once (Table IV. 1)  For IP groups,  fish were 
injected one time with 10 Ag, 10 ng and 1 pg TNP-LPS using Eppendorff repeater pipette 
(Brinkmann Instruments, Inc, Westbury, NY) fitted with 26 gauge needle. Immersion 
immunization was done according to Velji et a1.37 with the following modifications. 
Fish were exposed to three different concentrations of TNP-LPS by reducing the water 
levels in each tank from 125 liters to 25 liters. The flow of water was stopped, aeration 137 
was started and antigen was added to the respective tanks. The fish were exposed to the 
antigen for 15 minutes in aerated water.  After 15 minutes flowing water was resumed 
and the tanks were allowed to fill at a rate 2.8 liters/minutes,  removing the antigen 
through normal effluent flow.  The control group fish were fed with normal diet 
incorporated with non-antigen coated microspheres for 30 days. 
TNP-KLH immunized fish were divided into groups of 13 fish/treatment. 
Treatments were oral ECAM, IP injection and anal intubation of antigen. The oral TNP­
KLH groups were immunized the same manner as the oral TNP-LPS groups. Antigen 
concentrations were at 100 Ag,  5Ag and 0.5tig per fish per day.  In IP and anal 
intubation group each fish was immunized with 100p.g TNP-KLH solubilized in 100/21 
sterile phosphate buffered saline (PBS, table II.  2).  Fish immunized by the anal 
intubation method were given 100A1 of 100Ag TNP-KLH in sterile PBS with an apex 
clear pipette tip (West Coast Scientific, Hayward, CA). The control fish were fed with 
normal diet incorporated with non-antigen coated microspheres for 30 days. 
Sampling 
Fish were pre-bled prior to the experiment to check background serum antibody 
titers.  Anti-TNP antibody activities of TNP-LPS experiment fish were determined by 
collecting the serum samples from five fish of each tank at 4, 6, 8 weeks post 
immunization. Just prior to the blood collection, fish were anesthetized by benzocaine 
(Sigma Chemical Co., St. Louis, MO). The caudal peduncle was severed and blood was 138 
collected from the caudal vein in a 1.5 ml microfuge tube (West Coast Scientific, 
Hayward, CA).  TNP-KLH immunized fish were individually marked and bled 
repeatedly from caudal peduncle at 4, 6 and 8 weeks after vaccination in order to monitor 
individual antibody titers throughout the experiment.  After collection,  the blood 
samples were stored overnight at 4°C to facilitate clotting and separation of serum from 
the erythrocytes.  Sample tubes were centrifuged for 2 minutes (Beckman model E 
microfuge, Beckman Instruments, Palo Alto, CA) to pellet the cells.  Sera were drawn 
off the pellet and stored in microfuge tubes at -70°C until assay. 
Antibody Activity Determination 
The antibody activity was determined by using an enzyme-linked immunosorbent 
assay (ELISA) procedure described previously by Arkoosh & Kaattari (1991)38 and 
Arkoosh & Kaattari (1990)39. A 96-well ELISA plate (Costar, Cambridge,  MA) was 
coated overnight with 0.1 ml of a 0.2 item' solution of TNP-bovine  serum albumin 
(TNP-BSA).  After coating, the wells were blocked with 0.1 ml of a 1% BSA in tris­
buffered saline (TBS) for 1 hour at 37°C. The plates  were then washed twice with 1% 
Tween TBS (TTBS).  After the plate was washed, various dilutions of each collected 
sera were made in TTBS.  100 /Al of each dilution was added to the well in triplicate. 
Each plate contained standard anti-TNP serum to normalize the data and to determine the 
standard antibody activity unit per pl of serum.  One unit of antibody activity is the 
volume of serum required to produce 50% of the maximum optical density generated by 
the standard antiserum.  Samples and standards were incubated at room temperature for 139 
1 hour.  The plate was then washed again four times  as before and 0.1 ml of 1/2000 
dilution of a biotinylated monoclonal antibody against trout immunoglobulin was added. 
After the plate was incubated and washed again,  the 1/200 dilution of strepavidin­
horseradish peroxidase (SA. HRPO, Sigma Chemical Co., St. Louis, MO) was applied 
followed by another 45 minutes of incubation. The substrate (ABTS) was finally added 
after the plate was washed. The optical density was read at 405 nm wavelength after 10 
minutes reaction by an ELISA reader (Autoreader Model EL 310, Bio-Tek Instruments, 
Inc.,  Burlington, VT). 
Statistical Analysis 
To evaluate the statistical significance of the differences  in serum antibody 
activities between treatment and control groups, an analysis of variance (ANOVA) with 
95% confidence limits was used.  Analysis was performed by PC version of 
Statgraphics® (STSC, Inc. Rockville, MD). 140 
RESULTS AND DISCUSSION
 
Pre- and post-immunization serum samples were analyzed for antibody activities 
for TNP-LPS or TNP-KLH immunized fish by ELISA. The results indicated  that IP 
injection induced the highest antibody titers followed by oral ECAMs  at high and 
medium dose level of TNP-LPS. Immersion method elicited the lowest antibody levels. 
Fish antibody titers stimulated by high and medium doses of TNP-LPS with IP injection 
and oral routes were significantly higher than negative control fish (p< 0.01) at 4 and 6 
weeks post immunization (Fig.IV. 1, 2, 3).  During this period there was no evidence 
that the antibody titers of immersion vaccinated fish were significantly different from that 
of control (p > 0.05) .  The antibody titers of fish immunized by three different routes 
with high dose of TNP-LPS increased at 4 weeks and reached the peak level at 6 weeks 
post immunization and then declined to the baseline level at 8 weeks post vaccination 
(Fig. IV. 3).  Although the IP method induced the highest immune response in fish, 
no statistical differences could be seen from serum antibody activities of IP and oral 
groups of fish at 4 and 6 weeks post vaccination (p =0.1).  Only at 8 weeks post 
immunization did fish treated by IP injection have significantly higher antibody activities 
than fish vaccinated with oral ECAMs.  In this study,  fish immunized by immersion 
method did not yield significantly higher antibody activities than control fish at any of 
the sampling times (p > 0.05). 
Serum antibody titers of fish treated by IP injection or anal intubation with TNP­
KLH were significantly higher than control fish at 6 and 8 weeks post vaccination 141 
(p <0.05).  Fish treated with high and medium doses of TNP-KLH by oral ECAMs did 
not show greater antibody activities than control fish (p> 0.05, Fig. IV. 5, 6), while the 
fish fed with low dose of ECAMs showed significantly higher antibody activities. 
Lillehaue reported  that  oral vaccination with enteric-protected  Vibrio 
aguillarum was not as effective as unprotected vaccine because the enteric-protected 
vaccine not only prevented degradation,  but also protected against the vaccine 
absorption.  The results in present study were opposite compared to the method used 
by Lillehaug.  The present antigen delivery system in preliminary dissolution studies 
demonstrated that ECAMs possess the enteric-protection in acid environments and 
provide a rapid release rate of antigen when the system is in the most favorable 
absorption area of small intestine.  Some potentially confounding factors may have 
obscured the possible immunogenic superiority of their enteric-protected vaccine.  The 
different results between this study and Lillehaug's may be due to the frequency of the 
antigen administration.  In their study, the vaccine was administered only once,  while 
in this study,  fish were fed with ECAMs continuously for 30 days.  Early studies 
concluded that the dosage form,  dose and frequency of administration of an antigen 
play important roles  in  stimulating an effective immune response. 41,42,43,44,45 
McGhee"' also reported that a relatively higher dose and more frequent administration 
of antigen were necessary for oral vaccination due to the digestion of antigens by the 
gastrointestinal enzymes and the antigen's limited absorption from the gastrointestinal 
tract.  The differences may also be due to the GI tract motility.  In their study the 
antigen was administered by oral intubation under anesthesia.  The fish GI tract 142 
movement may be slower under anesthetic conditions,  and therefore the gastric 
retention time of the enteric-protected vaccine in fish stomach may be longer with the 
resultant low absorption of the antigens.  Wong" suggested that the success of delivery 
of enteric-protected antigen beads depends  upon the size of the delivery system.  He 
indicates that the diameter of the pyloric sphincter is dependent upon the weight of the 
fish and length of the fish.  Relatively larger sized enteric-protected vaccine beads may 
remain in the stomach and not pass on to the pyloric caeca.  The antigen is not going 
to be released in the stomach for absorption and interaction with immune system due to 
the protective characteristics of the enteric-protected film of the beads.  The size of 
enteric-protected vaccine dosage form or prills used by Lillehaug  were considerable 
larger compared to the weight of the fish used,  therefore the movement of the vaccine 
delivery system to small intestine might be delayed by the size of the pyloric sphincter. 
Thus the antigen released from the system would be minimized and the low efficacy of 
vaccination would be expected.  Also the conclusion of the efficacy of vaccination 
solely from the total mortalities or survival rates may not be adequate. Serum immunity 
such as serum antibodies should always be measured to support the comparison.  In 
addition,  the inferiority of enteric-protected vaccine of their study to unprotected 
vaccine may also be due to the fact that lipopolysaccharide from Vibrio anguillarum  cell 
walls is a relatively stable antigen to the acid environment and digestive enzymes of the 
gastrointestinal tract in that they have little effect on its degradation or deactivation.  It 
is the total amount of antigens that are available to gut-associated lymphoid tissues 
(GALT) and to second gut segment where the transformation of intact antigens from 143 
lumen to intraepithelial macrophages occurs that play  an important role in the induction 
of a protective immune response.  The efficacy of oral vaccination may be equivalent 
should the bioavailability of enteric-protected vaccine (solid form) be similar  to the 
unprotected vaccine (liquid form). 
It is well known that  parenteral administration of antigen will result in the 
formation of a systemic immune response directed to specific determinants  on that 
antigen.  Depending on the characteristics of the antigen,  the applied dose and the 
genetic capabilities of the animal,  a humoral immune response usually results after 
parenteral administration.  While similar mechanisms must occur to stimulate immunity 
to antigens which are present in the mucosal surface, including the gastrointestinal  tract, 
less is known about the specific form or dose of antigens which would best  elicit the 
production of immunity in the mucosa itself.  Antigen incorporated into liposomes, 
as described by Michalek et a149 and Childers et a150,  or biodegradable microcapsules." 
have yield promising results.  Both types of formulations have been shown the induction 
of secretory and/or systemic immune responses.  In terms of delivery,  it is very 
important to ensure that the vaccine will reach the appropriate inductive site in adequate 
quantities and appropriate form for an effective induction of a mucosal response.  The 
very basis of this delivery requires the protection of the antigen from the unfavorable 
environment of the stomach.  Wong 's" study confirmed that assumption.  He found 
that the serum and mucosal antibody activities of fish vaccinated with enteric-coated 
Vibrio anguillarum vaccine were higher than fish given with unprotected  vaccine. 
Denaturation of highly purified antigens such as viral glycoproteins,  bacterial enzymes 144 
by gastric hydrochloric acid,  and their digestion by proteolytic  enzymes limit their 
absorption''',  which essentially presents only minute amounts of ingested antigens, 
for their interaction with the immune system.  Using enteric-protected technology to 
minimize the possibility of fragile antigen denaturation and/or deactivation by the  GI 
tract,  less antigens may be used to induce the same immune response in fish as antigen 
given without enteric-protection. 
The low dose of TNP-conjugated protein,  KLH could elicit relatively higher 
immune responses.  It was also found that the antibody activities of fish immunized by 
low doses of oral ECAMs were higher than that induced by IP injection (Fig. IV. 4) at 
6 and 8 weeks post immunization.  The results demonstrate that ECAMs might protect 
the protein antigen, TNP-KLH,  from acid degradation  or deactivation during transit 
through the low pH environment of fish stomach, and release the antigen in the intestine 
where rapid antigen absorption and recognition of antigen by GALT produces immune 
responses.  It is interesting that fish treated with high and medium doses of TNP-KLH 
oral ECAMs did not show greater antibody activities than control fish (p > 0.05,  Fig. 
IV. 5, IV. 6).  It is postulated that the fish immune response to oral TNP-KLH might 
be a dose-dependent process.  High doses may be sub-optimal  in inducing the fish 
immune system to TNP-KLH  while the low dose could  elicit the highest immune 
response.  This indication of immune response may indicate a dose-dependent antigen 
absorption.  It was observed when tilapia were intubated with human -y globulin (HGG) 
orally or anally, antigen absorption  was lower at very low or very high doses of HGG, 
but had maximal absorption with medium dosage of HGG.'  A low dose of oral TNP­145 
KLH ECAMs might deliver the optimal amount antigen that could be absorbed by fish, 
and thus induced the maximal immune  response.  The effectiveness of antigen 
containing microspheres as  an oral antigen delivery system is due not only  to the 
protection provided by the film material during transit through the gut, but also to the 
efficient targeting delivery of intact antigens to the GALT and for second gut segment. 
The immune response of the fish immunized by anal intubation was equivalent 
to fish given IP injection at every time point for TNP-KLH.  These results confirmed 
the observations by Johnson & Amend' and Kuwano et al.' that high efficacy  of 
vaccination would be seen when antigens  were directly delivered to the second gut 
segment of fish. 
No significantly higher serum antibody activities were detected in fish immunized 
by immersion compared to that observed in control fish.  The present study confirmed 
the observations that immersion vaccination appears to primarily induce mucus antibodies 
and not systemic immunity.  Lobb55 pointed out that immersion was not an effective 
method to stimulate the systemic immune system of the fish.  In their study there was 
no detectable change in the level of systemic antibody titers in five of six fish following 
primary and secondary bath immunization. 
In summary, enteric-coated antigen microspheres  represent an antigen delivery 
system which has the potential for wide application for  mass oral vaccination of fish. 
The technology can be employed to improve the efficacious delivery of currently used 
vaccines and may be of benefit to develop  a prototype vaccine for bacterial kidney 146 
disease which is currently one of the more economically devastating of all salmonid 
bacterial diseases in the U.S. and worldwide.  With some modifications, enteric-coated 
antigen microspheres can be applied to any size of fish.  With combined immunological 
and pharmaceutical technology,  a more effective oral vaccination may be achieved 
simply by incorporation of immunostimulants into  the microspheres  to enhance 
immunophylaxis.  Nild in 199156 found that Vita-Stim-Taito (VST,  13-1,3 glucan) 
significantly increased the level of protection against the furunculosis when the agent was 
added to Aeromonas salmonicida bacterin over the bacterin alone.  Evidence suggests 
that this compound acts to enhance disease resistance  by stimulating the macrophage 
component of immune system.'''  Also cyclophosphamide (CY) when administered in 
low dose  before  and  after  antigen  exposure may enhance  specific  immune 
59,60,61,62 response.  Kawabata et al.' in 1988 found that these immunoenhancing effects 
are attributed to the down-regulation of T suppressor cell activity.  High doses of CY 
(500 mg/kg) can completely eliminate functional  lymphocytes from trout,'  whereas 
a low dose of 150 mg/kg significantly enhanced antibody activities.'  By using similar 
fluid-bed spray coating method as the one used for ECAMs and employing pH dependent 
polymers together with water-insoluble polymers,  immunostimulants such as 0-1,3 
glucan or CY can be incorporated into oral antigen  delivery system,  in which the 
immunostimulant vaccine can be delivered in any desired manner.  Mansell' in 1990 
conducted research on "sandwich" coating techniques  to control the release of 
acetaminophen.  It was shown that multilaminar membranes composed of individually 
applied, homogeneous layers of insoluble or pH sensitive polymeric coating material 147 
provided a rate-limiting barrier and sustained acetaminophen release.  Fish immunity 
may be enhanced simply by coating the substrate beads with two layers,  one coating 
layer for immunostimulant, another layer for antigen.  By switching the order of 
application of immunostimulant and antigen coating and by applying a sustained release 
polymer between the two coating layers,  the release of immunostimulant can be 
controlled either before or after the antigen is delivered.  The final vehicles, if 
necessary,  may then be protected by application of enteric-coated polymer on the 
outer-most surface. 
Another strategy to increase the efficacy of oral vaccination is to employ the  use 
of adjuvants in the delivery system.  The use of saponin adjuvants such as Quil-A have 
been shown to increase the level of antigen absorbed  in mammals after  oral 
administration" and potentiate the immune response to these antigens.  Jenkins et al. 
in 1992' found that the uptake of antigen HGG into plasma of tilapia was increased with 
prior or concurrent administration of Quil-A, but this enhancement action of antigen 
absorption by Quil-A was in dose-dependent manner.  The adjuvant effects of Quil-A 
are likely to be on the permeability of the intestine of the fish,  and on GALT cells such 
as macrophages by direct modification of antigen and/or by inhibitory effects on digestive 
enzymes.  Fish immunity may also be potentiated by incorporation of  supper 
disintegrants into the vaccine delivery system.  A super disintegrant can be mixed with 
antigens and applied with them before the application of enteric-protected polymer.  The 
antigen release rate may increase dramatically from the delivery system due to the water 
uptake and swelling forces generated by the disintegrant.  This would provide larger 148 
amounts of antigen to be available for absorption in intestinal tract reducing the transit 
time limits of the fish GI tract for uptake and interaction with  GALT.  In this way the 
immunity may be enhanced. 149 
CONCLUSIONS 
Oral administration of TNP-LPS or TNP-KLH ECAMs  may prevent their 
degradation and/or deactivation from the acidic environment and digestive enzymes of 
stomach and produce specific immune responses in salmonid fish.  Oral enteric-coated 
antigen vaccination was as effective as conventional methods in the production  systemic 
antibody activities if an appropriate dose regimen was provided.  Oral administration of 
ECAM vaccines may be more convenient and cost effective than IP injection  and 
immersion vaccination. Oral immunization may, due to the simplicity and acceptability 
of administration,  significantly improve the chances in elimination  or alleviating 
infectious diseases caused by bacteria or viruses. 150 
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Figure IV. 1  Serum Antibody Activities of Coho Salmon Immunized with Low Dose of 
TNP-LPS.  Antigen  dose  regimen:  IP= 1pg/fish,  once; 
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Figure IV. 2 Serum Antibody Activities ofCoho Salmon Immunized with Low Dose of 
TNP-LPS.  Antigen  dose  regimen:  IP = lOng/fish,  once; 
Immersion =107/g/fish,  once;  Oral =107/g/fish/day, 30 days;  Oral 
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Figure IV. 3 Serum Antibody Activities of Coho Salmon Immunized with Low Dose of 
TNP-LPS. Antigen dose regimen: IP=10pg/fish,  once;  Immersion= 
IP =10//g/fish, once;  Oral =10pg/fish/day, 30 days;  Oral control= 
IP =0/ig/fish/day, 30 days. 153 
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Figure IV. 4 Serum Antibody Activities of Coho Salmon Immunized with TNP-KLH. 
Antigen  dose  regimen:  IP=10014g/fish,  once;  Anal  intubation = 
IP=100Ag/fish, once;  Oral=0.5pg/fish/day, 30 days;  Oral control= 
IP=Opg/fish/day, 30 days. 154 
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Figure IV. 5 Serum Antibody Activities of Coho Salmon Immunized with TNP-KLH. 
Antigen  dose  regimen:  IP=100Ag/fish,  once;  Anal  intubation= 
IP=100/.4g/fish, once;  Ora1 =5ng/fish/day, 30 days;  Oral control= 
IP=Ong/fish/day, 30 days. 155 
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Figure IV. 6 Serum Antibody Activities of Coho Salmon Immunized with TNP-KLH. 
Antigen  dose  regimen:  IP=100/Ag/fish,  once;  Anal  intubation= 
IP=100itg/fish, once;  Oral=100itg/fish/day, 30 days;  Oral control= 
IP=Oitg/fishiday, 30 days. 156 
Table IV. 1.  Antigen Dose Regimens For TNP-LPS Experiment 
Administration  High Dose  Medium Dose  Low Dose  Given Period 
Oral  10 /.4g  10 ng  1 pg  30 days 
In traperitoneal  10 itg  10 rig  1 pg  Once 
Immersion  10 lig  10 lig  1 pg  Once 
Control  Non-antigen coated beads with fish diet  30 days 157 
Table IV. 2.  Antigen Dose Regimens For TNP-KLH Experiment 
Administration  High Dose  Medium Dose  Low Dose  Given Period 
Oral  100 Ag  5 jg  0.5 pg  30 days 
Intraperitoneal  100 ihg  Once 
Anal intubation  100 iig  Once 
Control  Non-antigen coated beads with fish diet  30 days 158 
Table IV.  3  Abbreviation Used In Chapter IV 
LPS  lipopolysaccharide 
TNP-LPS  trinitrophenylated-lipopolysaccharides 
KLH  keyhole limpet hemocyanin 
TNP-KLH  trinitrophenylated-keyhole limpet hemocyanin 
BSA  bovine serum albumin 
TNP-BSA  trinitrophenylated-bovine serum albumin 
PBS  phosphate bufferred saline 
TNBS  2,4,6-trinitrobenzensulfonic acid, picrylsulfonic acid 
GALT  gut-associated lymphoid tissues 
TBS  tris-bufferred saline 
TABS  tween tris-bufferred saline 
ECAM  enteric-coated antigen microspheres 
IP  intraperitoneal injection 
SA. HRPO  strepavidin-horseradish peroxidase 
ABTS  azino-bis(ethylbenzthiazoline-6-sulfonic acid) 
ELIS A  enzyme-linked immunosorbent assay 159 
Table IV. 4 Buffer used in ELISA 
Coating buffer 
Na2CO3  1.59 g 
NaHCO3  2.93 g 
NaN3  0.20 g 
H2O  1000 ml 
q. s. 
Adjust pH to 9.6 and store at 4°C for less than 2 weeks 
Trizma base 
EDTA 
NaCL 
H2O 
q. s.
 
pH adjusted to 8.0
 
Tris-buffered saline (TBS) 
6.07 g 
0.37 g 
8.70 g 
1000 ml 
Tween tris-buffered saline (TTBS) 
Add 1% of tween 20 to above tris-buffered saline 
Substrate solution 
Citric acid buffer 
H202 
ABTS (2,2'-azino-bis(ethylbenzthiazoline-6-sulfonic acid) 
1itg/m1 in distilled water 
10 ml 
5 ml 
75 pi 160 
Table IV. 5 Serum Antibody Activity of Fish Immunized with TNP-LPS 
Antibody Activities (units/ml, Mean +SD)a
 
Treatment
 
4 weeksb  6 weeksb  8 weeksb 
High Oral  8460+1782  5641+1287  3840+842 
Medium Oral  4460+349  3450+0.00  2340 +1458 
Low Oral  4980+ 1886***  3634+545  9230+4052 
High IP  25350+6853  6580+2501  3068+649 
Medium IP  6400+1643***  9460+2515  3740+763 
Low IP  3700 ±370  4268+391  4952+1265 
High Imm.  6292 ±2708  7520+1798  2200+200 
Medium Imm.  3560+624  2360+406  4996+906 
Low Imm.  3800+414  3844+851  3764+451 
Negative Control  3350+1969  1650+0.00  1570+263 
'Each data set represents the mean value and the standard error of antibody activities 
analyzed from serum samples of five fish of that group. Serum samples were taken from 
five fish at each time point and  the serum antibody activities were determined by 
ELISA. 
bBlood samples of five fish were taken at 4, 6, 8 weeks post-immunization. 
The serum antibody titers  are significantly greater than negative control 
(p <0.05). 161 
Table IV. 6  Serum Antibody Activities of Fish Immunized with TNP-KLH 
Serum Antibody Activities (units/ml, Mean +SD)a 
Treatment 
4 weeks"  6 weeks"  8 weeks" 
High Oral  232+113  971 +275  494 ±243 
Medium Oral  143+98  619+450  2461+1506 
Low Oral  3171+1167  9723+3191'  15440+6460*** 
IP Injection  20676+7756***  6100+2107***  5667+ 1488" 
Anal Intubation  24952+8659'  43507+34263***  5295+2051' 
Negative Control  436+243  1250+580  658+541 
'Each data set represents the mean value and the standard error of antibody activities 
analyzed from serum samples of 13 fish. Serum samples were repeatedly taken from each 
fish at each time point and the serum antibody activities were determined by ELISA. 
"Blood sample of each fish, total of 13 fish each time, was taken repeatedly at 4, 6, 
8 weeks post-immunization. 
***The serum antibody titers are significantly greater than negative control 
(p <0.05) 162 
Buffer and Agent 
1. Benzocaine
 
10 gm ethyl p-aminobenzoate (Sigma, St. Louis, MO)
 
90 ml ethanol
 
Mix thoroughly.
 
2. RPMI-1640 
1 packet of RPMI-1640 with L-glutamine, without sodium bicarbonate (Gibco, Grand 
Island, NY) 
2.0 gm NaHCO3 (Sigma)
 
Dissolve in one liter of nanopure water. Adjust pH to 7.2 and filter sterilize. Store at
 
4°C.
 
3. Cacodylate buffer (0.28 M) 
44.8 gm (anhydrous) Cacodylate acid or 60 g /ml (trihydrate) (Sigma) 
Dissolve in one liter of distilled water.  Adjust pH to 7.0 with 0.1 molar NaOH 
4. Citric acid buffer
 
Prepare a 0.2% w/v of citric acid and adjust pH to 4.0.
 163 
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CHAPTER V 
EFFECT OF SUPERDISINTEGRANT ON ANTIGEN RELEASE
 
FROM ENTERIC-COATED ANTIGEN MICROSPHERES
 
ABSTRACT 
The effect of incorporation of a superdisintegrant into an oral enteric-coated 
antigen microsphere (ECAM) delivery system was studied. The mixture of antigen and 
sodium starch glycolate (SSG, Explotab ®) was applied onto 25-30 mesh nonpareil beads 
followed by coating with polymethacrylic acid-ethylacrylate (PMA-EA, Eudragit® L­
30D). Lipopolysaccharide was used as a model antigen. The amount of antigen released 
from the ECAMs in dissolution medium as a function of time was determined by a size 
exclusion HPLC method with UV detection.  The amount of superdisintegrants 
incorporated was studied by adding different levels of SSG onto the beads. Study results 
indicated 12% (w/w) SSG provided the significantly faster  release of LPS than other 
formulations. The time of the beads with SSG incorporated began  to break apart the 
enteric-film was 1.24, 1.26, 1.34, 1.58, 1.86 minutes for 12, 9, 5, 3 and 1% super 
disintegrant added formulation respectively. The disintegrating  time of SSG beads was 
significantly less than that of non-SSG incorporated beads (2.97 minutes, P < 0.05). 
Beads incorporated with 9% and 12% SSG beads always yielded  significantly larger 
swelling and liquid uptake capacity. The significantly faster antigen release rate and the 
reduced time needed for breaking the Eudragit® film  may due to the swelling forces 
generated by incorporation of the super disintegrant in the  beads.  12% (w/w) SSG 170 
formulation has the fastest release rate and the shortest film breaking time because 12% 
SSG may uptake a larger amount of water and provide higher swelling forces. 171 
INTRODUCTION
 
Oral  administration  of  antigens  containing  proteins,  glycoproteins, 
polysaccharides, lipopolysaccharides, or haptens with carriers can result in the induction 
of humoral and cellular immune responses, however, the required doses of antigens are 
much higher when compared to doses used for systemic immunization'''''.  This fact has 
been a major reason why the oral immunization  route has not been widely used. 
Denaturation of highly purified antigens such as viral glycoproteins and bacterial enzymes 
by gastric hydrochloric acid, digestion of antigens by proteolytic enzymes, and limited 
antigen absorption''' are also the factors of low efficacy of oral vaccination. 
Enteric-coated antigen microspheres (ECAMs) can protect antigens from gastric 
secretion and increase  their presentation  to the immune system throughout the 
gastrointestinal tract, thereby inducing a more effective antibody response'''.  Further 
modification of this antigen delivery system by incorporation of a superdisintegrant in the 
formulation may increase the antigen's bioavailability,  and therefore decrease the amount 
of antigen needed to induce an immune  response,  increasing the efficacy of oral 
vaccination. 
Drug dissolution from tablet matrix  or encapsulated dosage forms' can be 
improved significantly with the addition of disintegrating agents in the formulation. A 
superdisintegrant,  such as sodium starch  glycolate  is now frequently used in 
pharmaceutical formulations to improve the rate and extent of dissolution and thereby 
increase the rate of drug absorption.  When a superdisintegrant is incorporated into 172 
enteric-coated antigen microspheres (ECAMs),  it may aid swelling processes helping to 
release antigen upon the dissolving of the enteric-protected film when ECAMs reach the 
small intestine.  Rapid release of antigens within a short period of time allows for better 
antigen absorption or uptake causing stimulation of the lymphocytes and induction of the 
immune response. 
The properties of disintegrants  have been evaluated  in  terms of water 
uptake9,10,11,12,13,  swelling rate', and disintegrating force 10,12,14,15 to interpret the drug 
release behavior of tablets. The liquid uptake and swelling capacity of enteric-coated 
microspheres have not been reported. The purpose of present study  was to determine 
the effect of SSG incorporation on swelling capacity and liquid uptake of ECAMs. 173 
MATERIALS AND METHODS 
Sodium starch glycolate (Explotab®, Lot: E5158x, Edward Mendell,  Patternson, 
NY), 25-30 mesh size of NU-PARELL® PG, Sugar Spheres NF (Ingredient Technology 
Corporation, Pennsauken, NJ),  Lipopolysaccharide (LPS, Lipopolysaccharide, Lot: 
30H4010, Sigma Chemical Co., St. Louis, MO, serotype: 055:B5), Eudragit®  L-30D 
(Rohm Pharma, Weiterstadt, West Germany), Triethyl citrate (TEC, Aldrich Chemical 
Company, Inc., Milwaukee, WI), Dibutyl sebacate (DBS, Sigma  Chemical Co., St. 
Louis, MO), talc (USP powder, Matheson Coleman & Bell,  East Rutherford, NJ). 
Formulation Preparation 
100 grams of non-pareil sugar beads were loaded into a pre-heated modified fluid 
bed bottom spray coater (Lab-line/PRL, Melrose Park, IL) at 60°C. When the sugar 
beads' temperature equilibrated with the coating unit, 0.03% LPS (based on the weight 
of sugar beads loaded in the coating chamber), which  was dissolved with appropriate 
amount of gelatin solution, was applied onto the beads.  In superdisintegrant study, 1 %, 
or 3%, 5%, 9%, 12% SSG was incorporated with the above antigen solution before 
being applied on the beads. A 0.8  mm bottom spray nozzle was used and the nozzle 
pressure was maintained at 18+2 psi, blower speed was set at 40 to 50% of full capacity 
to cause the beads free movement. LPS was constantly delivered by a peristaltic pump 
(Gilson Medical Electronics, Middleton, WI) at rate of 2 to 3 ml/minute.  After applying 
LPS and SSG, the pellets were dried in the coating chamber for another 5 minutes at 174 
the same temperature and air flow. When the antigen coated beads were removed from 
the coating chamber, they were kept in a 37°C oven overnight to remove residual 
moisture before application of PMA-EA enteric-coating. A mixture of Eudragit L-30D, 
15 % DBS and 15 % TEC (based on enteric coating solid contents) and talc was applied 
in the same manner as antigen coating to form enteric-protected film.  20% (w/w) 
Eudragit L-30D was applied based on the final dry weight of antigen loaded beads. 
Superdisintegrant Study 
The disintegrant was tested either alone or incorporated into enteric-coated and 
non-enteric coated antigen microspheres. 
1. Liquid Uptake Measurement 
A laboratory liquid penetration apparatus16,17,18,19,20 (Fig. v .  1) was employed to 
determine liquid uptake and swelling of powder compact or enteric-coated and non 
enteric-coated beads. The apparatus consisted of a buchner funnel (15 ml) fitted with a 
sintered glass filter connected to a horizontally positioned 2 ml graduated pipette via 
tubing. The penetration liquid was simulated intestinal  fluid.  Compact of pure 
disintegrant was prepared by placing 0.5 mg of powder into the up section of the funnel. 
For enteric-coated or enteric-coated beads measurements, one gram of beads was placed 
into the up section of funnel. To prevent loss of water due to evaporation, the glass 
filter was covered with parafilm during the entire course of measurement. Ten replicate 
measurements were carried  out for each group of formulated beads.  In  each 175 
measurement, the timing was started as soon as the beads surface touched the moist glass 
filter.  The volumetric change of simulated intestinal fluid in the pipette as a function 
of time was recorded.  The water uptake rate profiles were generated by plotting the 
volume of liquid penetrated into the beads versus time. 
2. Swelling Work Measurement 
The apparatus shown in Fig. V. 1 was also used to measure the swelling work of 
the pure superdisintegrant. Measurement was done in triplicate Each sample of power 
(0.5 g) was compressed to the same thickness.  A glass stopper weighted at 24.7 gram 
was placed on the top of the powder. The swelling work made by the unit weight of the 
polymer bed was determined using the following equation: 
W = M * g * d/m 
where M is the mass of the load, g is the gravitational acceleration, d is the distance of 
migration, and m is the powder weight. 
3. Swelling Percentage of Antigen Loaded Microspheres 
The diameters of enteric-coated and uncoated beads  were measured under 
microscope before and after being exposed to 300 µl of liquid. 
The swelling percentage increased from original volume was determined by 
%Swelling = [rVafter  Vbefore)/ Vbefore]*100,  where V indicates the volume of the 
sphere shaped beads. 176 
4. Enteric Film Coating Rupture Time 
Ten enteric-coated antigen beads as a group from each formulation with and 
without SSG were tested. Each bead of a test group was placed under the microscope. 
The time after adding 400 Al simulated intestinal fluid to the point when the coating film 
began to rupture was noted. 
Dissolution 
The dissolution of LPS from enteric-coated microspheres with different percentage 
of SSG incorporated were studied by using modified USP rotation basket method on six-
spindle dissolution tester (Vanderkamp® 6000, Van-Kel Industries,Inc., Chatham, NJ) 
at a speed of 100 rpm. Dissolution tests were performed in triplicate.  Each replicate 
contained 5 grams of antigen loaded beads or both Explotab and antigen loaded beads. 
The first hour of dissolution testing was conducted in enzyme-free pH 1.5 simulated 
gastric fluid followed by transferring the coated beads into simulated intestinal fluid ( pH 
7.2) for the remainder of the test procedure.  The amount of LPS released in the 
dissolution medium as a function of time was normalized each time with a batch antigen 
coating efficiency and was determined by a modified size exclusion HPLC method with 
UV detection described in Chapter II and 1.25 µg /ml methylparaben (Methyl p-
Hydroxybenzoate, J.T. Baker Chemical Co., Phillipsburg, NJ) was used as the internal 
standard. 177 
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Figure V. 1  Apparatus for Measurement of Liquid Uptake and Swelling Capacity 178 
Antigen Coating Efficiency 
For each batch of enteric-coated or enteric-uncoated product, 5 grams of antigen 
beads were randomly taken and ground into a fine powder and then transferred to a 50 
ml volumetric flask with 30 ml of intestinal fluid. The powder sample was agitated for 
4 hours. An aliquot of this solution was filtered through 20 gauge 5µm filter needle and 
assayed by a HPLC method. These triplicate determinations were obtained and used as 
the batch antigen coating process efficiency.  The amount of LPS released in the 
dissolution medium was normalized each time with the batch coating efficiency. 
Statistical Analysis 
The statistical significance of the differences in total volume of liquid uptake and 
swelling percentage was evaluated by an analysis of variance (ANOVA), and Tukey's 
studentized Range (HSD) Test was used for multiple range analysis. The analysis was 
performed using SAS (SAS Institute, Cary, NC) with P < 0.05 being considered 
statistically significantly different for all tests. 179 
RESULTS AND DISCUSSION 
Swelling Work and Volumetric Liquid Uptake of Superdisintegrant Powder 
The swelling of SSG was investigated by measuring the swelling work of a 
slightly compressed powder with a given weight. The swelling work of SSG powder per 
unit weight at different time points is shown in Figure V. 2 (Table IV. 6). The swelling 
work increased with the time and reached a maximum value at about 30 minutes. The 
liquid uptake profile of Explotab powder is shown in Figure V. 3 (Table IV. 5).  The 
total amount of liquid absorbed by SSG powder compact was 8.8 ml/g within 2 minutes. 
It was reported that SSG can swell about 50 times its original volume in cold water'. 
The great swelling capacity and fast water uptake rate provided by SSG will potentiate 
the antigen release. Furthermore, since the sodium starch glycolate is insoluble in water 
and the swollen particles remain intact,  there is no formation of a viscous barrier,  so 
that the antigen in the microspheres will release quickly. 
Determination of Volumetric Liquid Uptake of Antigen Microspheres 
It was observed that an increase in SSG disintegrant concentration from 1 to 12% 
(w/w) resulted in an increase in the total volume of liquid taken up by the beads, as well 
as faster rates of liquid uptake (Figs. V. 4, V. 5). At 60 minutes, the total volume of 
liquid taken up by 5, 9 and 12% SSG incorporated beads were significantly greater than 
that of 0, 1 and 3% SSG incorporated bead formulations (Fig. V. 4).  However, among 
5, 9 and 12% SSG incorporated formulations the total volume of liquid uptake was not 180
 
significantly different.  The volume uptake was similar for the 0,  1 and 3% SSG 
formulations.  In non enteric-coated beads, only  12 and  9% SSG incorporated beads 
absorbed more liquid than the non-SSG bead formulations. The total volume of liquid 
uptake of enteric-coated microspheres was significantly larger than that of non-enteric 
coated beads (Figs. V. 4, 5).  This indicates that the enteric-film of PMA-EA also 
absorbed liquid. 
Swelling Capacity 
The percentage increase in swelling from the original volume of 5, 9 and  12% 
SSG incorporated enteric-coated beads was significantly greater than the 0% SSG 
formulation. Microspheres incorporated with  12%  SSG have significantly larger swelling 
capacities than other formulations. The same results were observed in non-enteric coated 
antigen microspheres (Fig. V. 6,  V. 7 ).  The statistical results of liquid uptake and 
swelling  capacity  of enteric-coated  and  non  enteric-coated  microspheres  with 
superdisintegrant incorporated are summarized in table V. 1 and table V.  2. 
Enteric Film Coating Rupture Time and Dissolution of LPS 
The time of enteric-coated film starts to break up was influenced by the amount 
of the SSG in the formulation. The time that the film began to break apart decreased as 
the amount SSG in the formulation increased.  It took 2.97, 1.86, 1.58, 1.34,  1.26, 1.24 
minutes for 0, 1, 3,  5, 9, 12% SSG incorporated beads to break apart respectively (Fig. 
V. 8). Beads with disintegrant incorporated require significantly less time to rupture the 181 
enteric-film coat than non-disintegrant incorporated beads.  In vitro dissolution results 
indicate that with increasing amounts of SSG in the formulation the antigen release rate 
increased. However, the release rate of LPS was not significantly different when 1, 3, 
5 and 9% of SSG was incorporated in the beads (Fig. V. 9). When the amount of SSG 
was increased to 12%, the LPS release rate increased significantly. The time to release 
50% of LPS was 2.21, 2.83, 2.47, 2.52, 2.31 and 1.34 hours for 0, 1, 3, 5, 9 and 12% 
SSG incorporated beads respectively. 
There was no detectable LPS released in one hour in pH 1.5 simulated gastric 
fluid.  During the microspheres exposure to the acidic environment the coating film 
showed minimum  swelling.  Lehamann22  et  al.  indicated  that  the  anionic 
polymethacrylates with coating thickness 20-40iim have minimum swelling in the acid 
milieu of the stomach at pH 1-4 and remain largely impermeable within a period 2-4 
hours and free from technical imperfections.  The present results confirmed their 
observation. The faster antigen release rate and the significantly less time needed for 
breaking the film in SSG incorporated formulations may due to the swelling forces 
generated by a superdisintegrant. When the pH is increased to 7.2 in simulated intestinal 
fluid the coated film swells and might create large pores on the surface of the film. 
Because of the pores water can easily penetrate into the film.  As the water contacts the 
sodium starch glycolate, the disintegrant swells and creates sufficient swelling forces to 
break the film barrier causing rapid release of LPS. The rapid antigen release rate of 
LPS from the beads may be caused by a rapid absorption of water into beads plus an 
enormous swelling of the SSG particles.  The swelling of enteric-coated beads is an 182 
important factor in controlling the release of a bioactive agents as it affects PMA-EA film 
permeability, the available surface area for contact with the surrounding solution, and 
the intrabead concentration of active agent. 
It was observed that 12% SSG formulation has the fastest antigen release rate and 
the shortest time for rupturing the enteric film coat.  This may be due to the fact that 
12% SSG beads can take up more liquid and generate larger swelling forces. 
Incorporation of SSG in enteric coated antigen microspheres provides rapid release of 
antigens at a high pH environment which may improve the antigen absorption and/or 
uptake in the intestinal tract,  and thereby increase both the systemic and secretory 
immunity. 183 
Table V. 1	  Multiple Range Analysis of Disintegration Characteristics of Enteric­
coated Microspheres Incorporated with Explotab® by Tukey's (HSD) Test 
Explotab Level  Total Liquid*  Grouping"  % Swelling  Grouping"
 
[%(w/w)]  Uptake* (ml)
 
0  0.57+0.05  A  276.13+92.86  A 
1  0.63+0.32  A  288.07+77.79  A 
3  0.63+0.32  A  345.15 ±75.16  A 
5  0.81 +0.08  B  633.25+148.13  B 
9  0.86+0..09  B  792.04+243.38  B C 
12  0.88+0.03  B  1115.33+280.91  C 
"mean value of ten replicates and the standard error, experiment was conducted in 
simulated intestinal fluid. 
"Tukey's Studentized Range (HSD) Test was used as multiple range analysis, 
values with the same letter are not significantly different. 184 
Table V. 2	  Multiple Range Analysis of Disintegration Characteristics of Non Enteric 
coated Microspheres Incorporated with Explotab 
Explotab Level  Total Liquid*  Grouping**  % Swelling  Grouping 
[%(w/v)]  Uptake (ml) 
0  0.21+0.05  A  23.14+10.35  A 
1  0.31+0.01  A B  65.95+56.56  A 
3  0.44+0.10  ABC  263.35+128.74  A B 
5  0.49+0.05  A B C  537.77+221.23  B 
9  0.64+0.25  B C  1085.12+542.44  C 
12  0.70+0.21  C  1317.43+536.55  C 
'represents the mean value of five replicates and the standard error, experiment 
was conducted in simulated intestinal fluid. 
**Tukey's Studentized Range (HSD) Test was used as multiple range analysis, mean 
with the same letter are not significantly different. 185 
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Figure V. 2  Swelling Work of Sodium Starch Glycoloate as a Function of Time. 186 
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Figure V. 3  Liquid Uptake of Sodium Starch Glycolate as a Function of Time 187 
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Figure V. 4	  Volumetric Liquid Uptake Rate Profiles for Enteric-coated Antigen 
Microspheres Containing Different Levels of Superdisintegrant. Each data 
point represents the mean of ten replicates. F
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Figure V. 6	  Effect of Different Levels of Superdisintegrant on Swelling Capacity of 
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Figure V. 7	  Effect of Different Levels of Superdisintegrant on Swelling Capacity of 
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Figure V. 8	  Effect of Different Levels of Superdisintegrant on Enteric Film Coating 
Rupture Time. 192 
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Figure V. 9	  LPS Dissolution Rate Profiles from Enteric-coated Antigen Microspheres 
with Different Levels of Superdisintegrant Incorporated. Dissolution was 
conducted in pH 7.2 simulated intestinal fluid with one hour  pH 1.5 
simulated gastric fluid pre-treatment. 193 
CONCLUSIONS
 
Water wicking (uptake) and disintegrant swelling represent two means commonly 
used in determining disintegrant performance. Sodium glycolate starch has outstanding 
water wicking capacities and good swelling properties. This dual functionality translates 
into superior disintegrating characteristics in enteric-coated antigen microspheres. SSG 
aids in breaking up an enteric-coated film and increases  LPS dissolution,  therefore 
improving  its  subsequent  bioavailability  and  absorption.  Incorporation  of  a 
superdisintegrant into an enteric-coated antigen delivery system can increase the release 
rate of a bioactive agent. The fluid-bed spray coating of the disintegrant onto the beads 
with the antigen provides a quick and effective way of speeding up the antigen release 
rate, which may be useful to improve bioavailability of oral delivery of enteric-coated 
drugs, proteins or other bioactive molecules, and may potentiate the effectiveness of oral 
vaccination. 194 
Table V. 3  Time of Breaking Up Explotab® Incorporated Enteric-coated Films 
Time of Breaking up Enteric- Diameter of the Beads, 
Formulation  Coated Film', (mean ±SD)b  (mean+SD)b 
0%  Explotab  2.97 ±0.87  0.77 ±0.04 
1%  Explotab  1.86+0.59*  0.84+0.05 
3%  Explotab  1.58+0.25***  0.82+0.06 
5%  Explotab  1.34+0.19  0.81+0.06 
9%  Explotab  1.26+0.32  0.82+0.07 
12% Explotab  1.24+0.37***  0.81+0.06 
aTime was counted immediately after the film started to break up.
 
b  mean value of six replicates and standard error.
 
significantly smaller than 0% Explotab incorporated beads
 Table V. 4  Percentage of LPS Released from Enteric-coated Beads Incorporated with Explotab® 
Cumulative Percentage of LPS Released in Dissolution Medium' (Mean+ SD)­
Time(Hr)  Non­ 1%  3%  5%  9%  12% 
disintegrant  Explotab  Explotab  Explotab  Explotab  Explotab 
0.00  0.00 ±0.00  0.00 ±0.00  0.00 ±0.00  0.00 ±0.00  0.00 ± 0.00  0.00 ±0.00 
0.25  0.00 ±0.00  0.00+0.00  0.00 ±0.00  0.00 ±0.00  0.00 ±0.00  0.00 ±0.00 
0.50  0.00 ±0.00  0.00+0.00  0.00 ±0.00  0.00 ± 0.00  0.00 ± 0.00  0.00 ± 0.00 
0.75  0.00 ±0.00  0.47 ±0.82  0.00 ±0.00  0.00 ±0.00  0.00 ± 0.00  0.00 ± 0.00 
1.00  0.00 ±0.00  1.02±1.05  1.29 ±1.45  0.00 ±0.00  0.00 ±0.00  0.00 ±0.00 
1.25  6.20 ±5.43  2.13+1.19  4.14 ±3.75  1.07 ±2.14  0.34 ±0.60  20.60 ±3.69 
1.50  21.31 +6.70  9.82 ±7.59  18.00 ±4.62  14.54 ±13.17  15.46+1.69  100.84 ±23.83 
1.75  38.50 ±6.68  26.53 ±7.70  25.74 ±7.42  30.92 ±11.55  32.66 ±5.26  100.30 +8.79 
2.00  45.30 ±8.99  34.96 ±10.57  37.38 ±13.51  34.31+12.05  43.72 ± 2.59  100.14 ±6.64 
2.50  55.99 ±5.58  48.15 ±8.53  54.36 ±21.23  53.73 ±18.62  56.71 ±11.17  100.27 ±5.16 
3.00  62.56 ±1.04  56.83 ±16.62  67.29 ±12.78  64.47 ±12.96  68.88 ±5.82  100.90 ±8.25 
4.00  73.05 ±2.33  68.48 ±13.29  81.97 ±13.53  77.02 ±15.97  83.47 ±5.40  100.35 ±4.50 
6.00  90.89 ±5.02  85.62±15.61  97.50 ±14.29  95.02 ±9.45  98.50 ±1.05  100.97+5.61 
9.00  102.80 +4.40  101.04+10.80  112.42 +16.10  108.38 +10.18  100.68 +12.60  100.00 ±9.33 
Dissolution in pH 7.2 simulated intestinal fluid with one hour acid pre-treatment in pH 1.5 simulated gastric fluid. 
Cumulated percentage LPS released from ECAMs was measured by size exclusion HPLC method with UV detection. 
mean value of three replicates and the standard error. 196 
Table V. 5  Water Uptake of Pure Explotab® Powder 
Time (seconds)  Volume (ml), (mean+SD).
 
0  0.00+0.00
 
15  1.18+0.09
 
30  1.95 +0.08 
45  2.51+0.08 
60  2.99+0.07 
75  3.42 +0.09 
90  3.81+0.08 
105  4.15+0.09 
120  4.44+0.010 
'mean value of five replicates and the standard error. 197 
Table V. 6  Swelling Work Generated by Pure Explotab® Powder 
Time (minutes)  Swelling Work (J/gx103, Mean+SD)* 
0  0.00+0.00 
1  2.50+0.23 
2  3.25 ±0.08 
3  4.01 ±0.08 
4  4.77 ±0.00 
6  5.60+0.08 
8  6.43+0.15 
12  7.19+0.15 
16  7.49 ±0.13 
20  7.64 +0.27 
25  7.39+0.17 
30  7.72 ±0.26 
40  7.72 ±0.26 
'mean value of three replicates and standard error. Table V.7 Liquid Uptake of Enteric-coated Beads Incorporated with Different Level of Explotab® 
Liquids Uptake Volume (Mean ±  ml) 
Time 
(min)  0 %Explotab  1 % Explotab  3 % Explotab  5 % Explotab  9 %Explotab  12%Explotab 
0  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00 
0.5  0.27+0.18  0.04+0.01  0.09+0.06  0.22+0.16  0.21+0.13  0.31+0.07 
1  0.35+0.16  0.16+0.03  0.26+0.02  0.36+0.26  0.35+0.11  0.49+0.06 
2  0.46+0.03  0.39+0.03  0.47+0.04  0.43 +.22  0.57+0.08  0.56+0.05 
3  0.47+0.03  0.51+0.03  0.47 + 0.04  0.47+0.16  0.58+0.07  0.56 ±0.06 
5  0.48+0.03  0.52+0.03  0.49+0.03  0.58+0.06  0.60+0.07  0.59+0.05 
7  0.49 ±0.03  0.53+0.03  0.51 ± 0.03  0.62+0.07  0.65+0.08  0.63 ± 0.06 
10  0.50+0.03  0.55+0.03  0.53+0.03  0.66+0.07  0.69+0.08  0.69+0.04 
13  0.51+0.03  0.56+0.02  0.55+0.03  0.69+0.07  0.71±0.09  0.71+0.03 
15  0.52+0.03  0.57+0.03  0.56+0.03  0.70+0.07  0.73+0.09  0.72±0.04 
20  0.53 +0.04  0.58+0.03  0.57 +0.03  0.72+0.07  0.75+0.09  0.75+0.04 
30  0.54+0.04  0.60+0.02  0.59+0.03  0.76+0.08  0.78±0.09  0.79±0.03 
40  0.55+0.05  0.62+0.02  0.61+0.03  0.78+0.08  0.82+0.08  0.82+0.04 
60  0.57 ±0.05  0.63+0.03  0.63+0.03  0.81+0.08  0.86+0.09  0.88+0.03 
*experiment was conducted in simulated intestinal fluid. 
.4. 
mean value of five replicates and the standard error. Table V.8  Liquid Uptake of Non Enteric-coated Beads Incorporated with Different Level of Explotab® 
Time 
Liquid* Uptake Volume (Mean + SD, ml) 
(min)  0%Explotab  1%Explotab  3%Explotab  5 %Explotab  9 %Explotab  12%Explotab 
0  0.00+0.00  0.00+0.00  0.00+0.00  0.00+0.00  0.00±0.00  0.00±0.00 
0.5  0.11 ±0.07  0.01+0.00  0.07+0.13  0.098+0.13  0.05+0.06  0.12+0.14 
1  0.14+0.07  0.048+0.05  0.09+0.15  0.12+0.14  0.07+0.08  0.15+0.13 
2  0.14+0.07  0.04+0.02  0.11 +0.17  0.16+0.15  0.09+0.08  0.19+0.12 
3  0.146667  0.07±0.02  0.15+0.16  0.18+0.15  0.11±0.08  0.22+0.12 
5  0.15+0.07  0.11+0.01  0.19+0.15  0.21+0.13  0.17+0.04  0.25+0.09 
7  0.15+0.07  0.12+0.01  0.21±0.15  0.24±0.11  0.20+0.02  0.28+0.07 
10  0.15+0.06  0.13+0.01  0.23+0.16  0.26 ±0.09  0.22+0.02  0.32+0.11 
13  0.15+0.06  0.13+0.00  0.24+0.15  0.29+0.09  0.24+0.02  0.35+0.11 
15  0.16+0.06  0.14+0.01  0.25+0.15  0.30+0.09  0.25+0.02  0.36±0.11 
20  0.16+0.06  0.15±0.01  0.27+0.14  0.32±0.08  0.30±0.05  0.40+0.10 
30  0.17+0.06  0.20+0.01  0.33+0.12  0.38+0.06  0.42+0.13  0.51 +0.09 
40  0.19+0.05  0.25+0.01  0.38+0.11  0.42+0.05  0.50+0.17  0.57+0.11 
60  0.21+0.05  0.31+0.01  0.44+0.10  0.49+0.05  0.64+0.25  0.70+0.21 
*experiment was conducted in simulated intestinal fluid. 
. 
mean value of five replicates and the standard error. 200 
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